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Summary 
By 2050 the number of people aged 60 years and over is projected to reach 2 billion, of 
which an estimated 131 million will have dementia, therefore there is an urgent need to 
identify public health strategies aimed at promoting better brain health in our ageing 
populations. A review of the literature within this thesis identified certain dietary patterns, 
as well as specific nutrients, which could be beneficial in preventing or delaying the onset 
of brain disorders, with the strongest evidence supporting roles for folate and 
metabolically related B-vitamins. The biological mechanism whereby these B-vitamins 
are linked with the brain is likely related to their crucial roles as co-factors in one-carbon 
metabolism. The overall aim of the original studies in this thesis was therefore to 
investigate the impact of folate-related B-vitamins on brain health in older adults recruited 
to the Trinity, Ulster and Department of Agriculture (TUDA) cohort study. Results from 
new analysis of existing data from the TUDA cohort (n = 5071) in relation to mental 
health showed that lower biomarker status of folate (<1520nmo/L), vitamin B6 
(<51.9nmol/L) or riboflavin (EGRac ≥1.46) were each associated with an increased risk 
of depression (by up to 80%), while an increased risk of anxiety was found in TUDA 
participants with a deficient status of vitamins B6 (but not any other B-vitamin). Daily 
intake of fortified foods was associated with improved B-vitamin biomarker status and a 
50% reduction in the risk of depression. A new investigation of the TUDA cohort, the 
BrainHOP trial (n = 328), identified a protective effect of supplementation with combined 
folic acid, vitamin B12, vitamin B6 and riboflavin on visuospatial cognitive function. In 
a pilot study, involving a subset of the BrainHOP cohort (n = 25) who were examined 
post-intervention using magnetoencephalography, the results suggested a protective 
effect of B-vitamins on neuronal function. In conclusion, the findings of this thesis have 
identified the potential importance of optimising B-vitamin status as a means to help 
achieve better brain health in older people, which in turn could have a significant impact 
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Burden of declining brain health in ageing 
Populations around the world are ageing rapidly, with estimates that one fifth of the 
world’s population will be 60 years or over by 2050 (United Nations Department of 
Economic and Social Affairs/Population Division 2015). An estimated 23% of the global 
burden of disease arises in older people (Prince et al. 2015), of which dementia and 
depression are reported as the leading causes (World Health Organisation 2016). 
Dementia currently affects 46.8 million people worldwide and is projected to affect over 
131 million people by 2050 (Prince et al. 2016), whilst depression is anticipated to be the 
second leading cause of disability worldwide by 2020 (National Collaborating Centre for 
Mental Health 2010). The economic burden of cognitive decline and depression is 
profound. Experts have calculated that dementia is a trillion dollar disease (Prince et al. 
2016). Figures for depression are currently estimated at £7.5 billion in England (National 
Collaborating Centre for Mental Health 2010) and over €3 billion in Ireland (including 
other metal health conditions such as schizophrenia, bipolar disorder) (O'Shea and 
Kennelly 2008). With no disease-modifying treatments for dementia (Frankish and 
Horton 2017) and poor response to antidepressant medication (Rush et al. 2006) health 
systems are in danger of becoming overwhelmed by the future cost of caring for people 
with dementia (Frankish and Horton 2017). Estimates suggest that even a delay in onset 
of 1 year could prevent more that 9 million cases of dementia by 2050 (Frankish and 
Horton 2017). There is an urgent need therefore to identify modifiable factors for targeted 
interventions to promote better brain health in our ageing populations.  
 
Role of dietary patterns and nutrients in brain health in older adults 
Epidemiological evidence supports a role for certain dietary components or dietary 
patterns in brain health, opening up new potential avenues for prevention of dementia and 
mental illness in ageing (Panza et al. 2008; Rechenberg 2016). Within this thesis and 
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other ageing research publications, older adults are considered to have healthy brain 
function when their cognitive assessments scores do not exceed the threshold limits for 
the testing regime being applied. For example those with a score ≥25 within the Mini 
Mental State Examination (MMSE; (Folstein et al. 1975), or >15 in the Frontal 
Assessment Battery (FAB; (Dubois et al. 2000) or >80 in the Repeatable Battery of 
Neuropsychological Assessment (RBANS; (Randolph 2010) are considered to have good 
cognitive health. Furthermore, depression scores that are <16 within the Centre for 
Epidemiological Studies Depression Scale (CES-D) (Radloff 1977), and anxiety scores 
that are <11 within the 7 item Hospital Anxiety and Depression scale (HAD) (Zigmond 
and Snaith 1983), are indicative of good mental health. These assessments are often used 
in isolation however they can be used with age-appropriate magnetic resonance imaging 
(MRI) brain templates, which have been gathered from healthy adults, to define a healthy 
brain (Fillmore et al. 2015). More recently however, the American Heart 
Association/American Stroke Association identified specific metrics to define optimal 
brain health in adults including ideal health behaviours (non-smoking, physical activity, 
healthy diet and normal body mass index) and ideal health factors (untreated blood 
pressure, untreated total cholesterol and fasting blood glucose) (Gorelick et al. 2017). The 
Mediterranean diet is receiving significant attention as regards its potential role in 
preserving cognitive health and protecting against depression in ageing (Wu and Sun 
2017). There is also evidence supporting roles for specific nutrients including omega-3 
polyunsaturated fatty acids (PUFAs), polyphenols, vitamin D and B-vitamins. Most 
studies to date in this area, however, focus on specific dietary patterns or components, 
making it difficult to appreciate the overall role of nutrition in brain health and disease. 
Therefore, a broad review of the role of diet and nutrition in the ageing brain seems timely 
in terms of future public health implications.  
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B-vitamins and the ageing brain 
Folate and the metabolically related B-vitamins (vitamin B12 and vitamin B6) are 
nutrients which have received particular attention in relation to their role in protecting 
against depression and cognitive decline in ageing. The potential biological mechanisms 
explaining their relationship are not fully known, but most likely arise as a result of the 
crucial roles played by these B-vitamins in the one-carbon metabolic network. 
Tetrahydrofolate (THF) obtains a carbon unit from serine in the presence of B6 which 
results in the formation of 5,10 methylenetetrahydrofolate (MTHF). 5, 10 MTHF is 
catalysed to 5 MTHF by the enzyme methyltetrahydrofolate reductase (MTHFR) with 
flavin-adenine-dinucleotide (FAD) as a cofactor which riboflavin is the precursor. It is 5 
MTHF that is the single methyl donor in the remethylation of homocysteine to 
methionine, which take place in the presence of B12 and is catalysed by the enzyme 
methionine synthase. The activation of methionine by adenosine triphosphate (ATP) 
results in the subsequent generation of S-adenosylmethionine, (SAM). SAM, the 
universal methyl donor, is involved in the methylation of DNA, phospholipids, proteins 
and neurotransmitters, thus reduced status of one or more of the B-vitamins involved in 
one-carbon metabolism may impair methylation processes (Selhub et al. 2000; Bottiglieri 
et al. 2000). The inhibition of methylation reactions may in turn influence cognitive 
impairment in ageing in various ways (Smith and Refsum 2016). Additionally, reduced 
tissue concentration of SAM may be linked to depression through perturbing monoamine 
(serotonin, dopamine and noradrenaline) synthesis and methylation (Bottiglieri et al. 
2000).  
 
Intake and status of B-vitamins in relation to depression and cognition in older age 
Historically, clinical deficiencies of folate and vitamin B12 were associated with a range 
of neuropsychiatric symptoms, including depression (Carney 1967; Reynolds et al. 1970; 
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Shorvon et al. 1980), raising the possibility that optimising relevant B-vitamin intake and 
status could improve mental health. Research to date in this area has, however, focused 
predominantly on folate, and to a lesser extent vitamin B12 (Kim et al. 2008; Almeida et 
al. 2014; Almeida et al. 2015; Petridou et al. 2016) whereas related B-vitamins, i.e. 
vitamin B6 and riboflavin, also necessary for one-carbon metabolism, have received 
much less attention. Furthermore, there are important nutrient-nutrient interactions within 
this network of pathways, therefore, investigating the role of all four B-vitamins in 
depression is crucial.  
 
Epidemiological studies have linked lower biomarker status of folate, vitamin B12 and 
vitamin B6 (or higher concentrations of the related metabolite homocysteine) with an 
increased risk of cognitive dysfunction (Smith and Refsum 2016; Porter et al. 2016) and 
depression (Hvas et al. 2004; Kim et al. 2008; Ng et al. 2009; Robinson et al. 2011). The 
evidence however from randomised trials, in terms of depression is weak, due to the small 
number of available trials (Almeida et al. 2015), and in the case of cognition, the evidence 
has not been consistent (McMahon et al. 2006; Durga et al. 2007). Furthermore numerous 
limitations in various trials have been highlighted including: too short in duration 
(Lewerin et al. 2005; Pathansali et al. 2006); inappropriate target populations (McMahon 
et al. 2006; Kwok et al. 2011; van der Zwaluw et al. 2014); too small a sample size for 
adequate statistical power (Pathansali et al. 2006). Despite these inconsistencies, the 
strongest evidence to date comes from the VITACOG trial where pharmacological doses 
of folic acid, vitamin B12 and vitamin B6 over 2-years were shown to protect cognitive 
function and reduce brain atrophy in older adults with Mild Cognitive Impairment (MCI) 
(Smith et al. 2010; de Jager et al. 2012; Douaud et al. 2013). Furthermore, a recent review 
concluded that research on dietary interventions with B-vitamins should be a high priority 
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(Kane RL et al. 2017). Therefore, further well-designed trials using a combined B-
vitamin at doses within the dietary range are needed to further advance this area.   
 
Assessing brain health and the role of novel technologies 
Assessing and monitoring brain health in ageing is a complex task, thus investigating the 
influence of diet and/or specific nutrients on cognition or depression, present great 
challenges and should ideally be conducted using a multidisciplinary approach (Mak and 
Caldeira 2014).  Most often assessments are conducted via questionnaire-based 
assessments (Macready et al. 2010), which can have limitations including inter and intra-
rater variability and there is often limited evidence regarding their performance 
(Velayudhan et al. 2014). It is recommended that brain-imaging outcomes should be 
included as secondary outcomes to clinical and cognitive measures (de Jager and 
Kovatcheva 2010) in studies investigating the role of nutrition in brain health. The 
availability of neuro-imaging techniques has improved in recent years and they are 
increasingly being utilised in nutrition and brain health studies, potentially providing 
objective and highly robust means of assessing brain structure, function and response to 
nutrition (Sizonenko et al. 2013). Available studies using MRI and functional MRI have 
strengthened the evidence supporting beneficial effects of  the Mediterranean Diet, 
vitamin D, B-vitamins and polyphenols on brain and brain blood volumes (Brickman et 
al. 2014; Hooshmand et al. 2014; Smith et al. 2015; Staubo et al. 2017). 
Magnetoencephalography (MEG) is a relatively new neuroimaging technique, which 
measures the magnetic fields that are generated by neuronal activity, and thus directly 
measures oscillatory (neural) activity. MEG is a completely non-invasive technique, has 
the highest temporal resolution compared to other imaging techniques and overall may 
be able to identify the earliest functional changes that may occur as a result of 
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neuropathological processes, but prior to the onset of neurological disorder dementia 
(Zamrini et al. 2011).  
 
Public health implications 
Maintaining brain health in older age is a significant public health priority. Within the 
current literature, there is strong evidence for the protective role of folate and the related 
B-vitamins in cognitive function, while there is less evidence in relation to their roles in 
depression. Furthermore, as older adults are at particular risk of B-vitamin deficiencies 
(ter Borg et al. 2015; Porter et al. 2016)  the potential effect of B-vitamin fortified food 
consumption (which provides a highly bioavailable source of B-vitamins) (Hopkins et al. 
2015) and B-vitamin supplement use should be explored in relation to depression and 
cognitive function in ageing.   
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Thesis Aims: 
The overall aim of this thesis was to investigate the role of B-vitamins in brain health in 
ageing. In fulfilment of this aim, the objectives were to provide: 
1. A comprehensive review exploring the influence of ageing on brain health and the 
emerging evidence linking diet and specific nutrients with cognitive function and 
depression in ageing, and to consider the use of novel imaging technologies in 
nutrition and brain research. (Chapter 2) 
2. An investigation of folate, vitamin B12, vitamin B6 and riboflavin intake and 
status in relation to depression and anxiety in ageing, including the potential for 
fortified foods to optimise B-vitamin status and reduce the risk of these mental 
health disorders. (Chapter 3) 
3. An investigation of the effect of B-vitamin supplementation with combined folic 
acid, vitamin B12, vitamin B6 and riboflavin over 2 years on cognitive function 
and depression in older adults. (Chapter 4) 
4. An investigation of the role of B-vitamins in brain function in older adults using 
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Globally populations are ageing. By 2050, it is estimated that there will be 2 billion people 
aged 60 years or over, of which 131 million are projected to be affected by dementia, 
while depression is predicted to be the second leading cause of disability worldwide by 
2020. Preventing or delaying the onset of these disorders should therefore be a public 
health priority. There is some evidence linking certain dietary patterns, particularly the 
Mediterranean diet, with a reduced risk of dementia and depression. Specific dietary 
components have also been investigated in relation to brain health, with emerging 
evidence supporting protective roles for omega-3 polyunsaturated fatty acids (PUFAs), 
polyphenols, vitamin D and B-vitamins. At this time, the totality of evidence is strongest 
in support of a role for folate and the metabolically related B-vitamins (vitamin B12, 
vitamin B6 and riboflavin) in slowing the progression of cognitive decline and possibly 
reducing the risk of depression in ageing. Future studies incorporating new technologies, 
such as magnetic resonance imaging and magnetoencephalography, offer much promise 
in identifying effective nutrition interventions that could reduce the risk of cognitive and 
mental disorders. This review will explore the ageing brain and the emerging evidence 
linking diet and specific nutrients with cognitive function and depression in ageing, with 
the potential to develop strategies that could improve quality of life in our ageing 
population. 
  





Globally the population is ageing, with predictions that the number of people aged 60 
years and over will reach up to 2 billion by 2050. An estimated 23% of the global burden 
of disease arises in older people (≥60 years) and mental disorders are reported as the 
leading cause of disability and ill health (Prince et al. 2015). Dementia and depression 
are the most common of these disorders in ageing as identified by the WHO (World 
Health Organisation 2016). Cognitive function declines with age, ranging in severity from 
Mild Cognitive Impairment (MCI) to dementia, with up to 50% of those with MCI going 
on to develop dementia within 5 years (Gauthier et al. 2006). MCI can be defined as 
“cognitive decline greater than expected for an individual's age and education level but 
that does not interfere notably with activities of daily life” (Gauthier et al. 2006), whereas 
dementia interferes with activities of daily living (World Health Organisation 2015). 
Dementia currently affects 46.8 million people worldwide and is projected to affect over 
131 million people by 2050 (Prince et al. 2016), whilst depression is anticipated to be the 
second leading cause of disability worldwide by 2020 (National Collaborating Centre for 
Mental Health 2010), with 22% of males and 28% of females over the age of 65 years 
affected by depression  (Craig et al. 2007). The economic burden of cognitive decline and 
depression is profound. Experts have calculated that dementia will be a trillion dollar 
disease by 2018 (Prince et al. 2016). Figures for depression are currently estimated at 
over €3 billion in Ireland (O'Shea and Kennelly 2008) and £7.5 billion in England 
(National Collaborating Centre for Mental Health 2010). With mental health considered 
to be one of the greatest global challenges (Livingston et al. 2017), there is an urgent need 
to identify modifiable factors (well recognised examples include early life education, 
hypertension, obesity, hearing loss, smoking, depression, physical inactivity, social 
isolation and diabetes) for targeted interventions to promote better brain health in our 




in brain health, opening up new potential avenues for prevention of dementia and mental 
illness in ageing (Panza et al. 2008; Rechenberg 2016). 
This review will explore the influence of ageing on brain health and the emerging 
evidence linking diet and specific nutrients with cognitive function and depression in 
ageing. The use of novel imaging technologies in nutrition and brain research will be 
discussed, along with the potential for nutrition to play a protective role in preserving 
better brain health in ageing. 
 
1. The Ageing Brain 
a) Physiology and pathophysiology 
The structure and metabolic pathways within a healthy brain are progressively altered 
with ageing, though the precise aetiologies of ageing have not been fully elucidated. As 
people age, there is a reduction in brain volume in both grey and white matter (Resnick 
et al. 2003), while white matter lesions increase (Peters 2006) and there is development 
of amyloid plaques, neurofibrillary tangles, Lewy bodies, synaptic dystrophy and neuron 
loss (Svennerholm et al. 1997; Elobeid et al. 2016), which have been suggested to parallel 
the progression of cognitive decline (Serrano-Pozo et al. 2011). There are also changes 
in the production of neurotransmitters – in particular serotonin and dopamine – which 
have been reported to decline by up to 10% per decade from early adulthood (Peters 
2006). Additionally, there is an increase in oxidative stress response (Bishop et al. 2010) 
and more dysfunction of the blood brain barrier (Goodall et al. 2017). The blood brain 
barrier (BBB) protects the brain, by regulating the flux of nutrients and metabolites from 
the blood to the brain using six major transport pathways (Campos-Bedolla et al. 2014). 
These pathways control the influx of nutrients such as glucose, amino acids and specific 




Within normal ageing, the permeability of the BBB increases and is further increased 
with dementia where increased permeability is suggested to be involved in the 
development neurodegenerative diseases, specifically those related to the cerebral 
vasculature (Farrall and Wardlaw 2009). Interestingly however, specific nutrients and 
natural compounds including omega three fatty acids, folate and plant polyphenols, have 
been suggested to have protective roles in maintaining BBB function in ageing (Campos-
Bedolla et al. 2014). 
 
Normal ageing is associated with a decline in cognitive function, with most cognitive 
change observed in memory during the ageing process. MCI is a recognised clinical 
condition where individuals have evidence of cognitive impairment but do not meet the 
criteria for the diagnosis of dementia (Winblad et al. 2004). Alzheimer’s disease (AD) is 
the most common form of dementia, accounting for 62% of cases, with other forms 
including vascular dementia, mixed, Lewy body, dementia of Parkinson’s disease and 
frontotemporal dementia (Prince et al. 2014). Depression in older adults (≥70 years)  is 
often referred to as ‘late–life depression’ and is reported more commonly in females than 
males (Luppa et al. 2012; Büchtemann et al. 2012; Polyakova et al. 2014). The depressive 
symptoms of older adults (≥70 years) are thought to be different from those experienced 
by younger adults, as somatic and psychological symptoms are often accompanied by 
fatigue, hopelessness about the future, loss of appetite and sleep disturbance (Luppa et al. 
2012).  
 
b) Pharmaceutical treatments 
Pharmacological treatment for dementia is prescribed by specialist clinicians (National 
Institute for Health and Care Excellence 2017b), but only a limited number of medications 




Institute for Health and Care Excellence (NICE) recommendations for dementia 
interventions. These include acetylcholinesterase (AChE) inhibitors (donepezil, 
galantamine, rivastigmine) and memantine (N-methyl-D-aspartate receptor antagonists). 
There are however a variety of pharmacological treatment options available for 
depression including tricyclic antidepressants, selective serotonin reuptake inhibitors, 
serotonin and noradrenaline reuptake inhibitors and selective noradrenaline reuptake 
inhibitors (Mann 2005; Rang et al. 2016). Overall, poor response rates to these costly 
pharmacological treatments for depression have been observed (Rush et al. 2006; Ilyas 
and Moncrieff 2012), and despite significant investigation into the role of 
pharmacological treatments for dementia, no licenced medication can cure these diseases 
of the brain. Therefore, much efforts are currently focusing on options for prevention 
rather than treatment of brain disorders.  
 
2. Assessment of Brain Function 
The assessment of brain function for neurodegenerative diseases and depressive disorders 
in ageing is a developing area. There are numerous neurological tests available which are 
designed to assess and distinguish different individuals in their response to day-to-day 
cognitive tasks (de Jager et al. 2014) and for the detection of common mental health 
disorders (Ali et al. 2016). NICE has provided guidance on the recommended diagnostic 
criteria for depression (National Institute for Health and Care Excellence 2017c) and 
dementia (National Institute for Health and Care Excellence 2017a).  For dementia, the 
guidelines emphasise the need to assess the following domains; attention and 
concentration, orientation, short- and long-term memory praxis, language and executive 
function. Furthermore, NICE recommends that formal tests should be conducted, 
including the Mini Mental State Examination (MMSE), 6-Item Cognitive Impairment 




Screen and that other factors known to influence performance such as education level, 
should also be taken into account. Lastly, only healthcare professionals with expertise in 
differential diagnosis and using international standardised criteria (such as the National 
Institute of Neurological Communicative Disorders) should be responsible for diagnosing 
subtypes of dementia (National Institute for Health and Care Excellence 2017a). 
 
Investigating cognitive and mental health outcomes via questionnaire-based assessments 
is the most common approach for assessing the effects of nutrition (Macready et al. 2010). 
For assessing brain health and function in relation to nutritional factors, studies should be 
aimed at prevention rather than treatment, and non-nutrition factors contributing to 
cognitive impairment and depression should be incorporated into studies and considered 
at the time of analysis (de Jager and Kovatcheva 2010). Concerning the specific tests to 
assess cognitive function, these should be carefully selected and should be based on a 
known or hypothesized relationship of a specific food/nutrient with cognitive function 
and not solely on their availability or ease of administration. It is also important that the 
tests are suitable for repeated administration, are appropriate to the population being 
studied, and are relatively simple to interpret and administer. More work is required using 
standardised tests across laboratories so that the specific tests or markers that are most 
sensitive to the nutrients tested can be established (de Jager and Kovatcheva 2010; de 
Jager et al. 2014). Lastly, computerised cognitive assessments have been utilised and 
these should be considered for use in future trials in terms of their accuracy and ability to 
capture reaction-time data, standardisation of administration, availability of parallel 
versions of tasks for testing at multiple time-points, and availability in multiple languages 
(de Jager and Kovatcheva 2010). 
 




a) Foods and dietary patterns 
Increasing evidence implicates certain dietary patterns such as higher intake of fruits and 
vegetables (Kang et al. 2005) and fish (Barberger-Gateau et al. 2007) as being beneficial 
to brain health. The Mediterranean diet is receiving significant attention as regards its role 
in preserving cognitive health and protecting against depression in ageing. This diet is 
typically characterised by higher intakes of fruit, vegetables, wholegrains, fish, 
unsaturated fatty acids and a regular but moderate consumption of alcohol. A recent meta-
analysis (n 34,168) showed that the highest Mediterranean diet score was associated with 
reduced incidence of developing cognitive disorders (RR 0.79 95% CI 0.70, 0.90) (Wu 
and Sun 2017) while supplementation of the Mediterranean diet with olive oil or nuts was 
associated with improved cognitive function (Valls-Pedret et al. 2015). Of note, studies 
using Magnetic Resonance Imaging (MRI) have shown that adherence to the 
Mediterranean diet was associated with larger cortical thickness (which in turn is 
associated with a lower risk of cognitive impairment) (Staubo et al. 2017). There is also 
accumulating evidence to support a potential role for the Mediterranean diet in preventing 
depression in older adults (≥50 years; Skarupski et al. 2013), with cross-sectional and 
prospective studies showing inverse associations between Mediterranean diet score and 
risk of depression (Psaltopoulou et al. 2013; Hodge et al. 2013; Skarupski et al. 2013; 
Rienks et al. 2013; Veronese et al. 2016). Further well-designed intervention studies are 
however required to more fully investigate the potential role of the Mediterranean diet as 
a means of helping to preserve better brain health in ageing. 
 
b) Specific Nutrients 
Protein and carbohydrates 
The role of dietary protein intake on cognitive function or mental health has not been 




observed in older people (>60 years) with lower dietary protein intakes (Goodwin et al. 
1983). Additionally, higher dietary protein intake was found to be positively correlated 
with nonverbal learning, verbal memory and reduced risk of mild cognitive impairment 
or dementia (Koehler et al. 1997; Roberts et al. 2012). One randomised controlled trial 
(RCT) investigating the effects of dietary protein from red meat on cognitive function in 
older adults (≥65 years) is in progress (ACTRN12613001153707) with results expected 
in 2018 (Daly et al. 2015). Investigations have focused on the essential amino acid 
tryptophan in brain health in ageing as it is the sole precursor of the monoamine 
neurotransmitter serotonin and therefore a plausible mechanism exists. A recent review 
in the area concluded that lower serotonin levels cause cognitive impairment, in specific 
cognitive domains associated with memory and learning such as cortex, amygdala, and 
hippocampus (Jenkins et al. 2016). Furthermore, supplementation with tryptophan 
appears to have beneficial effects on attention and memory in human subjects.  
 
The association between carbohydrates and cognitive function is unclear because 
available evidence is scarce, with one Cochrane review identifying only one relevant RCT 
in older adults (≥55 years) (Ooi et al. 2011; Power et al. 2015). However, higher dietary 
carbohydrate and sugar intakes were associated with lower cortical thickness, which is in 
turn associated with high risk of late life mild cognitive impairment and dementia (Staubo 
et al. 2017). Whilst more research has focused on carbohydrates and depression, the 
available evidence is somewhat conflicting. One study of community dwelling adults 
(mean age 74.0 years in those suffering from depression) and 76.1 years (those without 
depression), found that those with depressive symptoms consumed a diet with a higher 
glycaemic index (GI) and glycaemic load (GL) (Mwamburi et al. 2011). A prospective 
investigation also reported that a high GI diet was associated with an increased risk of 




older adults (≥ 65 years) with depression were reported to consume diets with a lower GL 
(Aparicio et al. 2013). Given the inconsistencies in this area, there is clearly a need for 
further well-designed studies. 
 
Omega 3 fatty acids 
The membranes of the cells within the nervous system are made of phospholipid bilayers 
which are mainly composed of long-chain n-3 polyunsaturated fatty acids (PUFA). These 
are directly affected by diet and thus attention has focused on the role of dietary fatty 
acids in brain health. There is evidence that PUFAs, eicosapentaenoic acid (EPA) and 
docosahexaenoic acid (DHA) have potential benefits in cognitive and mental health 
(Gillette-Guyonnet et al. 2013; Grosso et al. 2014a). These PUFA lipid groups are 
postulated to positively influence brain health by helping to maintain neuronal cell 
membrane functioning, by preventing hypo-perfusion and by decreasing inflammation 
(Janssen and Kiliaan 2014).  Furthermore, DHA itself has been suggested to be 
neuroprotective via its’ ability to increase production of brain derived neurotrophic factor 
and also plays roles in improving synaptic membrane fluidity and antioxidant capabilities 
(Cole et al. 2010).  One meta-analysis of 10 RCT studies concluded that n-3 fatty acids 
may have a protective effect on certain cognitive domains in cognitively impaired 
patients, however, no effects were seen in healthy people or in AD sufferers (Mazereeuw 
et al. 2012). A recent Cochrane review, which identified three RCTs for inclusion 
involving 632 patients with mild to moderate AD, concluded that there was no convincing 
evidence that PUFA had a role in the treatment of people with existing dementia 
(Burckhardt et al. 2016). 
 
On the other hand, systematic reviews and meta-analyses of RCTs have reported 




use of predominantly EPA compared with DHA supplementation appears to have greater 
efficacy (Grosso et al. 2014b; Hallahan et al. 2016). Furthermore, supplementation with 
EPA-predominant formulas as an adjuvant therapy to antidepressants was found to have 
greater clinical efficacy in the treatment of depression (compared to antidepressants 
alone), but did not prevent depressive symptoms among populations without a diagnosis 
of depression (Grosso et al. 2014b; Hallahan et al. 2016). A Cochrane review in this area 
reported a small to modest non-clinical beneficial effect of n-3 PUFA in depression 
symptomology, but concluded that there was not enough good quality evidence to 
determine the effect on depression (Appleton et al. 2015).  
 
Polyphenols 
Phenolic compounds have at least one aromatic ring with one or more hydroxyl groups 
attached and are classified as flavonoids and nonflavonoids (Del Rio et al. 2013). 
Polyphenols are the biggest group of phytochemicals, and many of them have been found 
in plant-based foods including nuts, berries, cocoa, red wine and tea beverages. They are 
structurally diverse compounds, with in excess of 8000 structures having been reported. 
The role of these polyphenols in brain health and ageing is an emerging area (Schaffer et 
al. 2012; Brickman et al. 2014; Ward and Pasinetti 2016). Large prospective studies have 
identified associations between the dietary intakes of total or specific polyphenols and 
cognitive function after up to 13 years of follow-up investigation (Letenneur et al. 2007; 
Kesse-Guyot et al. 2012; Rabassa et al. 2015).  Supplementation with cocoa flavanol for 
periods of up to 2 months was reported to improve cognitive performance in a group of 
cognitively intact older adults with the mean age 70 years (Mastroiacovo et al. 2015). Of 
note, Brickman and colleagues (Brickman et al. 2014) conducted a 3-month intervention 
and showed significant increases in cerebral blood volume in the dentate gyrus as 




treatment. Research into the role of polyphenols in depression in humans has been limited 
(Pase et al. 2013), though animal studies show promise in demonstrating antidepressant-
like effects of polyphenols in mouse models (Zhu et al. 2012).  
The exact mechanisms linking polyphenols with brain health are unknown, however a 
recent review presented three postulated mechanisms: firstly, polyphenols may protect 
synaptic plasticity via their actions on pathways involving extracellular signal-regulated 
kinases; secondly, their anti-inflammatory properties are also thought to decrease neuro 
inflammation and finally evidence from human studies suggests that they protect brain 
health via improving both peripheral and cerebrovascular blood flow (Vauzour 2017). 
 
Vitamins 
Specific vitamins have been investigated in relation to brain health and disease. Oxidative 
stress is thought to be a major contributor to neurodegeneration and depression (Bishop 
et al. 2010), thus antioxidants have received much interest. The roles of vitamin C  
(Luchsinger et al. 2003; Devore et al. 2010; Hamer et al. 2011; Payne et al. 2012),  β-
carotene (Engelhart et al. 2002; Tsuboi et al. 2004; Kim et al. 2015) and vitamin E 
(Morris et al. 2002; Owen et al. 2005; Banikazemi et al. 2015; Farina et al. 2017) have 
been explored, but no clear conclusions can be made and further work in the form of 
intervention studies is warranted. Epidemiological studies have shown that high plasma 
vitamin E concentrations are associated with better cognitive outcomes. The protective 
mechanisms associated with high plasma vitamin E concentrations are thought to go 
beyond their anti-oxidant functions, as they are also postulated to regulate signal 
transduction between neurons, decrease expression of the Amyloid Precursor Protein 
binding protein as well as regulating genes involved in the formation of neuronal cells 




intervention with vitamin E (in the form of alpha-tocopherol) prevents either progression 
of cognitive impairment to dementia or improves cognitive function in those with MCI; 
however evidence from a single study suggests that it may slow functional decline in 
Alzheimer’s disease (Farina et al. 2017). The postulated roles of vitamin D and B-
vitamins have been more fully investigated in relation to their effects on brain health in 
ageing.  
 
Following the discovery of the vitamin D receptor in the brain (Eyles et al. 2005), 
evidence for the role of vitamin D in brain health has been accumulating. Systematic 
reviews and meta-analyses have shown that AD sufferers have lower serum vitamin D 
status than healthy controls, and that low serum 25-hydroxyvitamin D (25OHD status is 
associated with worse cognitive outcomes (van der Schaft et al. 2013; Annweiler et al. 
2013a; Annweiler et al. 2013b). Recent longitudinal studies with mean follow-up periods 
of over 4 years found that lower 25OHD status was also associated with declining MMSE 
scores and accelerated cognitive decline (Toffanello et al. 2014; Miller et al. 2015). 
Furthermore, Hooshmand et al. used MRI to demonstrate that higher 25OHD status was 
associated with greater brain volumes (2014), which is generally regarded as a valid 
marker of disease state and progression. A U-shaped relationship between 25OHD 
concentrations and cognition has been suggested within a prospective cohort of adults 
(>70*), where both lowest and highest concentrations of 25OHD were associated with an 
increased risk of cognitive impairment (Granic et al. 2015). Research investigating the 
role of vitamin D in depression is much less clear. Large cross-sectional and prospective 
studies reported that lower serum 25OHD status was associated with an increased risk of 
depression (Williams et al. 2014; Brouwer-Brolsma et al. 2016). One detailed systematic 
review, which included cross sectional, prospective and RCT data, concluded that lower 




c) One-carbon metabolism and related B-vitamins 
Historically, B-vitamin deficiencies, in particular folate (Carney 1967; Reynolds et al. 
1970) and vitamin B12 (Strachan and Henderson 1965; Shorvon et al. 1980), and to a 
much lesser extent vitamin B6 (Carney et al. 1982a), have been linked with poorer 
psychiatric wellbeing. Furthermore, Vitamin B12 deficiency is most commonly 
associated with peripheral neuropathy (Reynolds 2006). These B-vitamins play crucial 
roles in one-carbon metabolic pathways where they act as co-factors in DNA synthesis 
and repair, amino acid metabolism and methylation reactions, including the remethylation 
of homocysteine (Hcy) to methionine and subsequent generation of S-
adenosylmethionine (SAM). SAM, the universal methyl donor, is involved in the 
methylation of DNA, phospholipids, proteins and neurotransmitters, thus reduced status 
of one or more of the B-vitamins (Table 1) involved in one-carbon metabolism may 
impair this metabolic pathway, thus increasing Hcy and 5-methyltetrahydrofolate 
concentrations and disrupting methylation processes (Selhub et al. 2000; Bottiglieri et al. 
2000). The inhibition of methylation reactions may in turn influence cognitive 
impairment in ageing in various ways (Smith and Refsum 2016), by perturbing the 
regulation of gene expression in the Beta amyloid pathway, by reducing the activity of 
protein phosphatase-2A or by impairing the formation of phosphatidylcholine enriched 
omega-3 fatty acids (Smith and Refsum 2016). Additionally, reduced tissue concentration 
of SAM may be linked to depression through perturbing monoamine (serotonin, 
dopamine and noradrenaline) synthesis and methylation (Bottiglieri et al. 2000). Apart 
from folate, vitamins B12 and vitamin B6, which have well-recognised roles in these 
pathways, riboflavin (in its co-factor forms flavin adenine dinucleotide, FAD and flavin 
mononucleotide, FMN) is also essential in one-carbon metabolism but its potential role 





Numerous observational studies have shown that lower status of folate, vitamin B12 and 
vitamin B6 (and/or higher concentrations of Hcy) are associated with cognitive deficit in 
ageing as extensively reviewed elsewhere (Smith and Refsum 2016; Porter et al. 2016). 
Furthermore, meta-analyses of prospective studies (Wald et al. 2011; Nie et al. 2014; 
Beydoun et al. 2014) also support the view that higher Hcy concentrations (a marker of 
low status of folate, vitamin B12, vitamin B6 and riboflavin) is a predictor of cognitive 
decline . RCTs in older adults (≥50 years) that include intervention with high-dose folic 
acid, vitamin B12 and vitamin B6 over 2 years or more have shown, not only improved 
cognitive performance (Durga et al. 2007; Smith et al. 2010; de Jager et al. 2012; Douaud 
et al. 2013), but also a reduced rate of brain atrophy in studies which have incorporated 
MRI (Smith et al. 2010; Douaud et al. 2013). Notably the greatest slowing in atrophy 
(53%) was seen among participants with MCI and the highest Hcy concentrations at 
baseline (>13µmol/L), while cognitive function was preserved in those supplemented 
with B-vitamins and with a baseline Hcy concentration >11.3 µmol/L (de Jager et al. 
2012). The RCT evidence is not entirely consistent, however, as one recent and rather 
controversial meta-analysis in this area concluded that neither folic acid nor vitamin B12 
had a beneficial effect on cognition in older adults (≥50 years)  (Clarke et al. 2014). This 
paper was however widely criticised at the time of publication, mainly as a result of the 
inclusion criteria used to select the trials for investigation, and thus the findings are in 
general not widely accepted by experts in this area (Garrard and Jacoby 2015; Smith et 
al. 2015). It is clear that further appropriately designed RCTs are needed, especially those 
targeting participants with low B-vitamin status (and in those at most risk of cognitive 
decline) as they are likely to benefit the most from optimising B-vitamin concentrations 
to achieve better cognitive health in ageing. Furthermore, research investigating the 
protective role of riboflavin on cognitive function is greatly lacking, albeit some evidence 




associated with cognitive impairment (Carney et al. 1982b; Xiu et al. 2012). Clearly there 
is a need for riboflavin to be considered in future RCTs.  
The role of B-vitamins in depressive disorders has not received as much interest as studies 
of cognitive disorders, although some observational (Table 2) and intervention (Table 3) 
evidence exists. A meta-analysis of 19 observational studies concluded that low folate 
status was associated with a significantly greater risk of depression (Gilbody et al. 2007). 
Low dietary intakes (≤4.5 µg/d; <5.4 µg/d; (Sánchez-Villegas et al. 2009; Skarupski et 
al. 2010a) or biomarker status (lowest quintile serum vitamin B12; serum B12 <180 
pmol/L;  (Reynolds 2006; Kim et al. 2008; Ng et al. 2009a; Robinson et al. 2011) of 
vitamin B12 have also been linked with an increased risk of developing depression. Only 
a limited number of studies have considered the role of vitamin B6, but available evidence 
suggests an inverse association between vitamin B6 biomarker status (plasma pyridoxal 
5'-phosphate) and depression (Hvas et al. 2004; Merete et al. 2008; Skarupski et al. 
2010a). Far less evidence exists in relation to riboflavin, although one early study reported 
lower biomarker status of riboflavin in psychiatric inpatients (Carney et al. 1982a). A 
number of RCTs have considered the role of B-vitamin supplementation alone (Ford et 
al. 2008; Walker et al. 2010; Almeida et al. 2010; Okereke et al. 2015) or as an adjunct 
to anti-depressant medications (Coppen and Bailey 2000; Almeida et al. 2014). The 
results are somewhat conflicting, however, and no clear conclusions have emerged, partly 
because of major methodological differences among studies. Reviews of the available 
evidence in relation to depression have concluded that folate and vitamin B12 may have 






Overall, there is considerable evidence to suggest that folate, vitamin B12 and vitamin 
B6 have protective effects on cognitive function, and potentially against depressive 
symptoms in ageing, however further RCTs of appropriate duration in suitable 
populations, and ideally interventions combining all four relevant B-vitamins, are 
required to support these findings.  
 
4. Genetic Factors 
Genetic factors have been identified as a non-modifiable risk factor for dementia and 
depression. Specifically, the APOE-4 allele on chromosome 19q3 is the only genetic 
factor that has unequivocally been identified to increase the susceptibility to late onset 
Alzheimer’s (Brouwers et al. 2008); furthermore some work also suggests it is associated 
with an increased risk of depression (Skoog et al. 2015). Genome-wide association 
studies for Alzheimer’s disease have been conducted and have identified other 
susceptibility genes including CLU, CR1, PICALM, BIN1, ABCA7, MS4A, CD33, 
EPHA1 and CD2AP (Reitz and Mayeux 2014), although to date there is no definitive 
association with major depression (Flint and Kendler 2014). The 
Methylenetetrahydrofolate Reductase (MTHFR) C677T polymorphism has also received 
attention as a risk factor for Alzheimer’s disease and depression (Rai 2017a). As noted 
earlier this enzyme plays a unique role in the one carbon metabolic pathway where it 
irreversibly catalyses 5, 10-methylenetetrahydrofolate to 5, methyltetrahydrofolate in the 
presence of its cofactor flavin adenine dinucleotide (FAD). The MTHFR C677T 
polymorphism results in an amino acid change from alanine to valine, which results in a 
thermo-labile enzyme and thus those with the “TT” genotype have a 70% reduction in the 
activity of this enzyme compared to those with CC phenotypes (Frosst et al. 1995). Recent 




an increased risk of Alzheimer’s disease however only insufficient evidence for its 
association with depression (Rai 2017a; Rai 2017b). 
 
5. Use of Novel Imaging Technologies in Nutrition and Brain Research 
Following the 2009 Nutrition and Mental Performance Task Force of the European 
Branch of the International Life Sciences Institute (ILSI Europe) workshop, a 
recommendation was developed suggesting the inclusion of brain imaging biomarkers as 
secondary endpoints to clinical and cognitive measures (de Jager and Kovatcheva 2010). 
Brain imaging techniques have been increasingly utilised in recent years and provide an 
objective and highly robust means of assessing brain structure, function and response to 
nutrition, with advantages and disadvantages associated with each of their use, as 
reviewed in detail elsewhere (Sizonenko et al. 2013) (Table 4). Electroencephalography 
(EEG) and magnetoencephalography (MEG) are two similar techniques for functional 
brain imaging and have the highest temporal resolution compared to other imaging 
techniques.  
 
In recent years, some of these brain-imaging techniques have been utilised to advance 
nutrition research in ageing. One notable study referred to earlier in this review (Smith et 
al. 2010) effectively used MRI and confirmed the beneficial effects of B-vitamins on 
cognition shown previously in older adults (≥ 70years) with MCI, in particular in those 
with good status of PUFA (Jernerén et al. 2015). Additionally, Brickman used fMRI and 
demonstrated higher brain activation in specific regions of the brain in participants who 
consumed high dose cocoa flavanols (2014). In a study of 239 older adults (≥ 65 years), 
diffusion tensor imaging (which in some cases has been suggested to be a better predictor 
of cognitive decline than other biomarkers) (Selnes et al. 2013), identified better white 




al. 2016). EEG has also been used, with one recent report showing improved memory and 
functional connectivity in the delta band in response to Souvaid®, a nutritional 
supplement containing PUFAs uridine, choline, phospholipids, folic acid, vitamin B6, 
B12, C, E and selenium in Alzheimer type patients who were not treated ACE inhibitors 
and/or memantine with MMSE scores between 20 -26 (Ritchie et al. 2014). Positron 
Emission Tomography Imaging (PET) has also been conducted within a 3-week 
intervention study, albeit in a very small study of only 11 women, leading to the 
conclusion that omega 3 supplementation did not affect brain glucose metabolism in 
healthy older people (76 ± 3 years) (Nugent et al. 2011).  
 
It is clear that imaging techniques provide an objective means to improve the evidence 
base in this area, in particular in relation to proposed mechanisms. At this time, however, 
the number of studies utilising brain-imaging techniques to investigate the role of diet in 
brain health in ageing are limited. MEG has been approved by the US Food and Drug 
Administration (FDA) for use within clinical and research settings as a means to assess 
and investigate cognitive dysfunction (Maestú et al. 2008), AD (de Haan et al. 2012; 
Cheng et al. 2012)  and depression (Kurita et al. 2016). However, to our knowledge, no 
work has been published using MEG for nutrition studies in older adults (≥60 years). The 
application of these new technologies in the field of nutrition, in combination with clinical 
and questionnaire-based assessments, could provide much potential for robust 
investigation in future studies, furthering knowledge and discovery.  
 
Conclusions and Public Health Implications 
Nutrition has important roles in preserving cognition and reducing the risk of late life 
depression. Emerging evidence in this area implicates subclinical deficiencies of certain 




the gaps in the literature, in particular in identifying of the threshold for optimal nutrient 
levels required to prevent or delay declining brain health. At this time, the evidence for 
potential protective effects is strongest in relation to B-vitamins, n-3 PUFAs and 
polyphenols. If confirmed, a public health strategy to improve status of these key nutrients 
may help to achieve better cognitive and mental health and thus improve quality of life 
in older age. Future well-designed RCTs (ideally incorporating imaging techniques such 
as MEG) may provide a more robust basis for confirming effective nutrition 
interventions, which if implemented could reduce the risk of cognitive and mental health 
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Table 1. B-vitamin biomarker cut offs 
B-vitamin Biomarker Cut off for deficiency Reference 
Serum folate <6.1nmol/L (Molloy and Scott 1997) 
Red blood cell folate <340 nmol/L (Molloy and Scott 1997) 
Serum vitamin B12 <148 pmol/L (Kelleher and Broin 1991) 
Vitamin B6 <30 nmol/L (Bates et al. 1999) 
Riboflavin >1.3 (Powers et al. 1983) 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Folate and related B-vitamins in relation to mental health 
in older adults from the TUDA cohort study 
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Abstract 
Background: Mental health disorders are major contributors to disease burden in older 
people. Low/deficient status of folate and/or metabolically related B-vitamins may play 
a role.  
Aim: To investigate folate, vitamin B12, vitamin B6 and riboflavin in relation to 
depression and anxiety in ageing. We also considered the role of fortified foods as a 
means of optimising B-vitamin status and potentially reducing the risk of these mental 
health disorders.  
Methods: A cross-section analysis was conducted on community-dwelling adults (60-
101 years old) who were recruited to the Trinity Ulster Department of Agriculture 
(TUDA) ageing cohort study (n = 5186); ClinicalTrials.gov Identifier: NCT02664584.  
Depression and anxiety were assessed using the CES-D scale and the HADS, 
respectively. B-vitamin biomarker status was assessed. All statistical analyses were 
performed using SPSS software (Statistical Package for Social Sciences, Version 23.0, 
SPSS UK Ltd., Chersey, United Kingdom). The risk of depression (CES-D score ≥16) 
and anxiety (HADS score ≥11) in relation B-vitamin biomarker status was determined 
using logistic regression and the model was adjusted for relevant co-variates and vitamin 
supplement use. 
Results: Participants with a biomarker value in the lowest 20% of status for folate 
(OR=1.79, 95% CI 1.23-2.61), vitamin B6 (OR=1.45, 95% CI 1.01-2.06) or riboflavin 
(OR=1.56, 95% CI 1.10-2.00), but not vitamin B12, were at increased risk of depression 
(CES-D score ≥16). Correspondingly, B-vitamin fortified foods were associated with a 
reduced risk of depression if consumed daily (OR=0.535, 95% CI 0.41-0.70). A 
low/deficient status of vitamin B6 (OR=1.73, 95% CI 1.07-2.81), but not other vitamins, 
was associated with increased anxiety.  
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Conclusions: The findings suggest that a B-vitamin biomarker status above defined cut-
off levels (folate ≥1520nmol/L, vitamin B6 >35.6nmol/L, riboflavin <1.46), plays a role 
in improving mental health in older adults. Regular intake of fortified foods can provide 
a means of optimising B-vitamin status and potentially reducing the risk of depression in 
older adults. Randomised trials are needed to confirm these observational findings. 
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Introduction 
Globally the population is ageing and by 2050 the number of people aged ≥60 years is 
predicted to reach 2.1 billion (United Nations Department of Economic and Social 
Affairs/Population Division 2015). Mental health disorders are a leading cause of 
disability and ill health in older age (Andreas et al. 2016). and are estimated to affect 20% 
of adults ≥60 years worldwide (World Health Organisation 2016), Given the considerable 
human and economic cost of mental health conditions and the generally poor response 
rates to costly pharmacological treatments (Rush et al. 2006), there is much interest in the 
potential roles of certain dietary components as modifiable risk factors for depression. 
Folate and vitamin B12 have received particular attention in this regard (Moore et al. 
2017). These B-vitamins have interrelated roles within one-carbon metabolism, where 
folate in the form of 5 MTHF and vitamin B12 in the form of methylcobalamin are 
required for the remethylation of Hcy to methionine which subsequently forms SAM 
(Bailey et al. 2015). SAM, in turn, is the essential methyl donor required for the 
production of monoamine neurotransmitters, phospholipids and nucleotides (Bottiglieri 
and Reynolds 2005). Historically, clinical deficiencies of folate and the related B-
vitamins were associated with a range of neuropsychiatric symptoms, including 
depression (Reynolds et al. 1970), raising the possibility that optimising relevant B-
vitamin intake and status could improve mental health. Research to date in this area has 
focused predominantly on folate, and to a lesser extent vitamin B12 (Petridou et al. 2016), 
whereas related B-vitamins, also required for one-carbon metabolism i.e. vitamin B6 and 
riboflavin, have received much less attention. The aim of this study therefore was to 
investigate biomarker status of all relevant B-vitamins - folate, vitamin B12, vitamin B6 
and riboflavin - in relation to mental health in ageing. Furthermore, we considered the 
role of fortified foods as a means of optimising B-vitamin status and potentially reducing 




The study involved new analysis of data from the TUDA ageing cohort study 
(ClinicalTrials.gov Identifier: NCT02664584). As described in detail elsewhere (McCann 
et al. 2018), 5,186 community-dwelling adults aged ≥ 60 years were recruited to the 
TUDA study between 2008 and 2012 from Northern Ireland (NI) and the Republic of 
Ireland (RoI). One of the aims of the TUDA study was to investigate the role of nutrition 
and lifestyle factors in the aetiology of common age-related diseases; namely, dementia, 
osteoporosis and cardiovascular disease (CVD). Thus, the TUDA study consists of three 
cohorts; cognitive, bone and hypertensive. The cognitive and bone cohort were recruited 
from the Department of Medicine for the Elderly at St. James’s Hospital, Dublin. Those 
in the cognitive impairment cohort had an RBANS score <80 and were recruited from 
geriatric clinics or day hospital services while the bone cohort participants had diagnoses 
of either osteoporosis or osteopenia and were recruited from the specialist bone health 
services (St. James Hospital, Dublin). Those in the hypertension cohort had a diagnosis 
of hypertension and were recruited form Western and Northern Health and Social Care 
Trusts in Northern Ireland. 
Participants were recruited in both jurisdictions using standardised protocols and 
centralised training, and deemed suitable if they (or their parents) were born on the island 
of Ireland and were without a diagnosis of dementia. Those who provided informed 
consent were deemed eligible to participate. For the current study, any participants 
receiving vitamin B12 injections were excluded from the analysis (Figure 1). 
Ethical approval for the TUDA study was granted by the Office for Research Ethics 
Committees Northern Ireland (ORECNI; reference 08/NI/RO3113), with corresponding 
approvals from The Northern and Western Health and Social Care Trusts in NI, and the 
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Research Ethics Committee of St James Hospital and The Adelaide and Meath Hospital 
in Dublin. 
General health, lifestyle and biophysical measures 
Health and lifestyle information was gathered using a detailed, researcher-assisted, 
questionnaire and included information on age, smoking, alcohol, medical history, drugs 
including antidepressant medications, proton pump inhibitors and vitamin supplement 
use. Anthropometric measurements were recorded (including weight, height, waist and 
hip) and blood pressure (BP) measurements were taken in accordance with standard 
operating procedures by trained researchers. In brief, in accordance with clinical 
guidelines, two measurements were taken from the reference arm (the arm with the 
highest BP reading) with a 5‐10 minute interval between each measurement; the mean of 
the two readings was used as the BP value.  The Timed Up-and-Go (TUG) test was 
performed as a measure of functional mobility. Participants were asked to stand from a 
seated position (seat height approximately 46 cm), walk 3 m at their usual pace, turn 
around, walk back to the chair, and sit down. No physical assistance was given, and the 
time taken from command “Go” to complete the task was measured with a stopwatch 
(Podsiadlo and Richardson 1991). The functional abilities of the participants were also 
assessed using the Physical Self-Maintenance Scale (PSMS) and the Instrumental 
Activities of Daily Living (IADL) scale. Area-level socioeconomic deprivation was also 
measured by adopting a cross-jurisdictional approach, whereby geo-referenced address-
based information was used to map and link participants to official socioeconomic 
indicators of deprivation within NI and RoI (McCann et al. 2018). As previously 
described in detail (McCann et al. 2018), participants in each jurisdiction were assigned 
a deprivation score relating to the area in which they lived and scores were categorised 
into comparable quintiles, which were then used to integrate the datasets from both 
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countries, providing deprivation data for the TUDA cohort as a whole ranging from the 
20% least to 20% most deprived areas. 
Dietary assessment 
Dietary information on habitual intake of certain foods was collected using a researcher-
assisted food frequency questionnaire (FFQ). This procedure allowed assessment of the 
frequency of consumption of specific foods including products known to be fortified with 
B-vitamins. Brand names of products were collected so that up-to-date details on relevant 
nutrient profiles could be obtained. Using this approach, participants were categorised 
according to intake of fortified foods and classed as non-consumers (0), low (1-4), 
medium (5-7) or high (8+) consumers based on servings of fortified foods per week.  
Vitamin supplement use was also recorded and participants were asked to bring specific 
products to their appointment so that accurate information on supplement usage including 
brand name, dose, frequency, and duration of use could be recorded. Where this 
information could not be confirmed at interview, it was followed up in a subsequent 
telephone call. 
Neuropsychiatric assessment 
Depression was assessed using the CES-D scale, which is a 20 item self-reported 
questionnaire, with a minimum score of 0 (no symptoms of depression) and maximum 
score of 60 (significant symptoms of depression). A score greater than or equal to 16 was 
used as a cut-off value suggestive of clinical depression (Radloff and Locke 1986). 
Anxiety was assessed using the 7 item HADS, with a minimum score of 0 (suggestive of 
no symptoms of anxiety) and a maximum score of 21 (significant anxiety). A score greater 
than or equal to 11 was used as a cut-off value for probable anxiety (Zigmond and Snaith 
1983). 
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For the purpose of the current analysis, cognitive function was assessed using the 
Folstein MMSE (Folstein et al. 1975), a short, structured cognitive test. The MMSE is 
the most widely used screening tool in clinical settings worldwide for identifying 
cognitive impairment and dementia and evaluates global cognitive function by assessing 
the domains of orientation, registration, attention and concentration, recall and language 
(Sheehan 2012; Roebuck-Spencer et al. 2017). The maximum score achievable is 30, with 
a score <25 indicating a possibility of cognitive impairment and a score <20 indicating 
dementia. 
Blood sampling and laboratory analysis 
A non-fasting blood sample (50ml) was obtained and analysed for routine clinical 
markers of health in participating hospital laboratories. For research biomarkers, all blood 
processing was carried out within 4 hours of collection and B-vitamins were analysed 
centrally in laboratories at Trinity College Dublin (vitamin B12, folate, Hcy) or Ulster 
University (vitamin B6, riboflavin) using established methods.  Red blood cell (RBC) 
folate and serum total vitamin B12 were measured by microbiological assay using 
Lactobacillus casei and Lactobacillus Leichmanni, respectively (Kelleher and Broin 
1991; Molloy and Scott 1997). Plasma Hcy was measured by fluorescence polarization 
immunoassay (Leino 1999). Riboflavin status was measured by erythrocyte glutathione 
reductase activation coefficient (EGRac), a functional assay that measures the activity of 
glutathione reductase before and after in-vitro reactivation with its prosthetic group flavin 
adenine dinucleotide, where a higher EGRac ratio indicates a lower riboflavin status 
(Powers et al. 1983). Vitamin B6 status (plasma pyridoxal-5-phosphate, PLP) was 
analysed by HPLC with fluorescence detection (Bates et al. 1999). For each assay, quality 
controls were provided by the repeated analysis of pooled samples covering a wide range 
of values. 
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Participants were given instructions to swab the inside of their cheeks with the 5 
cotton swabs to provide samples for DNA analysis of single nucleotide polymorphisms 
(SNPs). This included assessment for the common MTHFR polymorphism 677C>T 
(Frosst et al. 1995), which was identified by polymerase chain reaction followed by Hinfl 
digestion and polyacrylamide gel electrophoresis (conducted by LGC Genomics; Herts, 
United Kingdom). 
Statistical Analysis 
All statistical analysis was performed using SPSS software (Statistical Package for Social 
Sciences, Version 23.0, SPSS UK Ltd., Chersey, United Kingdom). Data were checked 
for normality and log-transformed as appropriate. Analysis of covariance with Bonferroni 
post hoc test was used for analysis of continuous data and chi-squared tests were used for 
categorical variables. Relationships of demographic, clinical and lifestyle factors with 
depression (CES-D score) and anxiety (HADS score) were investigated using multiple 
linear regression analysis. The risk of depression (CES-D score ≥16) and anxiety (HADS 
score ≥11) in relation B-vitamin biomarker status was determined using logistic 
regression and the model was adjusted for vitamin supplement use and relevant co-
variates (age, gender, age finished education, area-level socioeconomic deprivation, 
smoking, physical frailty, living alone, antidepressant usage, and previous ischaemic 
attack, BMI, hypertension). For this purpose, B-vitamin biomarkers were examined in 
quintiles ranging from lowest 20% to highest 20% of values. For all analysis P ≤ 0.05 
was considered significant. The risk of depression (CES-D score ≥16) and anxiety (HADS 
score ≥11) in relation to B-vitamin fortified food intake was determined using logistic 
regression and the model was adjusted for relevant co-variates (age, gender, age finished 
education, area-level socioeconomic deprivation, smoking, physical frailty, living alone, 
antidepressant usage, and previous ischaemic attack, BMI, hypertension). The reference 
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category for logistic regression analysis were non-consumers of fortified foods, against 
which low (1-4 portions/week), medium (5-7 portions/week), and high consumers (8+ 
portions/week), were compared. These specific categories of portions of fortified 
food/week were utilised as they have been previously been reported in the literature in 




The general characteristics of the study population are described in Table 1. Participants 
were predominantly female (67%), the majority were fortified food consumers (71.6%) 
and 10.9% were B-vitamin supplement users. Overall, higher rates of depression (CES-
D score ≥16.0) and anxiety (HADS score ≥11.0) were recorded in females compared to 
males; likewise self-reported depression and anxiety were also higher in females. Males 
were more likely to have a history of medical conditions such as diabetes, 
hyperlipidaemia, hypertension, myocardial infarction and previous stroke.  B-vitamin 
biomarker status was generally lower, and Hcy concentrations higher, in men compared 
to women. Although mean B-vitamin biomarker concentrations from this TUDA cohort 
fell within normal reference ranges (data not shown), using accepted laboratory cut-offs 
some evidence of deficiencies were identified for specific B-vitamin biomarkers: folate 
(RBC folate ≤ 340nmol/L: 2.3%); vitamin B12 (serum B12 ≤ 145pmol/L: 11.6%); 
vitamin B6 (PLP ≤ 30nmol/L: 12.2%); riboflavin (EGRac ≥1.3; 48.6%). 
B-vitamin intakes in relation to biomarker status 
The influence of B-vitamin fortified food and supplement intake on B-vitamin biomarker 
status (Table 2), in addition to the frequency of consumption of fortified food groups (per 
quintiles of biomarker status) was determined (Table 3). Participants were categorised 
based on their self-reported intake of B-vitamin fortified foods as low, medium or high 
consumers, and as users or non-users of B-vitamin supplements; ‘non-consumers’ did not 
consume fortified foods or supplements and hence depended on natural food sources of 
B-vitamins only. As dietary intake of B-vitamin fortified foods increased, the biomarker 
status increased in a stepwise manner with the highest B-vitamin biomarker status being 
observed in those participants who consumed 8 or more portions of fortified foods per 
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week and in those taking B-vitamin supplements. B-vitamin supplement users were 
identified on the basis of their reported current use; of those identified as supplement 
users (10.8% of overall TUDA sample) the majority also consumed fortified food. A 
small number of participants (n = 110; 2.2%) could not be classified as regards fortified 
food intake and supplement use and thus were excluded from the analysis investigating 
the effect of B-vitamin intake on biomarker status.  
 
Relationships of demographic, clinical and lifestyle factors with depression and anxiety 
The relationship of clinical and lifestyle factors with depression (CES-D score) and 
anxiety (HADS score) was examined by linear regression (not shown). The following 
factors were significantly associated with depression; age (β -0.99; P < 0.001), female 
sex (β 0.04; P = 0.008), age finished education (β -0.06; P < 0.001), area-level 
socioeconomic deprivation (β 0.09; P < 0.001), smoking (β 0.05; P = 0.001), physical 
frailty (β 0.19; P < 0.001), living alone (β 0.08; P < 0.001), antidepressant usage (β 0.21; 
P < 0.001), and previous transient ischaemic attack (β 0.04; P = 0.02). For anxiety, the 
following factors were identified as significant determinants; age (β -0.138; P < 0.001), 
female sex (β 0.08; P < 0.001), age finished education (β -0.10; P < 0.001), area-level 
socioeconomic deprivation (β 0.08; P < 0.001), BMI (β -0.05; P < 0.001), hypertension 
(β 0.04; P = 0.027) and anti-depressant usage (β 0.18; P < 0.001).  
 
Risk of depression and anxiety in relation to B-vitamin biomarkers, fortified food intake 
and supplement use 
The risk of depression (CES-D score ≥16) by B-vitamin biomarker status was examined 
after adjustment for the above co-variates and vitamin supplement use (Figure 2). Each 
B-vitamin was examined in quintiles of biomarker status and the general characteristics 
of the each quintile were explored (Table 4). The reference category was set at the highest 
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20% of values and Hcy was examined in quintiles of concentration. Compared with the 
reference category, those in the lowest quintile of RBC folate (OR = 1.79, 95% CI 1.23-
2.61; P = 0.002), vitamin B6 (OR = 1.45, 95% CI 1.01-2.06; P = 0.043) or riboflavin (OR 
= 1.56, 95% CI 1.10-2.00; P = 0.012) status were at significantly increased risk of 
depression. The risk of depression was found to be significantly increased in participants 
with the variant 677TT genotype for MTHFR, but only when this genotype occurred in 
combination with low status of riboflavin (i.e. the precursor of FAD required as a co-
factor for MTHFR): OR = 1.51, 95% CI 1.02-2.22; P = 0.038. No significant relationship 
with depression scores were identified in those with the CC or CT genotype (data not 
shown).  No statistically significant association between serum total B12 or Hcy was 
observed with depression. 
The risk of depression was also examined in relation to B-vitamin fortified food intake 
(Figure 2); for this purpose the reference category was non-consumers. Compared to non-
consumers (reliant on natural food sources of B-vitamins), among those who consumed 
8 or more portions per week of fortified food (but not lower amounts) the risk of 
depression was reduced (OR = 0.535, 95% CI 0.41-0.70; P < 0.001). After adjustment for 
relevant co-variates including fortified food intake, B-vitamin supplement usage was not 
associated with depression risk (OR = 0.941, 95% CI 0.68-1.30; P = 0.712). 
Similarly, the relationship of B-vitamins with risk of anxiety was examined in quintiles 
of biomarker status (data not shown). After adjustment for relevant co-variates and 
vitamin supplement use, only low/deficient status of B6 - but not other B-vitamins or Hcy 
concentrations were associated with an increased risk of anxiety (OR = 1.73, 95% CI 
1.07-2.81; P = 0.024) and there was no significant association of the MTHFR 677TT 
genotype with anxiety (data not shown). Likewise, no significant relationship was 
identified between B-vitamin fortified food intake (OR = 0.97, 95% CI 0.69-1.36; P = 




This study is the first large cross sectional study to investigate all four B-vitamins 
involved in one-carbon metabolism in relation to depression and anxiety in older adults. 
The findings show that low/deficient biomarker status of folate, vitamin B6 or riboflavin, 
but not vitamin B12, were each independently associated with an increased risk of 
depression. Correspondingly, the risk of depression was lower by 50% among 
participants who consumed at least one portion per day of B-vitamin fortified food. Only 
low/deficient status of vitamin B6 (but not the other B-vitamins) was associated with the 
risk of anxiety, and no significant relationship of fortified food with anxiety was shown. 
Comparison of findings with other studies investigating B-vitamins in relation to 
depression 
The current results showed 78% increased risk of depression among those with the lowest 
20% of RBC folate concentrations, adding to the increasing body of evidence linking low 
folate with depression. In one meta-analysis of 11 observational studies (n = 15,315 
participants), low folate biomarker status was associated with a 42% increased risk of 
depression (Gilbody et al. 2007a). Furthermore, a more recent meta-analysis of adults 
≥55 years (n = 8000) found that low serum folate concentrations were associated with a 
significantly higher risk of depression (OR = 1.23; 95% CI: 1.07-1.43) (Petridou et al. 
2016). The stronger relationship of folate with depression identified in the current study 
when compared with the aforementioned studies (Gilbody et al. 2007a; Petridou et al. 
2016), may be explained to some extent by the use of RBC folate, generally considered 
to be a better index of long-term folate status compared to plasma or serum concentrations 
(Bailey et al. 2015). The evidence linking folate with depression is however not entirely 
consistent. The Chicago Health and Aging Study (CHAP) (n = 3503) and the Quebec 
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longitudinal study on nutrition and Aging (NuAge) (n = 1368) found no association of 
folate with depression; however these observations were based on dietary intake data only 
with no corresponding folate biomarkers (Skarupski et al. 2010; Gougeon et al. 2016). 
Furthermore, the studies were conducted in regions with mandatory folic acid 
fortification, where more optimal folate biomarker status throughout the population 
would make a relationship with depression less likely. Despite the close metabolic 
relationship between folate and vitamin B12, the current study found no association of 
serum vitamin B12 with depression, which is in line with the findings from one large 
cohort study (n = 2,524) conducted in the USA (Beydoun et al. 2010), but at odds with 
other research which reported inverse associations of vitamin B12 intake (Skarupski et 
al. 2010; Gougeon et al. 2016) or biomarkers (Kim et al. 2008) with depression. The 
explanation for such discrepancy in the evidence linking vitamin B12 with depression is 
unclear, but may possibly relate to differences in B12 status among populations under 
investigation or methodological variation among studies, including the use of different 
B12 biomarkers to measure status, especially considering that no consensus exists as to 
the best biomarker for assessing B12 status in the laboratory. 
The current results showed that low status of vitamin B6 or riboflavin was associated with 
an increased risk of depression by up to 56%. Likewise, previous studies have reported 
inverse associations of vitamin B6 biomarkers with depression (Merete et al. 2008). In 
contrast to the other relevant B-vitamins, riboflavin has received very little attention as 
regards its potential role in depression, with previous evidence limited to one early study 
which reported that 27% of patients admitted to a psychiatric inpatient unit had riboflavin 
deficiency, whilst a recent study showed no significant relationship of dietary riboflavin 
intake with depression (Carney et al. 1982; Murakami et al. 2008). There is a well 
established metabolic dependency of vitamin B6 on provision of adequate riboflavin, in 
that the generation of the active B6 form, PLP, in tissues (via pyridoxine 5’phosphate 
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oxidase) requires riboflavin in its co-factor form of flavin mononucleotide (FMN). We 
previously confirmed this interrelationship in humans by showing that riboflavin 
supplementation of older adults not only improved biomarker status of riboflavin, but also 
enhanced vitamin B6 concentrations, suggesting that riboflavin may be the more limiting 
nutrient (Madigan et al. 1998). Previous studies have reported a significantly increased 
risk of depression among individuals homozygous for the common C677T polymorphism 
in MTHFR (Bjelland et al. 2003), whereas the current study found that the risk of 
depression was significantly increased only when this genotype occurred in combination 
with low status of riboflavin (i.e. which acts as cofactor for MTHFR). Indeed the 
importance of this gene-nutrient interaction for health outcomes has previously been 
reported by us in human trials showing that riboflavin supplementation results in 
significant blood pressure lowering only in those with the variant MTHFR 677TT 
genotype (McNulty et al. 2002). 
Given the interactions of riboflavin with vitamin B6 and with folate (via MTHFR 
genotype) as shown here, further studies (ideally randomised trials) should investigate the 
combined effect of these vitamins in relation to depression in older adults. 
Comparison of findings with other studies investigating B-vitamins in relation to anxiety 
In the current study, low/deficient vitamin B6 status was associated with an increased risk 
of anxiety, while no significant associations with anxiety were found for any other B-
vitamin biomarkers or fortified foods. The findings are generally in line with those of the 
Hordaland Homocysteine Study (n = 5948) which also reported no significant 
relationships of folate or vitamin B12 with anxiety (Bjelland et al. 2003). Research in the 
area of vitamin B6 and anxiety has been limited and the available evidence is conflicting. 
Although an earlier study in 198 patients with anxiety disorders concluded that low 
vitamin B6 status was unlikely to be significant in the aetiology of psychiatric disorders 
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(Emmanuel et al. 1994), a more recent RCT in 60 patients, which intervened with a 
supplement containing combined B-vitamins (including vitamin B6, vitamin B12 and 
folate) in  patients suffering from depression, observed short terms benefits in symptoms 
of anxiety (Lewis et al. 2013). 
B-vitamin status and good mental health 
The current findings suggest that maintaining good biomarker status of folate and the 
related B-vitamins help to maintain good mental health in older adults. Although the aim 
of the current study was to investigate the role of these B-vitamins in relation to 
depression and anxiety and not specifically good mental health, it was found that those in 
the top 20% of biomarker status for folate, vitamin B6 and riboflavin, appeared to have 
lower depression scores (CES-D) suggestive of better mental health compared to those 
with lower biomarker status. These findings in relation to folate status are consistent with 
conclusions from the meta-analysis conducted by Gilbody (2007b) where the overall 
trend among studies was for red cell and serum folate to be higher in healthy controls 
compared to those with questionnaire assessment scores indicative of clinical depression. 
As the current and aforementioned studies do not specifically measure ‘good mental 
health’ (rather the presence of symptoms suggestive of depression), further studies which 
aim to assess the role B-vitamin status in good mental health are required. 
Public Health Implications 
The current study not only showed that low biomarker status of specific B-vitamins was 
related to mental health, but importantly demonstrated the potential use of fortified foods 
as a means of reducing the risk of depression in older age. To our knowledge, this is the 
first study which has investigated the association between fortified foods and depression 
and suggests a reduced risk of depression (by up to 54%) in those who consumed fortified 
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foods on a daily basis. Fortified foods are known to provide a highly bioavailable source 
of B-vitamins, particularly folate, in the form of folic acid (Bailey et al. 2015). The impact 
of fortified foods in achieving more optimal B-vitamin biomarker status has also been  
previously reported (Hoey et al. 2007). The current results suggest that regular 
consumption of fortified foods, by improving B-vitamin biomarkers, may provide a 
practical means of reducing the risk of depression in older adults. Furthermore, these 
findings also suggest that consumption of folic acid rather than folate found in natural 
food sources plays a greater protective role in brain health. To our knowledge no 
intervention studies have investigated the role of natural food folate on depression, 
however the current findings are in line with the limited evidence from randomised trials 
in which intervention with folic acid was found to protect against depressive symptoms 
(Coppen and Bailey 2000; Almeida et al. 2014). 
Possible mechanism explaining the findings 
The biological mechanisms explaining the current and previous results linking folate and 
metabolically related B-vitamins with mental health (and most convincingly with 
depression) may involve perturbed monoamine synthesis. Folate deficient patients 
suffering from depression have been shown to have significantly lower concentrations of 
monoamine metabolites in cerebral spinal fluid (Bottiglieri and Reynolds 2005). As folate 
and related B-vitamins are required for the generation of SAM within one-carbon 
metabolism, lower B-vitamin status may reduce the methylation of the neurotransmitters 
serotonin, dopamine and noradrenaline (Bottiglieri and Reynolds 2005). Additionally, 
folate has a role in the synthesis of tetrahydrobiopterin (BH4), an essential co-factor in 
monoamine synthesis (Bottiglieri et al. 1992). Furthermore, the active form of vitamin 
B6 (PLP) is the cofactor for aromatic L-amino acid decarboxylase in the tryptophan 
serotonin pathway, thus suboptimal B6 status may lead to reduced concentrations of 
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serotonin and thus increased risk of depression (Hensler 2006). Lastly, as previously 
noted, riboflavin in the form of FMN is required as a coenzyme for the activation of B6 
in tissues and so its relationship with depression could be mediated through vitamin B6. 
Strengths and limitations of the current study 
Although the TUDA study is one of the largest and most comprehensively characterised 
cohorts of its kind, its cross-sectional design means that the possibility of residual 
confounding cannot be excluded. Also, the CES-D scale used in this study to assess 
depression, while widely considered to have an acceptable screening accuracy in primary 
care settings, is not as robust as other diagnostic instruments and this may have limited 
the interpretation of the current findings to some extent (Vilagut et al. 2016). However, 
the current study had a number of strengths. It is the first human study to investigate the 
effect of all relevant B-vitamin biomarkers (including riboflavin, rarely assessed in cohort 
studies or nutritional surveys) on the risk of depression and anxiety in older adults, and 
thus allowed an in-depth examination of the role of one-carbon metabolism in mental 
health. Finally, this is the first study to have considered the potential role of fortified foods 
as a practical means of reducing depression in older age. 
Implications 
This study in older adults indicated that lower biomarker status of folate or vitamin B6 or 
riboflavin may contribute to an increased risk of depression in ageing, while deficient 
status of vitamin B6 was associated with an increased risk of anxiety. Higher intakes of 
B-vitamin fortified foods (e.g. fortified breakfast cereals) or B-vitamin supplement use 
resulted in the achievement of optimal B-vitamin biomarker status, while fortified foods 
consumed daily were associated with a reduced risk of depression. Further work in the 
form of well-designed RCTs, investigating the role of all B-vitamins in the one-carbon 
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metabolism network and in populations with sub-optimal B-vitamin status, are needed to 
confirm these observational findings. These results, if confirmed, may have implications 
for dietary recommendations and health policy involving low cost non-drug alternative 
means of improving mental health and thus quality of life in older adults. 
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Figure.1 Flow diagram and study design of the TUDA Ageing Cohort 
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Table 1. General characteristics of TUDA study participantsa
Adjusted means (s.e.m) or n (%) Males 
(n = 1665) 
Females 
(n = 3406) 
P 
Age (year) 73.4 (8.0) 74.3 (8.4) <0.001 
Health and Lifestyle 
BMI (kg/m2) 28.4 (0.1) 27.7 (0.01) <0.001 
Waist to Hip ratio 0.97 (0.02) 0.88 (0.01) <0.001 
Timed Up and Go (seconds) 14.1 (0.2) 14.0 (0.1) 0.461 
Physical Self Maintenance Score 23.1 (0.05) 22.9 (0.3) <0.001 
Instrumental Activities of Daily Living 24.1 (0.1) 24.1 (0.1) 0.895 
Living alone n (%) 373 (22.4) 1335 (39.2) <0.001 
Area deprivation (most deprivation) n (%) 429 (26.4) 867 (26.2) 0.856 
Current Smoker n (%) 193 (11.6) 411 (12.1) 0.651 
Alcohol (units/week) 8.8 (0.2) 2.5 (0.2) <0.001 
Proton Pump Inhibitors n (%) 608 (35.8) 1367 (39.2) 0.020 
Fortified Food Consumer n (%) 1186 (71.2) 2443 (71.7) 0.888 
B-vitamin supplement user n (%) 163 (9.8) 382 (11.4) 0.098 
Vitamin D supplement user n (%) 533 (32.1) 1867 (55.3) <0.001 
Medical 
Diabetes n (%) 311 (18.7) 327 (9.6) <0.001 
Hyperlipidaemia n (%) 919 (55.3) 1774 (52.1) 0.037 
Hypertension n (%) 1318 (79.2) 2318 (68.1) <0.001 
Previous Myocardial infarction n (%) 266 (16.0) 244 (7.2) <0.001 
Previous Transient Ischemic Attack n (%) 135 (8.1) 286 (8.4) 0.774 
Previous Stroke n (%) 189 (11.4) 199 (5.8) <0.001 
Brain Health* 
Anti-depressant drugs n (%) 169 (10.2) 542 (15.9) <0.001 
Depression score (CES-D) 5.5 (0.2) 6.3 (0.1) 0.267 
  Depression n (%) 137 (8.3) 407 (12.0) <0.001 
  Self-reported depression n (%) 325 (19.5) 893 (26.2) <0.001 
Anxiety score (HADS) 2.8 (0.1) 3.4 (0.1) 0.513 
  Anxiety n (%) 61 (3.7) 190 (5.6) 0.004 
  Self-reported anxiety n (%) 264 (15.9) 832 (24.4) <0.001 
Cognitive Score (MMSE) 27.0 (0.1) 27.1 (0.0) <0.001 
  Impairment (MMSE <25) n (%) 187 (11.9) 444 (13.5) 0.134 
Biomarker 
Red blood cell folate (nmol/L) 1043 (13.5) 1094 (9.2) 0.001 
Serum vitamin B12 (pmol/L) 263 (3.1) 288 (2.1) <0.001 
Plasma vitamin B6 (PLP; nmol/L) 65.4 (1.0) 72.0 (0.7) <0.001 
Riboflavin (EGRac) 1.34 (0.00) 1.33 (0.00) 0.146 
Plasma total Homocysteine (µmol/L) 15.2 (0.1) 14.3 (0.1) <0.001 
MTHFR  677TT genotype n (%) 192 (11.9) 405 (12.2) 0.689 
TUDA, Trinity Ulster Department of Agriculture; MMSE, Mini Mental State Examination; CES-
D, Centre for Epidemiologic Studies Depression; HADS, Hospital Anxiety and Depression Scale; 
PLP, pyridoxal 5-phosphate; EGRac, erythrocyte glutathione reductase activation co-efficient (a 
higher EGRac ratio indicates lower riboflavin status).; MTHFR methylenetetrahydrofolate 
reductase.  
a. Differences were assessed using ANCOVA with Bonferroni post hoc tests on log-transformed
data when applicable, with adjustment for age, *BMI, smoking status, alcohol, anti-depressant 
medication usage, vitamin supplement usage and fortified food. Categorical variables were 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3.  Intake of fortified food groups relative to quintiles of B-vitamin status 
Q1 Q2 Q3 Q4 Q5 
RBC folate ≤623 623-8.25 825-1084 1084-1520 1520+ 
Breakfast Cereals 38.7 42.6 50.7 52.9 54 
Cereal bars 1.3 2.5 2.7 1.9 1.8 
Bread 18.7 16.2 18.9 18.6 19.6 
Fat spread 28.0 35.0 41.8 50.7 53.2 
Drinks 5.3 7.5 12.0 20.0 32.2 
Marmite 1.2 1.5 0.8 1.1 1.1 
Serum B12 ≤177 177-235 235-290 290-373 373+ 
Breakfast Cereals 44.4 45.9 47.9 51.0 48.7 
Cereal bars 1.8 2.0 3.3 1.8 1.3 
Bread 19.3 17.7 19.2 15.7 19.3 
Fat spread 31.4 38.3 46.1 44.7 48.3 
Drinks 10.3 14.0 15.5 13.7 21.8 
Marmite 1.3 1.0 1.0 1.3 1.1 
Vitamin B6 (nmol/L) ≤35.9 35.7-51.9 51.8-70.0 70.0-96.3 96.4+ 
Breakfast Cereals 39.9 44.6 49.0 48.7 56.5 
Cereal bars 2.1 1.8 1.9 2.2 2.3 
Bread 22.7 19.0 17.6 15.4 16.5 
  Fat spread 26.9 32.9 42.4 35.3 56.3 
Drinks 9.2 12.7 15.4 18.4 18.6 
Marmite 0.7 1.5 1.3 0.9 1.1 
Riboflavin (EGRac) 1.45+ 1.34-1.45 1.27-1.33 1.20-1.26 ≤1.19 
Breakfast Cereals 35.1 44.1 45.0 52.3 60.1 
Cereal bars 2.4 2.1 1.9 2.2 1.8 
Bread 20.2 16.8 18.3 16.7 18.8 
Fat spread 37.9 41.9 40.9 41.7 45.1 
Drinks 9.5 11.2 15.3 18.1 21.1 
Marmite 1.2 0.8 1.4 0.9 1.4 
Data presented as % of participants that reported to have consumed specific fortified 
food group within each biomarker quintile. EGRac, erythrocyte glutathione reductase 
activation co-efficient (a higher EGRac ratio indicates lower riboflavin status) 
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Table 4 .General descriptive for each quintiles of all B-vitamin biomarker status 
Q1 Q2 Q3 Q4 Q5 
RBC folate ≤623 623-8.25 825-1084 1084-1520 1520+ 
Age 74.2 (8.3) 73.7 (8.4) 74.0 (8.1) 73.1 (8.1) 74.7 (8.5) 
Male n (%) 337 (35) 330 (34) 332 (34) 305 (32) 267 (28) 
Age Finished education 15.8 (2.6) 15.9 (2.8) 16.3 (3.4) 16.2 (3.1) 16.1 (3.0) 
CEDS 5.7 (8.4) 6.1 (7.7) 5.8 (7.0) 5.9 (7.3) 5.6 (6.6) 
HADS 3.3 (3.8) 3.3 (3.7) 3.1 (3.5) 3.2 (3.7) 3.0 (3.5) 
MMSE 26.9 (2.8) 27.2 (2.5) 27.1 (2.5) 27.2 (2.5) 27.1 (2.6) 
Serum B12 ≤177 177-235 235-290 290-373 373+ 
Age 78.0 (8.5) 74.4 (7.9) 73.7 (8.0) 73.2 (8.1) 73.6 (8.5) 
Male n (%) 377 (37) 376 (37) 363 (36) 313 (31) 246 (24) 
Age Finished education 15.7 (2.7) 16.0 (3.0) 15.9 (2.8) 16.1 (3.0) 16.5 (3.4) 
CEDS 6.4 (7.8) 6.1 (7.6) 6.0 (7.4) 6.3 (7.7) 5.6 (6.9) 
HADS 3.2 (3.6) 3.0 (3.6) 3.17 (3.7) 3.3 (3.8) 3.2 (3.7) 
MMSE 26.9 (2.5) 27.0 (2.7) 27.2 (2.3) 27.2 (2.5) 27.1 (2.6) 
Vitamin B6 (nmol/L) ≤35.9 35.7-51.9 51.8-70.0 70.0-96.3 96.4+ 
Age 76.4 (8.5 75.2 (8.3) 73.8 (8.2) 72.9 (8.0) 72.1 (7.6) 
Male n (%) 334 (33) 348 (35) 362 (36) 338 (33) 295 (29) 
Age Finished education 28.2 (6.4) 15.7 (2.7) 16.1 (3.0) 16.2 (3.0) 16.6 (3.5) 
CEDS 7.5 (8.5) 6.6 (7.8) 5.9 (7.2) 5.5 (6.7) 5.0 (6.8) 
HADS 3.5 (4.1) 3.2 (3.7) 3.1 (3.6) 3.0 (3.5) 3.1 (3.5) 
MMSE 26.4 (3.1) 26.9 (2.6) 27.1 (2.4) 27.3 (2.4) 27.6 (2.3) 
Riboflavin (EGRac) 1.45+ 1.34-1.45 1.27-1.33 1.20-1.26 ≤1.19 
Age 73.0 (8.3) 73.2 (8.1) 73.8 (8.3) 74.5 (8.1) 75.5 (8.3) 
Male n (%) 353 (36) 352 (34) 294 (32) 325 (32) 350 (31) 
Age Finished education 15.7 (2.6) 16.0 (2.9) 16.0 (2.8) 16.2 (3.1) 27.6 (5.0) 
CEDS 7.1 (8.4) 6.0 (7.6) 5.8 (7.2) 5.8 (7.0) 5.6 (7.0) 
HADS 3.5 (4.1) 3.3 (3.7) 3.2 (3.5) 2.9 (3.4) 3.0 (3.6) 
MMSE 26.9 (2.8) 27.2 (2.4) 27.1 (2.6) 27.1 (2.6) 27.1 (2.6) 
Data presented as mean (SD)  unless stated otherwise.
MMSE, Mini Mental State Examination; CES-D, Centre for Epidemiologic Studies Depression; 




























Increasing intake of B-vitamin fortifed foods




































































Figure. 2 Risk of depression in relation to B-vitamin a) biomarker status and b) fortified food intake a
RBC, red blood cell; PLP, pyridoxal 5-phosphate; EGRac, erythrocyte glutathione reductase co-efficient 
(Values are odds ratios for risk of CES-D score ≥16 with 95% CI relative to reference category), with 
adjustment for age, gender, anti-depressant drug usage, age finished education, vitamin supplement usage, 
smoking status, physical frailty (Timed up and go), living alone, area deprivation and transient ischaemic 
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B-vitamins and Brain Health in Older People (BrainHOP): 
A randomised controlled trial (RCT) of B-vitamin 
supplementation on neuropsychiatric performance. 
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Abstract 
Background: Globally populations are ageing and mental health disorders, including 
dementia and depression, are reported as the leading cause of disability and ill health in 
older adults. Epidemiological and randomised trial evidence supports potential roles for 
folate and the metabolically related B-vitamins in preventing cognitive dysfunction and 
depression in ageing, but the evidence is inconsistent. 
Objective: The objective was to investigate the effect of B-vitamin supplementation with 
folic acid and related B-vitamins over 2 years on cognitive function (primary outcome) 
and depression (secondary outcome) in older adults. 
Design: A randomized controlled trial (RCT) was conducted over 2 years in adults aged 
70 years and older. Participants who had previously taken part in the TUDA cohort study 
were invited to participate. Those eligible were randomised to receive daily, either 
placebo or a supplement containing folic acid (400 µg), vitamin B12 (10 µg), vitamin B6 
(10 mg) and riboflavin (10 mg). Cognitive function was assessed before and after the 2-
year intervention using the MMSE, FAB and the RBANS. Depression was assessed using 
the CES-D scale. Statistical analysis was conducted using SPSS, repeated measures 
ANCOVA was used to analyse the time × treatment interaction assessing the effect of 
treatment versus placebo over time, the main outcome of the trial. 
Results: Of the 328 participants initially recruited (78 years; 44.8% male), 249 
participants completed the intervention (74%). Results showed that neither frontal lobe 
nor global cognitive function (as measured by FAB and RBANS, respectively) showed a 
significant effect of B-vitamin intervention. However, when specific domains within 
global cognition (i.e. RBANS index scores) were examined separately, B-vitamin 
intervention was found to protect against visuospatial cognitive decline over the two year 
period, with pre and post intervention values of 98.8 (1.6) and 95.8 (1.7) for the placebo 
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group and 95.0 (1.7) and 99.2 (1.7) for treatment group (P = 0.001; Repeated Measures 
ANCOVA, time x treatment interaction). In the case of depression, although the effect of 
B-vitamin intervention on depression (i.e. CES-D score) did not reach statistical 
significance, rates of depression (i.e. % with CES-D score > 16) doubled over the 2-year 
period in the placebo group (from 4.0% to 8.0%) compared with a minimal increase in 
the B-vitamin group (from 4.0% to 4.8%). 
Conclusion: Intervention with low dose B-vitamins (within the dietary range) resulted in 
beneficial effects on both visuospatial cognition and depression. Optimising B-vitamin 
status in older populations (through fortification or supplementation programs) may have 
important impacts on neuropsychiatric health and in turn help to preserve better quality 
of life in ageing. 
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Introduction 
An estimated 23% of the global burden of disease arises in older people, with mental 
health disorders considered to be the leading cause of disability and ill health in ageing 
(Prince et al. 2015) and a significant global challenge of our time (United Nations 
Department of Economic and Social Affairs/Population Division 2015; Livingston et al. 
2017). Dementia and depression are the most common of these disorders (World Health 
Organisation 2016) with predictions that dementia will affect over 131 million people by 
2050 (Prince et al. 2016), whilst depression is anticipated to be the second leading cause 
of disability worldwide by 2020 (National Collaborating Centre for Mental Health 2010). 
The economic burden of mental health disorders is profound, with dementia estimated to 
be a trillion dollar disease (Prince et al. 2016) and response rates to antidepressant 
medications being typically poor (Rush et al. 2006). Considering such immense social 
and economic costs, there is an urgent need to identify modifiable factors for targeted 
interventions to help preserve better brain health in our ageing populations. 
Evidence accumulated over many years suggests that folate and the metabolically related 
B-vitamins may play protective roles against depression (Carney 1967; Reynolds et al. 
1970; Clarke et al. 1998; McCaddon 2006) and cognitive decline (Carney 1967; Reynolds 
et al. 1970; Clarke et al. 1998; McCaddon 2006) in older age. Epidemiological studies 
report that lower biomarker status of folate, vitamin B12 and vitamin B6 (or higher 
concentrations of the related metabolite Hcy) is associated with an increased risk of 
cognitive dysfunction (Smith and Refsum 2016; Porter et al. 2016) and depression (Hvas 
et al. 2004; Kim et al. 2008; Ng et al. 2009; Robinson et al. 2011). There is also evidence 
from randomised trials demonstrating the beneficial effects of B-vitamin supplementation 
on cognitive function (Durga et al. 2007; Smith et al. 2010), albeit the evidence is not 
entirely consistent (McMahon et al. 2006). One notable and rather controversial meta-
analysis concluded that neither folic acid nor vitamin B12 had a beneficial effect on 
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cognition in older adults (Clarke et al. 2014), however, this paper was widely criticised, 
mainly as a result of the inclusion criteria used to select the trials for investigation, and 
thus the findings are in general not widely accepted by experts in this area (Garrard and 
Jacoby 2015; Smith et al. 2015). The strongest evidence to date to support the role of B-
vitamins protecting cognition in ageing comes from the VITACOG trial, where 
intervention over 2 years with a combined high dose B-vitamin supplement (folic acid, 
vitamin B12 and vitamin B6) in patients with MCI was found, not only to improve 
cognitive performance (de Jager et al. 2012), but also reduced the rate of brain atrophy, 
as measured by MRI (Smith et al. 2010; Douaud et al. 2013). However, given that the 
VITACOG trial intervened with pharmacological doses of B-vitamins in MCI patients, it 
remains unknown whether B-vitamins at lower doses (i.e. within the dietary range) could 
be beneficial for cognitive function in apparently healthy (non MCI) older adults. In the 
case of depression, some randomised trial evidence suggests a beneficial effect of certain 
B-vitamins on depression (Almeida et al. 2010; Almeida et al. 2014). Although one meta-
analysis concluded that neither folic acid nor vitamin B12 had a beneficial effect on 
depression, the number of published trials in depression for investigation was small, with 
a high degree of heterogeneity between studies (Clarke et al. 2014; Almeida et al. 2015). 
Therefore in order to address the current gaps in the existing literature base, and to 
consider all the relevant B-vitamins within one-carbon metabolism, the aim of this study 
was to investigate the effect of B-vitamin supplementation with combined folic acid, 
vitamin B12, vitamin B6 and riboflavin over 2 years on cognitive function and depression 
in older adults. We hypothesised that B-vitamins will be beneficial in helping to maintain 




The B-vitamin and Brain Health in Older People (BrainHOP) trial was conducted in 
participants who had previously been recruited to the TUDA ageing cohort study 
(ClinicalTrials.gov Identifier: NCT02664584). As described in detail elsewhere, 5,186 
community-dwelling adults aged ≥ 60 years were recruited to the TUDA study between 
2008 and 2012 from Northern Ireland (NI) and the Republic of Ireland (RoI) (McCarroll 
et al. 2015; McCann et al. 2018). The TUDA study initially aimed to investigate the role 
of nutrition and lifestyle factors in the aetiology of common age-related diseases, namely, 
dementia, osteoporosis and CVD. A total of 2093 participants from the TUDA study 
cohort were recruited within Northern Ireland, of which 689 participants met inclusion 
criteria for the current trial. These were determined at the time of initial recruitment to 
the TUDA study and were as follows:  aged ≥67 years old; not a user of B-vitamin 
supplement; MMSE score ≥21; normal renal function (Creatinine >130µmol/L) and 
plasma Hcy >12.05µmol/L. Reassessment for eligibility took place before being invited 
to participate in the BrainHOP trial and potential participants were excluded at this point 
if they had an MMSE <21 or were currently/recently on a B-vitamin supplement (Figure 
1). The BrainHOP trial was carried out according to the principles expressed in the 
Declaration of Helsinki and ethical approval was granted from Office for Research Ethics 
Committees Northern Ireland (ORECNI) 08/NIR03/113 and each participant provided 
written informed consent. 
The minimum sample size required for detecting an effect of B-vitamins on MMSE score 
was estimated to be 164 subjects in each treatment group (n = 328) accounting for a 20% 
dropout rate. The type 1 error rate was 0.05, with the desired power of 0.80 (Faul et al., 
2007). This sample size calculations were based on the size of the effect of B-vitamin 
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supplementation on Mini-Mental State Examination (MMSE) score in older adults as 
previously reported (de Jager et al. 2012). 
Study design and compliance 
This study was conducted as a double-blinded placebo controlled randomised controlled 
trial (Figure 1). Participants who agreed to take part were stratified by baseline MMSE 
score and age and subsequently randomised within each stratum to receive daily for the 
2 year intervention period either placebo or a low dose combined B-vitamin capsule (folic 
acid 400 µg, B12 10 µg, B6 10 mg and riboflavin10 mg) as provided by Healthspark Ltd, 
St Helier, Jersey. Once the supplements were delivered, independent analysis was 
conducted which confirmed that the supplements contained the target doses, albeit that 
there were small variations in the concentrations between the different companies 
(Appendix Supplemental Table 1). To ensure that the study was double-blinded, 
randomisation was conducted using the Minim software programme by the Human 
Interventions Studies Unit (HISU) Clinical Trials Manager at Ulster University 
Coleraine. The treatment and placebo were capsules administered daily and they were 
identical in size, shape, colour, smell, and taste and were packaged in identical blister 
packs. To maximise compliance, participants were provided with a 3-month supply of 
capsules (14 day, blister packed strips). Participants were asked to return all blister packs, 
including any untaken capsules, at 3 monthly intervals throughout the 2 years. Adherence 
to allocated treatment was measured by counting the number of tablets returned 
throughout the two years of the study.  
Participants were invited to attend two 90 minute appointments at the start and end of the 
trial at a number of locations including: the Nutrition Innovation Centre for Food and 
Health (NICHE) at Ulster University, Coleraine; the Clinical Translational Research and 
Innovation Centre (CTRIC) at Altnagelvin Area Hospital or within the participants home.  
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At each sampling point biophysical, neuropsychiatric, cognitive, and functional 
assessments were completed and information on nutritional intake, demography, medical 
and social history was also obtained. 
 
General health, lifestyle and biophysical measures 
As described in detail elsewhere (McCarroll et al. 2015; McCann et al. 2018) Health and 
lifestyle information was gathered using a detailed, researcher-assisted, questionnaire and 
included information on age, smoking, alcohol, medical history, drugs including 
antidepressant medications and vitamin supplement use. Anthropometric measurements 
were recorded (including weight, height, waist and hip) and BP measurements were taken 
in accordance with standard operating procedures by trained researchers. In brief, two BP 
measurements were taken from the reference arm (the arm with the highest BP reading) 
with a 5‐10 minute interval between each measurement; the mean of the two readings was 
used as the BP value.  The TUG test was performed as a measure of functional mobility. 
Participants were asked to stand from a seated position (seat height approximately 46 
cm), walk 3 m at their usual pace, turn around, walk back to the chair, and sit down. No 
physical assistance was given, and the time taken from command “Go” to complete the 
task was measured with a stopwatch (Podsiadlo and Richardson 1991), The functional 
abilities of the participants were also assessed using the PSMS and the IADL scale.  
 
Neuropsychiatric assessment   
Cognitive performance was assessed at both time points using 3 tests of cognition: the 
Folstein MMSE, the FAB and the RBANS. The MMSE is the most widely used screening 
tool in clinical settings worldwide for identifying cognitive impairment and dementia and 
evaluates global cognitive function by assessing the domains of orientation, registration, 
attention and concentration, recall and language. The maximum score achievable is 30, 
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with a score <25 indicating a possibility of cognitive impairment and a score <20 
indicating dementia (Folstein et al. 1975). The FAB specifically assesses frontal lobe 
function, with a maximum score attainable of 18, with a score ≤15 indicative of cognitive 
impairment (López et al. 2014). RBANS assesses specific cognitive domains including 
immediate and delayed memory, visual-spatial, language, and attention, with a score <80 
indicative of cognitive dysfunction (Radloff 1977). 
Anxiety and depression were assessed using the CES-D scale and the HADS. The CES-
D scale is a 20 item self-reported questionnaire, with a minimum score of 0 (no symptoms 
of depression) and maximum score of 60 (significant symptoms of depression). A score 
greater than or equal to 16 is generally indicative of clinical depression (Radloff and 
Locke 1986). HADS is a 7 item scale, with a minimum score of 0 (suggestive of no 
symptoms of anxiety) and a maximum score of 21 (significant anxiety). A score greater 
than or equal to 11 is generally indicative of probable anxiety (Zigmond and Snaith 1983). 
Dietary assessment 
Dietary intakes were assessed with the use of a 4-day food diary and a FFQ. This 
combined dietary method was previously validated at this Centre for the assessment of 
dietary intakes of folate, vitamin B12, vitamin B6 and riboflavin against each of their 
biomarkers (Hoey et al. 2007). The FFQ, designed specifically to investigate foods rich 
in the relevant B-vitamins including fortified foods, was completed by each participant. 
Details of brand names of the relevant products consumed were also obtained in order to 
establish the nutrient profile of any fortified foods. A 4-day food diary was completed by 
each participant in which all foods and beverages consumed over 2 week days and 2 
weekend days were recorded at the time of consumption. Each participant received 
detailed oral and written instructions on how to complete the food diary and FFQ.  Portion 
sizes were estimated using household measures such as bowls, spoons, etc., and counts 
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were taken for eggs and bread. The cooking method and brand names were also recorded. 
The 4-day food diaries were cross-checked using the FFQs to ensure the most accurate 
representation of the participants’ normal diet was obtained; where inconsistencies 
occurred these were clarified with the participant in a follow-up telephone call. 
To determine the nutritional content of the dietary records, the information from the 
crossed-checked food diaries was entered into a customised food composition database 
(Nutritics, Nutrition Analysis Software, v4.25 Research Edition, Dublin, Ireland). This 
software does not enable natural food folate to be distinguished from folic acid added to 
fortified foods by manufacturers, as it generates one value for total folate present in a 
food. The software was therefore customised in two ways as previously described (Hoey 
et al. 2007). Firstly, the software was customised to include folic acid as a new nutrient. 
This allowed dietary folate equivalents (DFEs) to be calculated (i.e. µg natural folate plus 
1.7×µg added folic acid).  Secondly, the database was updated to replace nutrient values 
with the most up-to date nutrient data for fortified food, obtained either from food 
companies where possible, otherwise the data were obtained from on-pack nutritional 
labelling. 
Statistical analysis 
All statistical analyses was performed using the SPSS statistical package for the social 
sciences (version 24.0, SPSS UK Ltd, Chersey, United Kingdom). Descriptive statistics 
are expressed as mean (SD), median (IQR) or adjusted means (SEM) throughout the 
article. Data were checked for normality and log transformed as appropriate. As dietary 
intakes of B-vitamins did not differ between treatment and placebo group at baseline, this 
was not controlled for within subsequent analyses. Differences in baseline characteristics 
between the treatment groups were analysed using independent t-tests for continuous 
variables and χ2 tests for categorical parameters. Response to intervention was conducted 
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only in participants who completed the intervention (n = 249). A change in either the 
cognitive function or depression scores (pre and post intervention) over the period of the 
study were examined using analysis of covariance (ANCOVA). When cognitive scores 
were being analysed the following were controlled for age, gender, baseline cognition, 
depression, anxiety, education, hypertension, hyperlipidaemia and smoking, while 
antidepressant medication usage was controlled for within the depression analysis. 
Repeated measures ANCOVA was used to analyse the time × treatment interaction 
assessing the effect of treatment versus placebo over time, the main outcome of the trial. 
The between-patient factor was the intervention group (placebo versus combined B-
vitamin), and the within-patient factor was time (pre and post). Repeated measures 
ANCOVA was used to assess the change in depression scores over the 5 year period prior 
to the RCT. In all analyses, P values <0.05 were considered significant. 
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Results
A total of 328 participants were recruited from the TUDA ageing cohort study and were 
randomised to receive the combined B-vitamin supplement (n = 163) or placebo (n = 165) 
(Figure 1). There was a slightly higher proportion of female participants, with an average 
age of 78 years. Within the cohort there was a high rate of hypertension and (87%) and 
hyperlipidaemia (57%) and 16% suffered from diabetes (Table 1). Overall, the baseline 
characteristics of both the treatment arms were similar with the exception smoking, 
hyperlipidaemia and hypertension which showed small but significant differences 
between the two groups. The majority of the participants were B-vitamin fortified food 
consumers, with no significant difference in dietary intake between the treatment arms at 
baseline. Overall, 249 participants completed the study, with a 24% drop out rate in both 
arms (Figure 1). The participants who discontinued the intervention were similar to those 
that completed however those who did not complete the study had a lower IADL score, 
significantly higher rates of hyperlipidaemia, anxiety and depression than those that 
completed the intervention (Appendix Supplemental Table 2). 
Overall, there was generally excellent compliance of participants with the intervention 
protocol (estimated by pill-counting to be 98.7%). There was no significant change in the 
global or frontal lobe cognitive function in response to B-vitamin supplementation over 
the 2 years (Table 2), as measured by MMSE (P = 0.337), RBANS (P = 0.105) and FAB 
(P = 0.959) respectively. B-vitamin supplementation however resulted in an improved 
visuospatial score by 3.4 points over the 2 year intervention period while those who 
received placebo declined by 2.4 points (P = 0.004). Likewise, when the response was 
examined using repeated measures ANCOVA with adjustment for relevant co-variates, a 
significant time × treatment interaction was observed for visuospatial score (P = 0.001), 
with pre- and post intervention values of 95.0 (1.7) and 99.2 (1.7) (treatment group) and 
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98.8 (1.6) and 95.8 (1.7) (placebo group) (Table 3). The responses detected in MMSE, 
FAB or in other RBANS index scores did not reach significance. 
In the case of depression, although no significant time × treatment interaction was 
observed for depression in the cohort as a whole or when split by the median age (Table 
3), rates of depression (i.e. % above cut point for clinical depression) doubled in the 
placebo group (from 4.0% to 8.0%) compared with a minimal increase in the B-vitamin 
group (from 4.0% to 4.8%) over the 2-year period (Table 2). Depression was also 
examined over a 7 year period in those who completed the intervention, i.e. by tracking 
depression data as recorded at the time of the original recruitment to the TUDA study 
(T1), to the start of the intervention (T2), to the completion of the intervention (T3). The 
results showed that whereas depression scores significantly increased over the 7 years 
period in those randomised to placebo (P < 0.001), no significant increase was observed 
in those randomised to B-vitamins, an effect that was particularly marked in older 
participants (>70 years) at time of randomisation (Figure 2). 
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Discussion 
The BrainHOP trial is the first randomised trial to investigate the potential benefits of 
combined folic acid, vitamin B12, vitamin B6 and riboflavin supplementation on 
cognitive function and depression in generally healthy older adults. Low dose B-vitamin 
supplementation for 2 years in adults aged 78 years resulted in a significant beneficial 
effect on visuospatial cognitive function, but no effect on global cognition or frontal lobe 
function. In the case of depression, B-vitamin intervention was found to prevent the 
significant increase in depression observed in participants assigned to placebo, with rates 
of depression (i.e. % with CES-D score ≥16) doubling over the 2-year period in the 
placebo group compared with a minimal increase in the B-vitamin group. 
B-vitamin supplementation over 2 years was found to significantly protect visuospatial 
cognitive function (measured using RBANS Index II); scores for this index increased by 
3.4 in those provided with B-vitamins compared to 2.2 decline in participants on placebo.  
These results are broadly in agreement with the findings from two other large-scale B-
vitamin intervention studies namely, the FACIT (Durga et al. 2007) and VITACOG 
(Smith et al. 2010) trials. Of particular note, the current results showing significant effects 
on visuospatial cognition are in line with findings from the VITACOG trial, which 
reported that supplementation with pharmacological doses of folic acid, vitamin B12 and 
vitamin B6, compared to placebo, stabilized executive function as measured by the CLOX 
tool (de Jager et al. 2012). Although the CLOX tool specifically measures executive 
function, it is similar to the visuospatial cognitive assessment conducted within the 
current study as part of the RBANS index II, with earlier studies noting significant 
correlations of CLOX 2 with more complex visuospatial tasks (Pena et al. 2008). The 
current study is the first to report a beneficial effect of B-vitamins on cognitive function 
in older adults without a diagnosis of cognitive impairment and using doses of B-vitamins 
within the dietary range; in contrast, the aforementioned VITACOG trial intervened in 
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patients diagnosed with MCI and used pharmacological doses of B-vitamins (de Jager et 
al. 2012). 
In line with the findings from the current study, the VITACOG trial also reported no 
significant effect of B-vitamin supplementation on overall global cognitive function (as 
measured by MMSE) (de Jager et al. 2012) with the exception of those with higher Hcy 
concentrations (>11.3mmol/L) (de Jager et al. 2012), which would in turn reflect 
generally lower B-vitamin biomarker status. The biomarker analysis for the BrainHOP 
trial is currently underway and, once completed, pre-defined sub-group analysis based on 
B-vitamin biomarker results will be conducted in line with current literature and to 
address the hypothesis that participants with sub-optimal biomarker status at baseline will 
show greater benefits of B-vitamins intervention (de Jager 2014; Smith and Refsum 
2016). Unlike the current study, the VITACOG trial also conducted brain imaging using 
MRI and showed that the rate of overall and grey matter brain atrophy was reduced in the 
B-vitamin intervention group compared with the placebo group over the 2 year 
intervention, an effect that was again dependant on baseline Hcy (Smith et al. 2010; 
Douaud et al. 2013). 
The findings from the current intervention study, BrainHOP, together with the 
aforementioned studies VITACOG and FACIT, generally supporting a protective role of 
folate and the related B-vitamins on cognitive function in older adults, are in contrast with 
another similar RCT which did not find significant effects of B-vitamin intervention on 
cognition function over a 3 year period (McMahon et al. 2006). This discrepancy could 
be explained by the fact that the study cohort in the latter trial had an already optimal B-
vitamin biomarker status, making it unlikely that further increases in B-vitamin 
biomarkers, as a result of intervention, would result in benefits on cognitive function. 
Furthermore, a recent meta-analysis of randomised trials concluded that “B-vitamin 
supplementation had no significant effect on individual cognitive domains or global 
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cognitive function or on cognitive aging” (Clarke et al. 2014), albeit the conclusions from 
this meta-analysis were not widely accepted by B-vitamins experts (Smith and Refsum 
2016). One of the most significant limitations of the latter meta-analysis was in relation 
to the inclusion criteria used to select the trials, and that baseline cognitive assessments 
(an important covariate to be considered in the analysis of response to intervention) were 
not available for 76% of the participants included in the study (Smith et al. 2015; Garrard 
and Jacoby 2015). Since the publication of this meta-analysis there have been two further 
trials, one investigating folic acid and vitamin B12 supplementation (B-Vitamins for the 
PRevention Of Osteoporotic Fractures (B-PROOF); (van der Zwaluw et al. 2014)) and 
the other investigating vitamin B12 alone (Older People and Enhanced Neurocognitive 
function study; (Dangour et al. 2015)). Neither of these trials found significant effects of 
B-vitamins supplementation, albeit cognitive function was not the primary outcome for 
either trial. The B-PROOF trial did show a slower rate of global cognitive decline, but 
surprisingly this was attributed to chance (van der Zwaluw et al. 2014), and one notable 
limitation of the Dangour et al (2015) trial was the finding that cognitive scores in the 
placebo group did not decline. Of note, visuospatial cognitive function was not assessed 
in either trial, yet it has recently been identified to demonstrate significant diagnostic and 
prognostic potential for dementia (Salimi et al. 2018). 
Over the 7 years observation of the BrainHOP cohort, intervention with B-vitamins for 
the last 2 years was found to prevent the significant increase in depression which occurred 
in participants assigned to placebo. Furthermore, rates of depression (i.e. % with CES-D 
score ≥16) doubled over the 2-year intervention period in the placebo group compared 
with a minimal increase in the B-vitamin group. These findings are somewhat in line with 
findings from the VITAmins TO Prevent Stroke-DEPression (VITATOPS-DEP trial; n 
273, 63 years)(Almeida et al. 2010), which reported a non-significant trend towards a 
reduction in odds of depression in those randomised to high dose B-vitamins. In contrast, 
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however, a recent RCT in over 4331 older females found no significant reduction in the 
risk of depression in response to 7 years of combined B-vitamin intervention (Okereke et 
al. 2015). However, this study was conducted in female health professionals in the United 
States, where mandatory folic acid fortification of flour has been in place since 1996, 
perhaps suggesting that optimal folate biomarkers may have limited the opportunity for 
improving B-vitamin status and thus influencing rates of depression. Of note, systematic 
reviews and meta-analyses in this area which concluded that B-vitamin intervention may 
delay the onset of clinically significant symptoms in people with existing or at risk of 
depression, have focused on the use of B-vitamins as a treatment rather than a preventive 
measure for depression (Taylor et al. 2004; Almeida et al. 2015). 
The biological mechanisms explaining the current and previous results linking folate and 
metabolically related B-vitamins with cognitive function and depression are likely related 
to their crucial roles in one-carbon metabolism. Douaud et al. (2013) proposed increased 
atrophy may be as a result of elevated plasma Hcy, which in turn has been suggested to 
increase phosphorylated Tau which is associated with greater deposition of 
neurofibrillary tangles and thus increased atrophy (Zhang et al. 2008). Furthermore, folate 
and related B-vitamins act as co-factors in DNA synthesis and repair, amino acid 
metabolism and methylation reactions, including the remethylation of Hcy to methionine 
and subsequent generation of SAM. SAM, the universal methyl donor, is involved in the 
methylation of DNA, phospholipids, proteins and neurotransmitters, thus reduced status 
of one or more of the B-vitamins involved in one-carbon metabolism may impair 
methylation processes. The inhibition of methylation reactions may, in turn, influence 
cognitive function in a number of ways, by perturbing the regulation of gene expression 
in the Beta amyloid pathway, by reducing the activity of protein phosphatase-2A or by 
impairing the formation of phosphatidylcholine enriched omega-3 fatty acids (Smith and 
Refsum 2016). Additionally, reduced tissue concentration of SAM may be linked to 
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depression through perturbing monoamine (serotonin, dopamine and noradrenaline) 
synthesis and methylation (Bottiglieri et al. 2000). In addition, folate has a role in the 
synthesis of tetrahydrobiopterin (BH4), an essential co-factor in monoamine synthesis 
(Bottiglieri et al. 1992). Furthermore, the active form of vitamin B6 (PLP) is the cofactor 
for aromatic L-amino acid decarboxylase in the tryptophan serotonin pathway, thus 
suboptimal B6 status may lead to reduced concentrations of serotonin and thus increased 
risk of depression (Hensler 2006). Lastly, as previously noted, riboflavin in the form of 
FMN is required as a coenzyme for the activation of B6 in tissues and so its relationship 
with depression could be mediated through a vitamin B6 dependent pathway. 
Considering the protective effects on cognitive function following supplementation with 
B-vitamins observed in this study, and in earlier work from the VITACOG and FACIT 
trials (Durga et al. 2007; de Jager et al. 2012), the impact of optimising B-vitamin 
biomarker status at a public health level could be considerable. It has been estimated that 
a 5-year delay in the onset of dementia could reduce the population prevalence by 50% 
(Livingston et al. 2017), thus improving B-vitamin status could have an important impact 
on dementia prevention at a societal level. Tsiachristas and Smith (2016) conducted a 
decision model to calculate the lifetime costs and quality-adjusted life years of providing 
B-vitamin treatment to people in the UK over 60 years with plasma Hcy >13 mmol/L. It 
was estimated that B-vitamin supplementation would save £60,021 per quality-adjusted 
life year gained and could thus be highly cost-effective (Tsiachristas and Smith 2016). 
Optimising B-vitamin biomarker status in older populations could also potentially be 
achieved (perhaps more efficiently) via food fortification, as research has highlighted that 
regular consumption of B-vitamin fortified products can significantly benefit biomarker 
status (Hoey et al. 2007; Hopkins et al. 2015), however further work in this area in the 
form of an RCT using such food products is required. 
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The main strength of the BrainHOP study is that it is a randomised trial and therefore has 
the ability to investigate potential causal links between B-vitamins and cognitive function 
and depression in older adults. Furthermore, participants were recruited based on having 
prior Hcy concentrations suggestive of lower B-vitamin status and were at an age where 
cognitive decline was likely to occur (Murman 2015). Also, rather than relying on 
assessments of global cognitive function alone, the battery of cognitive assessments 
conducted within the study allowed for the analysis of both global cognition as well as a 
variety of sub-domains, which have been found to be sensitive to the ageing process 
(Howieson et al. 1993). The current study provided all four B-vitamins involved in one-
carbon metabolism, thus fully optimising this network of metabolic pathways. Finally, 
the B-vitamin intervention lasted for a period of 2 years thus the likelihood of detecting 
changes in cognitive function was greater. This study was not however without 
limitations. The BrainHOP cohort were generally a healthy, well educated, older cohort 
and over 78% consumed fortified food products, thus the effect of B-vitamin 
supplementation on cognition and depression might be less than in other populations 
where lower levels of education are achieved and voluntary fortification is restricted. 
With regards to depression, the CES-D scale used in this study to assess depression, while 
widely considered to have an acceptable screening accuracy in primary care settings, is 
not as robust as other diagnostic instruments and this may have limited the interpretation 
of the current findings to some extent (Vilagut et al. 2016). Furthermore, the primary 
outcome of the current study was cognitive function (with sample size calculations based 
on MMSE scores) therefore, it is likely that the current study was underpowered to detect 
significant effects of B-vitamins on depression which was a secondary outcome. A final 
limitation of the BrainHOP trial at this time is that the biomarker results have not been 
included, as the analysis is currently ongoing. 
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In conclusion, the BrainHOP trial presents the first evidence from an RCT that 
supplementation with folic acid, vitamin B12, vitamin B6 and riboflavin within dietary 
ranges can protect against cognitive decline in healthy older adults, specifically in relation 
to visuospatial cognition. Results from this study appear to suggest that B-vitamin 
supplementation may also have a role in reducing the risk of depression in older age. The 
current findings are supported by the known biological mechanisms of folate and related 
B-vitamins within one-carbon metabolism and suggest that optimising B-vitamin status 
in older adults may contribute to reducing the significant social and economic global 
burden related to declining brain health in ageing. Further biomarker analysis from this 
trial will help to interpret the current findings more fully, while future trials which include 
objective brain imaging techniques will enable a fuller understanding of the biological 
and clinical nature of relationships of B-vitamins with brain health. 
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Eligible for BrainHOP 
 n 689 
Not Recruited (n 361) 
 Deceased n 102 
 Uncontactable n 88 
 Declined n 126 
 MMSE <21 n 3 
 Supplement User n 52 
Combined B-vitamin 
n 125 
Lost to follow-up (n 3) 
Discontinued intervention (n 76) 
 Developed new symptoms n 11 
 Medical problems n 43 
 No longer interested n 11 
 Started on B-vitamins n 5 
 Deceased n 6 
Combined B-vitamin 
(n 163) 
Folic acid 400µg 
Vitamins B12 10µg 









Figure 1. CONSORT flow diagram of participants from the BrainHOP trial 
1 Recruitment was from GP clinics in the Northern and Western Health and Social Care Trusts, Northern 
Ireland. Abbreviations: TUDA, Trinity Ulster Department of Agriculture; MMSE, Mini-Mental State 
Examination; Hcy, Homocysteine 
TUDA Ageing Cohort Study 
n 5186 
TUDA NI Cohort1 
n 2093 Excluded (n 1404) 
 Aged <68 years n 785 
 B-vitamin user n 143 
 Creatinine >130µmol/L n 70 
 Serum Hcy <12µmol/L n 389 


















Age (year) 78.0 (4.5) 78.2 (4.7) 77.9 (4.2) 0.607 
Gender (male) n (%) 147 (44.8) 80 (48.5) 67 (51.1) 0.218 
Education (years) 16.6 (3.1) 16.7 (3.3) 16.4 (2.8) 0.454 
Area deprivation (most 
deprivation) n (%) 
35 (10.7) 19 (11.5) 16 (9.8) 0.487 
Health and Lifestyle 
BMI (kg/m2) 29.3 (4.9) 29.2 (4.7) 29.4 (5.1) 0.713 
Waist to Hip ratio 0.9 (0.1) 0.9 (0.1) 0.9 (0.1) 0.256 
Timed Up and Go 
(seconds) 
11.3 (6.6) 11.4 (8.5) 11.3 (4.0) 0.456 
Hand Grip Strength (kg) 24.4 (10.5) 25.1 (10.6) 23.7 (10.5) 0.241 
PSMS score 22.9 (1.9) 23.1 (1.9) 22.8 (1.9) 0.093 
IADL score  26.4 (2.6) 26.6 (2.5) 26.3 (2.7) 0.340 
Living alone n (%) 93 (28.4) 45 (27.3) 48 (29.4) 0.738 
Current Smoker n (%) 17 (5.2) 14 (8.5) 3 (1.8) 0.014 
Alcohol (units/week) 4.7 (8.4) 4.8 (7.9) 4.7 (8.9) 0.682 
Medical 
Diabetes n (%) 53 (16.2) 25 (15.2) 28 (17.2) 0.727 
Hyperlipidaemia n (%) 188 (57.3) 105 (63.6) 83 (51.0) 0.027 
Hypertension n (%) 285 (86.9) 136 (82.4) 149 (91.4) 0.025 
Previous MI n (%) 37 (11.3) 21 (12.7) 16 (9.8) 0.510 
Previous TIA n (%) 34 (10.4) 17 (10.3) 17 (10.4) 1.000 
Previous Stroke n (%) 12 (3.7) 8 (4.8) 4 (2.5) 0.389 
Dietary intake 
Fortified Food n (%) 256 (78) 127 (77) 129 (79.1) 0.508 
Energy (MJ/d)  7.5 (1.8) 7.3 (1.8) 7.7 (1.8) 0.134 
DFE§ (µg/d) 310 (108) 306 (114) 313 (103) 0.954 
Vitamin B-12 (µg/d)  5.0 (2.0) 4.8 (2.1) 5.1 (2.0) 0.894 
Vitamin B-6 (mg/d)  1.9 (0.6) 1.9 (0.7) 1.9 (0.6) 0.517 
Riboflavin (mg/d)  1.7 (0.5) 1.6 (0.5) 1.7 (0.5) 0.212 
Data presented as means (SD), unless otherwise indicated. 
*Differences between treatment groups was assessed using independent sample t-tests on
log transformed data where required, categorical variables were assessed using chi square 
test, P < 0.005 was considered significant.  
§ Dietary Folate Equivalents were calculated as µg natural folate plus 1.7 µg × added folic
acid. 
Abbreviations: BrainHOP, B-vitamin and Brain Health in Older People; PSMS, Physical 
Self Maintenance Score; IADL, Instrumental Activities of Daily Living; MI, Myocardial 











































































































































































































































































































































































































































































































































































































Pre 27.8 (0.2) 27.4 (0.2) 
Post 27.7 (0.2) 27.3 (0.2) 0.922 
FAB score 
Pre 14.7 (0.2) 15.1 (0.2) 
Post 14.4 (0.2) 14.7 (0.2) 0.485 
RBANS score 
Pre 93.3 (1.3) 93.4 (1.3) 
Post 95.5 (1.4) 97.8 (1.4) 0.117 
Specific Domains 
Immediate Memory 
Pre 94.4 (1.4) 96.3 (1.4) 
Post 96.6 (1.5) 98.0 (1.5) 0.857 
Visuospatial 
Pre 98.8 (1.6) 95.0 (1.7) 
Post 95.8 (1.7) 99.2 (1.7) 0.001 
Language 
Pre 92.5 (1.0) 92.9 (0.9) 
Post 101.0 (1.0) 100.8 (1.0) 0.760 
Attention 
Pre 95.8 (1.5) 97.2 (1.5) 
Post 95.3 (1.5) 96.9 (1.6) 0.948 
Delayed memory 
Pre 93.8 (1.7) 93.9 (1.7) 
Post 95.3 (1.6) 96.3 (1.6) 0.602 
Depression, CES-D score 
Pre 5.3 (4.5) 4.8 (0.5) 
Post 6.2 (0.6) 5.4 (0.6) 0.855 
Younger (<77.0 years¥) 
Pre 5.2 (0.6) 3.9 (0.6) 
Post 5.3 (0.7) 4.6 (0.7) 0.767 
Older (≥77.0 years¥) 
Pre 5.4 (0.7) 5.6 (0.7) 
Post 7.1 (0.9) 6.1 (0.9) 0.555 
Data expressed as adjusted mean (SEM). 
*Time × treatment interaction (repeated measures ANCOVA, comparing the effect of treatment
vs placebo over time, controlling for age, education, depression, anxiety, hyperlipidaemia, 
hypertension and smoking status. Depression analysis was controlled for anti-depressant usage. 
¥ Median age pre-intervention. 
Abbreviations: BrainHOP, B-vitamins and Brain Health in Older People; MMSE, Mini Mental 
State Examination; FAB, Frontal Assessment Battery; RBANS, Repeatable Battery for the 








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Appendix Supplemental Table 2. General characteristics of BrainHOP trial 








Age (year) 78.0 (4.5) 77.9 (4.4) 78.4 (4.8) 0.427 
Gender (male) n (%) 147 (44.8) 117 (53.0) 31 (60.8) 0.282 
Education (years) 16.6 (3.1) 16.6 (3.2) 16.3 (2.7) 0.503 
Area deprivation (most 
deprivation) n (%) 
35 (10.7) 26 (11.5) 9 (11.8) 0.886 
Health and Lifestyle 
BMI (kg/m2) 29.3 (4.9) 29.1 (4.8) 29.7 (5.0) 0.366 
Waist to Hip ratio 0.94 (0.08) 0.94 (0.08) 0.93 (0.07) 0.296 
Timed Up and Go 
(seconds) 
11.3 (6.6) 10.9 (3.3) 12.8 (12.1) 0.056 
Hand Grip Strength (kg) 24.4 (10.5) 24.5 (10.1) 24.2 (11.9) 0.683 
PSMS score 22.9 (1.9) 23.0 (1.8) 22.8 (2.2) 0.834 
IADL score 26.4 (2.6) 26.6 (2.5) 26.0 (2.8) 0.033 
Living alone n (%) 93 (28.4) 70 (28.1) 23 (29.1) 0.863 
Current Smoker n (%) 17 (5.2) 10 (4.0) 7 (8.9) 0.161 
Alcohol (units/week) 4.7 (8.4) 4.6 (8.4) 5.1 (8.2) 0.837 
Medical 
Diabetes n (%) 53 (16.2) 40 (16.1) 13 (16.5) 0.934 
Hyperlipidaemia n (%) 188 (57.3) 133 (53.4) 55 (69.6) 0.011 
Hypertension n (%) 285 (86.9) 216 (86.7) 69 (87.3) 0.891 
Previous MI n (%) 37 (11.3) 24 (9.6) 13 (16.5) 0.143 
Previous TIA n (%) 34 (10.4) 21 (8.4) 13 (16.5) 0.068 
Previous Stroke n (%) 12 (3.7) 11 (3.4) 1 (0.3) 0.339 
Cognition 
MMSE score 27.4 (2.0) 27.6 (1.9) 27.2 (1.9) 0.110 
% impaired (MMSE <25) 33 (10.1) 15 (6.1) 8 (10.4) 0.208 
FAB score 14.9 (2.2) 14.8 (2.1) 14.8 (2.2) 0.792 
% impaired (FAB ≤15 ) 191 (58.2) 142 (57.0) 49 (62.0) 0.513 
RBANS score 93.0 (14.5) 93.6 (14.3) 91.3 (15.2) 0.228 
% impaired (RBANS <80) 63 (19.2) 44 (17.7) 19 (24.1) 0.276 
Depression score 5.3 (5.1) 5.1 (5.0) 6.96 (7.2) 0.059 
% depressed (CES-D ≥16) 20 (6.1) 10 (4) 10 (12.7) 0.012 
Anxiety score 2.8 (2.7) 2.7 (2.7) 3.2 (2.1) 0.292 
% anxious (HADS  ≥11) 9.0 (2.7) 5 (2.0) 4 (5.1) 0.026 
Data presented as means (SD), unless otherwise indicated. Differences between treatment groups was 
assessed using independent sample t tests on transformed data where required, categorical variables were 
assessed using chi square test, P < 0.005 was considered significant.  
Abbreviations: BrainHOP, B-vitamin and Brain Health in Older People; PSMS, Physical Self Maintenance 
Score; IADL, Instrumental Activities of Daily Living; MI, Myocardial infarction; TIA, Transient Ischemic 
Attack; MMSE, Mini Mental State Examination; CES-D, Centre for Epidemiologic Studies Depression; 
FAB, frontal Assessment Battery; RBANS, Repeatable Battery for the Assessment of Neuropsychological 
Status; HADS Hospital Anxiety and Depression Scale. 
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Chapter 5 
An investigation of the role of B-vitamins in brain 




Background: Evidence, in the form of epidemiological studies and randomised trials, 
indicates that B-vitamins can help maintain better cognitive health in ageing. The 
majority of previous studies have used questionnaire-based assessment of 
neuropsychiatric function. To our knowledge, no study has assessed the impact of B-
vitamins on brain function using Magnetoencephalography (MEG), the brain imaging 
technique with the highest temporal resolution. 
Objective: The aim of this study was to investigate the role of B-vitamins in brain 
function as measured using MEG in older adults. 
Design: Participants (n 25; 79.1 years) were healthy older adults who had just completed 
the B-vitamins and Brain Health in Older People (BrainHOP) randomised trial,  and had 
received either, a daily combined B-vitamin supplement (folic acid; 400µg, vitamin B12; 
10 µg, vitamin B6; 10mg and riboflavin; 10mg), or placebo, for 2 years. MEG was 
conducted in both groups at the end of the 2 year trial, using a working memory task and 
during resting state. 
Results: The B-vitamin group achieved higher accuracy in the working memory task: 
92.4% vs 76.7% for B-vitamin and placebo groups respectively (P 0.041). During resting 
state, MEG results showed better overall neuronal functioning in the B-vitamin group, as 
demonstrated by lower power in the lower frequencies [1-8 Hz]. In addition, participants 
that had received B-vitamin supplements for 2 years also had significantly lower power 
in the Delta [1-4 Hz] (P 0.021) and Theta [4-8 Hz] (P 0.011) bands, following interruption 
within the working memory task, suggesting better interference resolution compared with 
the placebo group.   
Conclusion: Findings from this MEG analysis, although preliminary, suggest that better 
B-vitamin status is associated with improved neuronal functioning. If confirmed these 
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results will provide robust evidence of the role of B-vitamins in brain functioning. In 
addition, these findings demonstrate the potential of this novel imaging technique in 
future nutritional investigations. 
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Introduction 
Normal ageing is associated with alterations in the volume, structure, metabolic and 
neural processes within the brain (Peters 2006; Bishop et al. 2010). Furthermore, 
cognitive function declines with age, ranging in severity from MCI to dementia, with up 
to 50% of those with MCI going on to develop dementia within 5 years (Gauthier et al. 
2006). Dementia, a trillion dollar disease, currently affects 46.8 million people worldwide 
and is projected to affect over 131 million people by 2050 (Prince et al. 2016). Dementia 
is a complex condition of multifactorial causation (Smith 2008) with limited treatment 
strategies, therefore the identification of potential modifiable risk factors is a major global 
health priority (Livingston et al. 2017). 
Nutrition has emerged as an important area of interest for cognitive impairment disorders 
and there is strong evidence to support the protective roles of certain dietary patterns and 
specific dietary components including B-vitamins, omega-3 PUFAs, polyphenols and 
vitamin D in brain health in ageing (Moore et al. 2018). Investigations into the influence 
of these nutritional factors on the ageing brain are challenging and are conducted most 
commonly using questionnaire-based assessments of cognitive function, however, this 
can be limited primarily owing to the reported Ceiling and Floor effects of the various 
tests. 
A European workshop entitled ‘Methodologies to assess long-term effects of nutrition 
and brain function’ in 2009 concluded among the recommendations that brain imaging 
biomarkers should be included as secondary endpoints to clinical and cognitive measures 
(de Jager and Kovatcheva 2010). Furthermore a recent European Commission JRC report 
(Mak and Caldeira 2014), identified as a major priority multidisciplinary research into 
nutrition and brain health in older people. Neuro-imaging techniques provide an objective 
and highly robust means of assessing brain structure, function and potentially, response 
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to nutrition interventions (Sizonenko et al. 2013). However, only recently have these 
techniques been utilised to advance nutrition research in ageing. The use of MRI, 
functional MRI and Diffusion Tensor Imaging have significantly enhanced the evidence-
base supporting protective roles for polyunsaturated fatty acids, polyphenols and vitamin 
D in brain health in ageing (Selnes et al. 2013; Brickman et al. 2014; Hooshmand et al. 
2014). However, the strongest evidence to date comes from the VITACOG trial, which 
incorporated MRI techniques in an investigation of the effect of B-vitamin 
supplementation in patients with MCI. This trial of high-dose folic acid, vitamin B12 and 
vitamin B6 showed improved cognitive performance (de Jager et al. 2012) and a 30% 
reduction in brain atrophy (Smith et al. 2010), most specifically in regions identified as 
vulnerable in Alzheimer’s disease (such as the “parieto–medial temporal pathway”, 
hippocampus, parahippocampal gyrus, inferior parietal lobule and retrosplenial cortex). 
These specific brain regions have been highlighted in earlier reports to play a role in 
visuospatial functioning (Kravitz et al 2011(Douaud et al. 2013). These brain imaging 
results are ground-breaking, as they provide for the first time, objective cause and effect 
evidence to support the protective role of B-vitamins on brain health. MRI however, does 
have limitations including its relatively low temporal resolution and the fact that 
functional MRI relies on hemodynamic response and therefore provides only an indirect 
measure of neural activity (Zamrini et al. 2011). Both EEG and MRI studies have 
identified significant associations between measures of neuronal function and brain 
volumes (Grunwald et al. 2001(Grunwald et al. 2001; Babiloni et al. 2009). 
Magnetoencephalography (MEG) is a relatively new neuroimaging technique, which is 
completely non-invasive and measures the magnetic fields that are generated by neuronal 
activity, and thus directly measures oscillatory (neural) activity and is reported as power 
(or oscillation) across the frequency (Hz) spectrum, including at specified bands delta ([1 
4] Hz), theta ([4 8]Hz), alpha ([8 12] Hz), beta ([12 30] Hz) and gamma ([30 60] Hz)
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(Figure 1). MEG provides a four-dimensional measurement of the brain- space, time, 
frequency and connectivity, allowing for a better description of brain function (Zamrini 
et al. 2011) and potentially improved understanding of the effect of nutrients on brain 
health. In order to achieve 4D accuracy, an additional neuro-imaging technique such as 
MRI is required to align the data with anatomical correlates (López et al. 2014)(review 
in here). MEG is somewhat similar to EEG however EEG measures electric signals and 
MEG has higher temporal and spatial resolution. Research to date has highlighted MEG 
potential ability to predict the development of dementia and MCI from normal cognitive 
function (Maestú et al. 2006; Fernández et al. 2006). 
Confirmation of the protective role of B-vitamins in brain health, would greatly 
strengthen the findings of the BrainHOP trial as reported in this thesis (Chapter 4). 
Conducting MEG imaging in participants with optimal and sub optimal B-vitamin status 
would enable a more in-depth understanding of the potential protective role of folate and 
the metabolically related B-vitamins in brain function. The aim therefore was to 




Participants were recruited from the B-vitamin and Brain Health in Older People 
(BrainHOP) trial which was conducted in participants who had previously been recruited 
to the TUDA ageing cohort study (ClinicalTrials.gov Identifier: NCT02664584) 
(McCarroll et al. 2015; McCann et al. 2018). This study was conducted as a double-
blinded, placebo-controlled, randomised controlled trial as described in Chapter 4. For 
this pilot study, a sample size of 48 was estimated, however this chapter presents the 
preliminary findings of the first 25 participants who have completed the study. 
Reassessment for eligibility took place once participants had completed the 2 year 
intervention period where they had received either placebo or a low dose combined B-
vitamin capsule (folic acid 400 µg, B12 10 µg, B6 10 mg and riboflavin10 mg) as 
provided by Healthspark Ltd, St Helier, Jersey. Participants willing to take part were 
invited to participate in the BrainHOP MEG pilot study if they did not have any 
ferromagnetic implants (which would affect the sensitive sensors) (Figure 2). All 
participants were right handed native English speakers. The BrainHOP MEG pilot study 
was carried out according to the principles expressed in the Declaration of Helsinki and 
ethical approval was granted from Office for Research Ethics Committees Northern 
Ireland (ORECNI) 08/NIR03/113 and each participant provided written informed 
consent. 
Participants completed their 90 minute appointment at the end of the 2 year trial at the 
Clinical Translational Research and Innovation Centre (CTRIC) at Altnagelvin Area 
Hospital and were invited to a 120 minute appointment in the Northern Ireland Functional 
Brain Mapping (NIFBM) Facility of the Intelligent Systems Research Centre (ISRC), 
Ulster University, Derry/Londonderry, UK. Biophysical, neuropsychiatric, cognitive, and 
functional assessments were completed and information on nutritional intake, 
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demography, medical and social history were obtained at their first 90minutes 
appointments. 
General health, lifestyle and biophysical measures 
As described in detail in Chapter 4, health and lifestyle information was gathered using a 
detailed, researcher-assisted questionnaire and anthropometric measurements were 
recorded. The functional abilities of the participants were also assessed using the Physical 
Self-Maintenance Scale (PSMS) and the Instrumental Activities of Daily Living (IADL) 
scale. 
Neuropsychiatric assessment  
As described in Chapter 4 cognitive performance was assessed using the Repeatable 
Battery for the Assessment of Neuropsychological Status (RBANS) (Randolph 2010). 
Experimental paradigm 
The stimuli utilised within this experimental paradigm were kindly provided by Prof 
Maestú’s team from The Laboratory of Cognitive and Computational Neuroscience 
(LNCyC) which is an interdisciplinary research group at the Center for Biomedical 
Technology of Madrid. It consisted of neutral unnamed male and female faces across a 
wide age profile. To avoid non-face specific cues affecting the participant’s responses, 
the presented faces had both their hairlines and their ears digitally removed. The 
experiment was computerised through Matlab Version 24 (Mathwork, Natick, USA). The 
participants performed a delayed recognition working memory paradigm with two 
interference conditions: no interference (NI) and interruption (INT) under one memory 
load (Figure 3). All of the conditions consisted of three main phases: encoding, 
maintenance and recognition. Thus, each participant performed 2 conditions (NI_1, 
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INT_1, NI_2, INT_2).  Each condition was presented in a block, which consisted of 30 
randomly presented trials, resulting in a total of 120 trials per participant. Before entering 
the shielded room for their MEG scan, instructions regarding the experimental paradigm 
were discussed with the participants. Following answering any questions posed by the 
participants, a practice session of each experimental condition (NI & INT) was conducted 
using a laptop. Once it was clear participants understood the task, they were set up for 
their scan (further details are provided within the data acquisition and analysis section 
below). Once in the scanner and before each condition was commenced, the instructions 
were repeated to the participant via a microphone, after which a practice session was 
conducted to ensure understanding. Subsequently, in the encoding phase, a face was 
displayed for a period of 1000 ms. In the maintenance period, the participants were 
instructed to keep the encoded face in mind for a 4000 ms. In the recognition phase, a 
single face was displayed for 1000 ms and the participants were instructed to press the 
right button if it was the same or the left button if it was different to the face presented in 
the encoding phase. Participants were instructed to respond as quickly as possible. To 
ensure that all of the participants had enough time to respond, a response slide (“same 
face yes/no”) was displayed after the recognition phase and was maintained for 4000 ms. 
In the NI condition, a fixation cross was displayed in the centre of the screen for the 4000 
ms of maintenance, and the participants were instructed to remember the encoded face 
during this period. The INT condition had an additional face stimulus (a face presented 
between two question marks, indicating the additional requirement to process the 
stimulus) as an interrupter after the encoding phase, which was displayed for 1000 ms 
after the first 1500 ms of the maintenance period. The participants were instructed to 
decide if the interruption face was aged over 60 years, while maintaining the encoded 
face. Twenty-five per-cent of the interruption faces were aged over 60. 
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Data acquisition and analysis 
The MEG signal was recorded with an Elekta Neuromag 306-channel MEG system in the 
Northern Ireland Functional Brain Mapping (NIFBM) Facility of the Intelligent Systems 
Research Centre (ISRC) (Figure 4). The signal was recorded with a sampling rate of 1 
kHz using 204 planar gradiometers and 102 magnetometers. Participants were 
encouraged to sit comfortably and requested to keep as still as possible. Head movement 
was recorded using head-position information (HPI) with coils attached to the scalp. HPI 
coils position and participants head shape were defined using a 3D digitizer (Fastrak 
Polhemus, Colchester, USA) referenced to three anatomical locations (the crus of helix 
of the right and left ear and the bridge of the nose). Eye movement was monitored by two 
bipolar electrodes attached above and below the right eye, two bipolar electrodes either 
side of the eyes and one ground electrode which was placed on the cheek (Figure 4 a). 
The heartbeat was monitored by two bipolar electrodes attached on the left and right collar 
bones. The Neuromag software Maxfilter 2.2 (Elekta-Neuromag Oy, Stockholm, 
Sweden) that implements Signal-Space Separation (SSS) was used to pre-process the 
signal. This method separates magnetic signals coming from within the brain from those 
coming from outside the brain. Finally, the signal was bandpass-filtered between 0.1 Hz 
and 330 Hz. 
Resting state was recorded with eyes open (5 minutes) and eyes closed (5 minutes).The 
analysis of the signals and the time-windows of interest were the following: the called 
pre- interference period (including a time-window of 1000 ms, from 1500 ms to 2500 ms 
after the  onset of the encoding stimulus) and the called post-interference period 
(including a time-window of 1000 ms, from 3500 ms to 4500 ms after the onset of the 
encoding stimulus). The frequency range of the band power was averaged in standard 
spectral bands: delta ([1 4] Hz), theta ([4 8]Hz), alpha ([8 12] Hz), beta ([12 30] Hz) and 
gamma ([30 60] Hz). The band power and time-window of interest (pre-interference and 
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post-interference) was selected and thereafter the trials were averaged in Matlab. The 
main analysis involved creating a subband of 1 Hz frequency and computing band power 
in each subband. For this analysis, the frequency started from 1 Hz to 60 Hz so the number 
of bands obtained is 59. Additionally, the band power was also computed in the delta, 
theta, alpha, beta, and gamma bands. The analysis focused on the eyes open resting state 
and the INT condition and the Power (oscillation) across the frequency spectrum and 
within the aforementioned bands. 
Statistical analysis was conducted using SPSS (Statistical Package for Social Sciences, 
Version 23.0, SPSS UK Ltd., Chersey, United Kingdom) where non-parametric 
approaches based on the Mann Whitney Test were applied to evaluate potential statistical 
differences of the power between the B-vitamin and placebo group and a Wilcoxon 
Signed Rank test was conducted to assess differences pre- and post- interruption within 
each group. The following comparisons were performed: pre- vs. post-interruption in 
placebo and B-vitamin participants separately, and pre-interference period of placebo vs. 
pre-interference period of B-vitamin; post-interference period of placebo vs. post -
interference period of those on B-vitamins. Power was normalised for presentation 
purposes to E*25. 
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Results 
Preliminary analysis of the BrainHOP participants (n = 25) that have completed the 
Magnetoencephalography (MEG) scan was conducted (Table 1). The average age of the 
cohort was 79 years and there was no significant difference between the treatment groups 
in terms of general health, cognitive function, or depression and anxiety scores.  
Analysis of the classification accuracy of the cohort was conducted for each condition 
(Table 2). Participants that had received B-vitamins for 2 years had a trend towards 
higher accuracy than those within the placebo group for each condition (No interference 
and Interruption), albeit a significant difference was detected only in the interruption 
condition, whereby those in the B-vitamin group reached a higher accuracy (92.4%) 
compared to those on placebo (76.7%; P = 0.041). 
Average band power vs frequency spectrum for all channels in the placebo and B-vitamin 
groups was conducted for eyes opened resting state and pre and post interruption in the 
working memory task. Increased power (oscillations) at lower frequencies was seen for 
those in the placebo group compared to the B-vitamin group under all conditions (Figure 
5 and Figure 6). 
Power (oscillatory activity) of each frequency band, pre and post interruption, within the 
working memory task (INT), were analysed within the treatment groups (Table 3). The 
placebo group had significantly lower power in the alpha, beta and gamma bands post 
interruption, while the B-vitamin cohort had significantly lower power across the delta, 
alpha and beta bands. 
Analysis comparing the difference in power post interruption between the placebo and B-




0.011) bands, with the placebo group having significantly higher power (oscillation) 
compared to the B-vitamin group (Figure 7).   
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Discussion 
The preliminary findings of this pilot study suggest that optimising B-vitamin status (via 
a combined B-vitamin supplement over 2 years) may protect neuronal functioning in 
older adults as measured by MEG during resting state. Furthermore, using a working 
memory task better interference resolution was observed in the B-vitamin supplemented 
group. In addition, a significantly higher rate of accuracy within a working memory task 
was seen in those supplemented with B-vitamins for 2 years. 
These preliminary results suggest that B-vitamin supplementation for 2 years resulted in 
protected neuronal functioning, as shown by lower power across the frequency spectrum, 
in particular in the lower frequencies [1-8Hz] during resting state and during the working 
memory tasks in those in the B-vitamin supplemented group compared to those on 
placebo. Notably, it has been previously reported during resting state MEG scans, that 
power in the theta band [4-8 Hz] was lower in healthy controls compared to those with 
poorer cognitive function (i.e. patients with MCI) (López et al. 2014). Evidence also 
suggests increases in the Delta power [1-4 Hz] in MCI patients when compared to healthy 
controls, and that spectral changes in Alzheimer’s disease start with an increase in the 
Theta power [4-8 Hz] (López et al. 2014). Preliminary results from the current study 
suggest that those supplemented with B-vitamins over 2 years appear to be protected from 
this increased Theta and Delta power [1-8 Hz] previously reported in patients with MCI 
and Alzheimer’s disease, while those in the placebo group appear to experience higher 
power in the lower frequencies. These are preliminary results, therefore no firm 
conclusions can be made. If however these results are confirmed, the power observed  in 
the delta and theta band within the current study would suggest that those who received 
B-vitamins for 2 years appear to be demonstrating similar MEG patterns to healthy 
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controls while the placebo group appear (in relative terms) seem to be following a similar 
MEG pattern to that observed previously in MCI patients (López et al. 2014). 
The preliminary findings also suggest that B-vitamins may have a role in maintaining 
successful interference resolution in ageing, as shown by the significant difference 
between the placebo and B-vitamin groups in the post-interference power in the Theta 
band [4-8Hz], where the placebo group has a significantly higher power than the B-
vitamin group. Research conducted using Electroencephalography (EEG), which like 
MEG, also measures neuronal activity but has poorer spatial resolution (as the electric 
fields are distorted by the skull and scalp), has specifically investigated the effects of 
interference on working memory and frequency band power. Interestingly a previous 
study using EEG suggested that higher levels of interferences are seen via higher power 
in the Theta band and that successful interference resolution causes a reduction in power 
in Theta band (Staudigl et al. 2010). These findings, although preliminary, suggest that 
B-vitamins may have a role in maintaining successful interference resolution in ageing, 
and thus a lower Theta value post interruption in the working memory task (Figure 5). 
Preliminary results from the current MEG study, specifically those relating to the Theta 
power [4-8 Hz], are somewhat in line with MRI outcomes of the VITACOG study where 
supplementation for 2 years appear to the protect against atrophy in the hippocampus 
(Smith et al. 2010; Douaud et al. 2013). Theta band power was higher in the placebo 
group compared to the B-vitamin group. Earlier evidence from an EEG study suggested 
that increased power in Theta band (as seen in those in the placebo group) is negatively 
correlated with hippocampal volumes (Grunwald et al. 2001). Likewise, in the 
VITCAOG trial reduced atrophy particularly of the hippocampal regions were seen after 
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2 years of intervention with B-vitamins (Smith et al. 2010; Douaud et al. 2013). These 
preliminary findings appear to support the earlier results from the VITACOG trial and 
provide new evidence further linking optimised B-vitamin status with improved brain 
health in ageing. 
Interestingly the participants investigated in the current study and the aforementioned 
VITACOG trial differ somewhat, in that the current participants are generally healthy 
while the VITACOG participants all suffered from MCI (Smith et al. 2010; Douaud et 
al. 2013). Despite these differences, the imaging results from both studies suggest similar 
protective effects of B-vitamins on brain health. MEG however, has the ability to detect 
the earliest functional changes that may occur as a result of neuropathological processes, 
but prior to the onset of the neurological disorder has been reported elsewhere (Zamrini 
et al. 2011). This highlights a significant benefit of utilising MEG within studies 
investigating the effect of nutrition on brain health and also its use in monitoring brain 
health before the onset of a significant disease. Other practical advantages of MEG which 
are important to consider in older cohorts are that MEG is non-invasive, does not require 
significant participant preparation and can be conducted in longitudinal or intervention 
studies as it a safe procedure (Braeutigam 2013). This pilot study highlights the potential 
for this imaging technique to be used in future studies investigating the role of nutrition 
in brain health. 
As mentioned in earlier chapters within this thesis, the postulated mechanism linking B-
vitamins with brain health in ageing are invariably associated with the one carbon 
metabolic pathways. Smith and Refsum (2016) have provided a detailed summary of the 




regulation of gene expression in the Beta amyloid pathway via s-adenosylmethionine. 
Interestingly amyloid Beta peptides have also been reported to contribute to the 
destabilisation of the neuronal networks (Palop and Mucke 2010) and thus may provide 
a biological explanation for the current results. Lopez et al (2014) have also highlighted 
the potential for MEG as a candidate “neuronal degeneration” marker of Alzheimer’s 
disease. Future studies exploring B-vitamins in relation to brain health may benefit from 
using MEG as a means to help elucidate the biological mechanism involved.  
 
Several studies have used MEG to measure neuronal activity in response to consumption 
of dietary components; these include interventions with alcohol, L-Theanine and water 
and studies investigating the effects of hydration (Müller et al. 2002; Müller et al. 2003; 
Marinkovic et al. 2014; White et al. 2016). Furthermore, combined nutrient interventions 
have been conducted; including a 24 week trial in mild Alzheimer’s disease patients (Van 
Straaten et al. 2016) using a specific oral nutritional supplement (Souvenaid which 
contains the nutrient combination Fortasyn® Connect by Nutricia Research). A further 6 
month intervention  (Scholey et al. 2013) using Lacprodan® in a larger cohort of mild-
Alzheimer’s disease patients was reported, however, to date no results for this trial are 
available. These aforementioned studies examined brain region specific analysis, 
functional connectively, network connectively and peak frequency analysis and were able 
to incorporate other imaging techniques such as fMRI. Once data collection from our 
study cohort is completed a more definitive comparison between correlates of brain 
function and nutritional interventions will be possible.  
A significant strength of this study is that it explores the effect of a combined B-vitamin 
supplement on brain function as measured using MEG and provides objective 
observational evidence for a protective role of B-vitamins in supporting brain health.  This 
study also had limitations. A cause and effect relationship cannot be assessed as the scans 
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were only conducted after the 2-year intervention. Additionally, B-vitamin biomarker 
data were not available at the time of writing; once available, it will enable a more robust 
analysis of the results in relation to B-vitamin status.  Finally, as previously noted the 
current findings are preliminary, therefore, no firm conclusion can be made, however the 
ultimate outcomes may help to support and guide further research in this area. 
In conclusion, findings from this MEG analysis, although preliminary, suggest that better 
B-vitamin status is associated with improved neuronal functioning. If confirmed these 
results will provide robust evidence of the role of B-vitamins in brain functioning. In 
addition, these findings support the potential of employing this novel imaging technique 
to determine if functional changes in neuronal activity can be achieved through nutritional 
intervention. Ideally, studies that utilise a combination of imaging techniques to assess 
structural anatomy (such as MRI) and the direct measurement of 4D neuronal activity 
(MEG) rather than indirect measures of neuronal activity via hemodynamic response 
alone (fMRI) should yield stronger mechanistic insights. 
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Figure 2. Flow diagram of the BrainHOP MEG pilot study 
MEG (target n 24) 




Placebo (n 165) 
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Age (year) 79.1 (3.9) 78.6 (4.0) 79.9 (3.9) 0.453 
Gender (male) n (%) 11 (44) 8 (57) 6 (55) 1.00 
Education (years) 16 (4.0) 16.9 (4.6) 15.8 (3.1) 0.570 
Health and Lifestyle 
BMI (kg/m2) 29.4 (4.6) 30.8 (4.3) 27.7 (4.7) 0.143 
Timed Up and Go 
(seconds) 
10.3 (3.0) 10.8 (3.7) 9.7 (1.9) 0.530 
PSMS score 23.8 (0.5) 23.9 (0.3) 23.6 (0.7) 0.504 
IADL score 27.8 (0.6) 27.9 (0.5) 27.6 (0.7) 0.211 
Living alone n (%) 5 (20.0) 3 (21.4) 2 (18.2) 1.000 
Alcohol (units/week) 5.4 (8.0) 6.3 (9.8) 4.3 (5.4) 0.431 
Medical 
Diabetes n (%) 6 (24.0) 3 (21.4) 3 (27.3) 1.000 
Hyperlipidaemia n (%) 10 (40) 7 (50.0) 3 (27.3) 0.459 
Hypertension n (%) 20 (80) 11 (78.6) 9 (81.8) 1.000 
Previous MI n (%) 2 (8.0) 2 (14.3) 0 (0) 0.573 
Previous TIA n (%) 1 (4.0) 0 (0) 1 (9.1) 0.902 
Cognition 
RBANS score 95.2 (11.8) 94.0 (12.6) 96.7 (11.0) 0.570 
Immediate Memory 100.4 (14.1) 97.7 (15.1) 104.1 (12.6) 0.287 
Visuospatial 93.4 (15.4) 92.5 (18.3) 94.5 (11.2) 0.760 
Language 100.8 (10.0) 101.4 (10.1) 99.9 (10.5) 0.722 
Attention 94.3 (14.6) 90.9 (15.9) 99.1 (11.7) 0.160 
Delayed Memory 96.4 (10.9) 97.0 (8.9) 95.6 (13.6) 0.751 
Data presented as means (SD), unless otherwise indicated. Differences between treatment 
groups were assessed using independent sample t-tests on transformed data where 
required, categorical variables were assessed using chi square test, P < 0.005 was 
considered significant. 
Abbreviations: BrainHOP, B-vitamin and Brain Health in Older People; PSMS, Physical 
Self-Maintenance Score; IADL, Instrumental Activities of Daily Living; MI, Myocardial 
infarction; TIA, Transient Ischemic Attack; RBANS, Repeatable Battery for the 
Assessment of Neuropsychological Status. 
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Table 2. Accuracy in working memory task after 2 years of intervention with B-vitamins 
or placebo  
Data presented as means (SD), unless otherwise indicated. 
*Data analysed using Mann-Whitney Test.
Classification Accuracy P* 
Placebo Treatment 
No interference 
Overall 84.9 (15.1) 90.3 (8.5) 0.415 
Block 1 83.1 (17.7) 89.4 (7.7) 0.698 
Block 2 87.7 (13.9) 91.2 (12.0) 0.346 
Interruption 
Overall 76.4 (22.1) 93.3 (7.5) 0.080 
Block 1 80.6 (21.5) 88.8 (8.3) 0.445 
Block 2 76.7 (20.9) 92.4 (7.3) 0.041 
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Table 3. Oscillation Power by MEG after 2 years of intervention with B-vitamin or 
placebo  
Placebo B-vitamins 
Hz Pre Post P1 Pre Post P1 
Delta 
[1 4] 
2.96 (3.46) 2.88 (4.57) 0.398 1.87 (0.32) 1.13 (0.19) 0.036 
Theta 
[4 8] 
0.13 (0.17) 0.12 (0.09) 0.310 0.06 (0.01) 0.05 (0.01) 0.093 
Alpha 
[8 12] 
0.09 (0.08) 0.07 (0.07) 0.028 0.06 (0.01) 0.05 (0.01) 0.017 
Beta 
[12 30] 
0.15 (0.12) 0.13 (0.13) 0.018 0.09 (0.01) 0.08 (0.01) 0.036 
Gamma 
[30 60] 
0.04 (0.04) 0.02 (0.02) 0.018 0.02 (0.00) 0.01 (0.00) 0.093 
Date presented as mean (SD) Data*E+25 
1Differences between pre and post interference within each treatment group were 




























































































































































































Figure 6. Average Power vs Frequency spectrum for all channels in the B-vitamin and 















































Figure 7. a) Delta b) Theta, Alpha, Beta and Gamma bands, pre and post-interference 
within the working memory task after 2 years of intervention with B-vitamin or placebo 
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The overall aim of this thesis was to investigate the role of B-vitamins on brain health in 
in the Trinity, Ulster and Department of Agriculture (TUDA) ageing study cohort. In 
fulfilment of this aim, the following objectives were addressed; a comprehensive review 
which explored the emerging evidence linking diet and specific nutrients with mental 
health in ageing (Chapter 2); an investigation of folate, vitamin B12, vitamin B6 and 
riboflavin in relation to depression and anxiety in older adults and to consider the role of 
fortified foods as a means of improving B-vitamin status and reducing the risk of these 
mental health disorders (Chapter 3); a randomised trial, BrainHOP, conducted in TUDA 
participants to investigate the effect of B-vitamin supplementation with folic acid and 
related B-vitamins over 2 years on cognitive function and depression in older adults 
(Chapter 4); an investigation of B-vitamins in brain function using MEG in older adults 
(Chapter 5). 
 
Summary of the current findings  
Declining brain health in older age is one of the greatest health challenges we face, given 
the significant increase in life expectancy. There is an urgent need to identify modifiable 
risk factors that could be targeted to help maintain brain health in ageing, with much 
interest in dietary patterns and specific nutrients which may have protective roles against 
mental health disorders. In Chapter 2 an extensive review of the available literature 
showed that the strongest evidence, in the form of randomised controlled trials, supports 
roles for the Mediterranean diet and B-vitamins, n-3 PUFAs and polyphenols, as having 
a beneficial effect on brain health in ageing. The majority of research in the nutrition and 
mental health sphere has relied on questionnaire-based assessment of brain health, 
however, studies that have also incorporated brain imagining technologies have provided 
the most objective and robust evidence to date.  In the case of B-vitamins, the VITACOG 
trial which used MRI showed that supplementation with B-vitamins over 2 years resulted 
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not only in improved cognitive performance (de Jager et al. 2012), but also reduced brain 
atrophy (Douaud et al. 2013). Although the evidence in this area is accumulating, it is not 
entirely consistent, and there are a limited number of published trials with considerable  
methodological heterogeneity between the available studies. The review indicated that 
there is an urgent need for future work in the form of randomised trials, ideally 
incorporating novel brain imaging technologies, to support and confirm the current 
evidence and also to enhance our understanding of the biological mechanism linking these 
nutrients with brain health in ageing.     
In relation to depression the review (Chapter 2) also identified that the majority of the 
research conducted to date involving B-vitamins has focused predominantly on folate and 
vitamin B12 with evidence that deficiency of either of these vitamins is associated with 
an increased risk of depression. There was however limited evidence available in relation 
to the roles of vitamin B6 and riboflavin in depression despite both B-vitamins 
functioning as co-factors within one carbon metabolism. An examination, therefore, of 
the impact of all four B-vitamins involved in one carbon metabolism on depression and 
anxiety in older adults was identified as a research priority. Analysis within Chapter 3 
showed that lower biomarker status of folate or vitamin B6 or riboflavin were each 
associated with an increased risk of depression in ageing (by up to 78%), while vitamin 
B6 deficiency was associated with an increased risk of anxiety (by up to 73%). Further 
investigations considered the impact of B-vitamin fortified food consumption on the risk 
of depression. B-vitamin fortified foods and/or B-vitamin supplement use was found to 
optimise B-vitamin biomarker status of older adults and importantly daily consumption 
of B-vitamins fortified foods (e.g. fortified breakfast cereals) was associated with a 50% 
reduction in the risk of depression in older adults. The biomarker results presented within 
Chapter 3 for folate, vitamin B6 and riboflavin were determined using what are 
considered to be the gold standard analysis methods, however as of yet the gold stand for 
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assessing vitamin B12 biomarker status is not clear (McNulty and Hughes 2017).As 
highlighted by Porter et al (2016) and Bailey et al (2015) there are direct and functional 
biomarkers for each B-vitamin, which may explain the discrepancy between B-vitamin 
status of participants in the TUDA cohort and other published work in the area.    
It was apparent, from the current evidence reviewed in Chapter 2 and the observational 
results found in Chapter 3, that further work in the form of a well-designed randomised 
trial are required to more fully investigate the role of B-vitamins on mental health in older 
age. The B-vitamins and Brain Health in Older People (BrainHOP) randomised trial of 
low dose B-vitamin supplementation over 2 years, was conducted in a sub-set of the 
TUDA ageing cohort, who were generally healthy adults aged 70 years and older at time 
of randomisation. To our knowledge this is the first trial to demonstrate that 
supplementation with folic acid, vitamin B12, vitamin B6 and riboflavin (at doses within 
the dietary range) could protect against visuospatial cognitive decline in healthy older 
adults (Chapter 4). These results build significantly on results from the VTIACOG trial 
which reported similar findings albeit using a different cognitive tool. Of note, 
visuospatial cognitive function has recently been identified to have diagnostic and 
prognostic potential for dementia (Salimi et al. 2018), but to date evidence of the role for 
nutrition influencing this cognitive domain is limited. Furthermore, the findings of the 
BrainHOP trial suggest that B-vitamin supplementation may also have a role in reducing 
the risk of depression in older age, albeit the study was not powered to detect the effect 
B-vitamin supplementation on depression (i.e. a secondary outcome) and therefore results 
in relation to depression need to be confirmed. In addition, the results of the BrainHOP 
trial as a whole are somewhat preliminary at this time given that the B-vitamin biomarker 
analysis has not been completed and thus final conclusions cannot be made. Once B-
vitamin biomarker data become available, sub-group analysis will be conducted to 
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examine responses (in relation to cognition and depression) in participants with the lowest 
B-vitamin status (and/or higher Hcy concentrations). 
 Considering the novel conclusions from the recent VITACOG trial where beneficial 
effects of B-vitamin supplementation were observed, not only in cognitive function (de 
Jager et al. 2012), as per the current findings, but also in brain atrophy (as measured using 
MRI) (Smith et al. 2010; Douaud et al. 2013), a pilot study utilising a novel brain imaging 
technique MEG was undertaken (Chapter 5).  A subset of participants from the 2-year 
BrainHOP trial were investigated using MEG in order to further explore the role of B-
vitamins in influencing neuronal functioning. Initial results confirmed the cognitive 
function findings from the main BrainHOP trial, in that significantly higher rates of 
accuracy (i.e. based on correct response within the working memory interruption task) 
were observed in those that had received B-vitamin supplementation (compared to 
placebo) over the previous 2 years.  For the first time, findings from the MEG analysis 
suggested that the B-vitamin supplement group had better neuronal functioning shown by 
their lower power in the lower frequencies of activity [1-8 Hz]. Furthermore, differences 
in relative power (at a given frequency, particularly lower frequencies) between the B-
vitamin and placebo groups in this study were similar to previous observations of 
differences in the relative power between healthy controls and MCI patients (López et al. 
2014). In addition, those that had received B-vitamin supplements also had significantly 
lower power in the Delta [1-4 Hz] (P = 0.021) and Theta [4-8 Hz]  (P = 0.011) bands 
following interruption within the working memory task, suggesting better interference 
resolution compared with the placebo group. 
 
Mechanism linking B-vitamins with brain health 
The biological mechanisms explaining the findings of this thesis showing a protective 
effect of folate and the metabolically relate B-vitamins (vitamin B12, vitamin B6 and 
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riboflavin) on brain health although unknown, are however likely to relate to the crucial 
roles of these nutrients within one carbon metabolism. Within this metabolic network, the 
aforementioned B-vitamins act as co-factors in DNA synthesis and repair, amino acid 
metabolism and methylation reactions, including the remethylation of Hcy to methionine 
and subsequent generation of SAM. Insufficient supply of any of these B-vitamins may 
impair methylation processes (Selhub et al. 2000; Bottiglieri et al. 2000). The findings 
within this thesis are consistent with the hypothesis that inhibition of methylation 
reactions influences cognitive impairment during ageing as reviewed by Smith and 
Refsum (2016). Another possibility relating to the protective role of B-vitamins on brain 
health could be via maintaining vascular health, as B-vitamins may be associated with 
lower risks of vascular events such as stroke (Spence et al. 2017). The role of vascular 
dysfunction (cerebrovascular disease) in the pathophysiology of declining cognitive 
function is more generally accepted (Gorelick et al. 2016) The role that B-vitamins play 
in protection of vascular function (BP, cardiovascular history and measures of vascular 
inflammation) and improving cognitive health will be further explored in the TUDA 
cohort. In the case of depression the results from this thesis are consistent with 
Bottiglieri’s work where reduced tissue concentrations of SAM are suggested to be linked 
to depression through perturbing monoamine (serotonin, dopamine and noradrenaline) 
synthesis and methylation (Bottiglieri et al. 2000). Furthermore the active form of vitamin 
B6 (plasma pyridoxal-5-phosphate; PLP), is the important co-factor for aromatic L-amino 
acid decarboxylase in the tryptophan serotonin pathway, thus lower vitamin B6 biomarker 
status may lead to reduced concentrations of serotonin and thus increased risk of 
depression (Hensler 2006). 
 
Wider public health implications  
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Dementia and depression are the leading causes of disease burden in older adults in our 
society which is ageing rapidly (World Health Organisation 2016). Without any disease-
modifying treatments for dementia (Frankish and Horton 2017) and with poor response 
rates to antidepressant medication (Rush et al. 2006), there is an urgent need to identify 
targeted interventions to promote better brain health in our ageing populations. It has been 
estimated that even a delay of one year in the onset of dementia could prevent more than 
9 million cases of dementia by 2050 (Frankish and Horton 2017). Results from this thesis 
support the potential benefits of optimising B-vitamin status using dietary doses, which 
would in turn be achievable on a population level via mandatory or voluntary fortification 
of food, as a measure to help delay the onset of dementia and potentially reduce the risk 
of depression in ageing. Mandatory fortification, which was introduced to reduce the 
incidence of neural tube defects, is currently implemented in 80 countries around the 
world and this measure has resulted in substantially reducing the prevalence of folate 
deficiency in these populations (Pfeiffer et al. 2005). Many European countries that do 
not have mandatory folic acid fortification, for example Ireland and the UK, have quite 
liberal voluntary fortification policies. Findings from the current thesis have highlighted 
the significant benefits of regular consumption of B-vitamin fortified foods on biomarker 
status as previously reported in Ireland (Hoey et al. 2007; Hopkins et al. 2015) and in  
The Newcastle 85+ Study in the UK (Mendonça et al. 2016). There are however certain 
concerns in relation to an adverse interaction of high dose folic acid and low vitamin B12 
in potentially leading to increased risk of cognitive impairment (Porter et al. 2016). From 
a population perspective, and to avoid potential adverse effects of one vitamin at high 
levels, a balanced approach to optimising the status of all relevant B-vitamins may be the 
most appropriate approach and this in turn could be achieved through food fortification 
or supplementation.  Tsiachristas and Smith (2016) conducted a decision model where it 
was estimated that B-vitamin supplementation would save £60,021 per quality-adjusted 
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life year gained and could thus be a highly cost-effective  means of prevention of brain 
disorders. Clinical practice and recommendations in other countries, including the United 
States and Sweden, proactively address low/deficient B-vitamins status by recommending 
older adults to consume the majority of their vitamin B12 in crystalline forms (Institute 
of Medicine Panel 2000) and offering B-vitamins to those with concerns regarding their 
memory and elevated Hcy concentrations (Lőkk 2013). Overall, the results from this 
thesis, if confirmed, will have important implications for dietary recommendations and 
future health policies targeting low cost non-drug strategies to improve brain health and 
thus quality of life in older adults. 
 
 
Strengths and limitations 
The main strength of this thesis is that the findings reported are based on analysis of data 
from the TUDA cohort, a large, well characterised cohort of 5,186 older adults. The 
inclusion of a highly controlled 2 year randomised trial of this older adult cohort enabled 
an investigation of potential causal links between B-vitamins and cognitive function, and 
to a lesser extent depression, in older adults. The 2 year trial followed-up TUDA 
participants found to have higher Hcy concentrations (i.e. indicative of lower B-vitamin 
status) and who were at an age where cognitive decline is more likely to occur (Murman 
2015). A further strength of this thesis was that the methods used to assess brain health 
included a battery of cognitive assessment tests which enabled the analysis of both global 
cognition as well as a number of sub-domains which have been reported to be sensitive 
to ageing process (Howieson et al. 1993). This thesis also included a novel and robust 
imaging technique (MEG) which, to our knowledge, is the first to investigate the effect 
of a combined B-vitamin supplement on cognitive function in cognitively intact older 
adults, although it has been utilised  to investigate the effect of a nutritional supplement 
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(containing B-vitamins among other nutrients) in cohorts suffering from mild 
Alzheimer’s disease (Van Straaten et al. 2016).  Finally, this thesis investigated the effect 
of all four B-vitamins involved in one-carbon metabolism and at doses within the dietary 
range, thus enabling the role of B-vitamins within this metabolic network to be more fully 
explored compared with previous studies in this area. However, this thesis was not 
without limitations. Overall, the TUDA cohort was in general a healthy, well educated, 
older cohort and thus the effect of B-vitamin supplementation on cognition and 
depression might be less than expected in other populations. One of the important risk 
factors for Alzheimer’s disease is the APOE4 polymorphism (Brouwers et al. 2008), 
however, this genetic information was not available for the TUDA cohort and could not 
be investigated. Also the CES-D scale used to assess depression, may not be as robust as 
other diagnostic instruments and this may have limited to some extent the interpretation 
of the current findings in relation to depression (Vilagut et al. 2016). A significant 
limitation of the BrainHOP trial findings, is that the final B-vitamin biomarker results 
were not available at the time of writing this thesis and therefore no sub-group analysis 
by B-vitamin status at baseline could be performed. For the chapter reporting the MEG 
analysis, the MEG scans were taken at one time point only and were not conducted prior 
to the B-vitamin intervention thus limiting the interpretation of the results with respect to 
verifying any beneficial effects of B-vitamins that were observed.   
 
Conclusions and future work 
In summary, the research presented in this thesis provides evidence to show that: 
1. Better B-vitamin biomarker status, specifically of folate, vitamin B6 and 
riboflavin, may each be associated with protective effects against depression in 
ageing. 
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2. Regular B-vitamin fortified food consumption and B-vitamins supplement usage 
can significantly improve B-vitamin biomarker status in older adults.    
3. The consumption of B-vitamin fortified foods consumed on a daily basis was 
associated with a 50% reduction in the risk of depression in older adults. 
4. Supplementation with folic acid, vitamin B12, vitamin B6 and riboflavin at doses 
within the dietary range, over 2 years was associated with protecting visuospatial 
cognition and reducing the risk of depression in older adults. 
5. Preliminary findings suggest that optimisation of B-vitamin status (following 2 
years of supplementation with combined B-vitamins) was associated with better 
brain function as measured using MEG.   
This thesis has also identified areas that require further investigation: 
1. Further randomised trials investigating brain health and disease in older age are 
warranted. Future trials should ideally target: 
a. Participants who have suboptimal B-vitamin biomarker status  at baseline 
(and thus most likely to benefit from B-vitamin supplementation) 
b. Use of brain imaging technologies to provide structural (MRI)  and 
functional (MEG) measurements of the brain pre and post intervention 
with B-vitamins 
c. Use of a sensitive validated tool for assessing depression 
d. Multidisciplinary approach including experts in nutrition, psychology, 
bioengineering, radiology and genetics 
e. A large multi-centre approach (across Europe) with standardised protocols 
for assessment of cognition and depression and centralised biomarker 
analysis.  
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2. A randomised controlled trial investigating the effect of intervention with B-
vitamin fortified foods on B-vitamin biomarker status and cognition and 
depression outcomes in older adults. 
3. Mechanistic studies to investigate the effect of B-vitamin supplementation in 
older adults on DNA methylation using a multi-disciplinary approach 
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Research Protocol 
Title 
The Trinity, Ulster and Department of Agriculture (TUDA) Cohort Study. 
Background 
Cardiovascular disease (CVD), osteoporosis and Alzheimer’s disease are chronic diseases of 
ageing that impact adversely on the lives of those affected and have major health, social and 
economic consequences. 
A number of factors are considered to be implicated in these diseases, ranging from the more 
established factors to those that are less well recognised. Lifestyle factors such as diet, body 
weight, smoking, physical activity and years of education are acknowledged as risk factors for 
the development of these chronic diseases. Of the nutritional factors, calcium and vitamin D 
are well-established as important nutrients for the maintenance of bone mineral density 
(BMD) and the prevention of osteoporosis (Lanham-New, 2008). However, new research now 
suggests that elevated homocysteine and/or sub-optimal status of the metabolically related B-
vitamins (folate, vitamin B12) may be associated not only with a higher risk of osteoporosis 
(Cagnacci et al, 2003; Dhonukshe-Rutten et al, 2005; Gjesdal et al, 2006), but also of CVD, in 
particular stroke (Hcy studies collaboration, 2002; Wald et al, 2002; Wang et al, 2007), and of 
cognitive decline and dementia (Quadri et al, 2004; Kado et al, 2005; Haan et al, 2007). In 
addition, genetic factors are increasingly recognised as playing a critical role in disease risk. 
Individuals who are homozygous (TT genotype) for the common 677C→T polymorphism in 
the gene coding for the enzyme methylenetetrahydrofolate reductase (MTHFR) that plays an 
important role in folate/homocysteine metabolism, are reported to have a higher risk of 
hypertension (Jiang et al, 2004), CVD (Wald et al, 2002; Klerk et al, 2002) and osteoporosis 
(Riancho et al, 2006) compared to those without the 677C →T polymorphism. Likewise, 
polymorphisms of the vitamin D receptor (VDR) gene have been associated with an increased 
risk of osteoporosis (Uitterlinden et al, 2006; Moffett et al, 2007). However, there are 
inconsistencies in the literature as to the importance of such genetic variants in disease risk. It 
is possible that the detrimental health effects associated with these genetic factors may only 
occur in particular population subgroups, such as those with low nutritional status. There is 
evidence to suggest that the typical phenotype (i.e. elevated homocysteine concentrations) 
associated with homozygosity for the MTHFR 677C→T polymorphism can be modified by 
folate (Klerk et al, 2002) and riboflavin status (McNulty et al, 2006), and that the risk of 
osteoporosis associated with polymorphisms of the VDR gene only occurs in those with low 
calcium intakes (MacDonald, 2003). 
Although the interplay between relevant genetic and nutrient factors (gene-nutrient 
interactions) is considered to be highly relevant in the development (and prevention) of 
chronic diseases of ageing, this relatively new area of research is as yet poorly understood. 
The collection of clinical, lifestyle, nutritional and genetic data on large numbers of patients 
would permit the investigation of those nutrients which interact with specific genes to 
increase the likelihood of a person developing chronic diseases of ageing. Funding has 
recently been secured from both Governments (Irish and UK) for a large cross-border project 
to investigate this research area. 
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Study Aim 
 
The aim of this study is to collect detailed clinical, lifestyle, dietary, genetic and biochemical 
data to investigate gene-nutrient interactions (particularly from the perspective of the B-
vitamins and vitamin D/calcium) in the development of CVD, osteoporosis and Alzheimer’s 
disease by studying older adults exhibiting the early stages of these common diseases, namely 
hypertension, low bone mineral density, and early memory loss, respectively. 
 
Study Design and Methods 
 
The current study (Trinity, Ulster and Department of Agriculture; TUDA) is one of three 
studies being undertaken as part of a cross-border collaborative project (the National Nutrition 
Phenotype Database Project), involving four universities: University College Dublin, Trinity 
College Dublin, University College Cork and the University of Ulster. The TUDA study is an 
observational study of a convenience sample of 6000 patients recruited from both the North 
and South of Ireland with phenotypic early evidence of Alzheimer’s disease, osteoporosis and 
CVD. Ethical approval has been applied for, and obtained in the South for the cognitively 
impaired (n=2000) and the osteoporotic cohorts (n=2000) who will be recruited from St 
James’s Hospital Dublin. Ethical approval is being sought here only for the recruitment of the 
2000 hypertensive patients who are under the care of Consultant Cardiologists at two separate 
Trusts in Northern Ireland (Western Health and Social Care Trust and, Northern Health and 
Social Care Trust) and for the examination of data from all 6000 participants.  
 
Patients under the care of the Consultant Cardiologists will be approached. Those patients 
who give their permission will be contacted by telephone by the researchers who will fully 
explain the study to them and then invite them to participate once current suitability is 
established according to the inclusion/exclusion criteria. The inclusion criteria are: patients 
over 60 years of age who attend (or have attended) a cardiology clinic and have been 
diagnosed with hypertension defined as a blood pressure of greater than 140/90 mmHg 
(British Hypertension Society, 2006) or are currently taking hypertensive medication. The 
exclusion criteria are as follows: patients under 60 years of age, patient (or their parent) not 
born in either the North or South of Ireland and those with severe dementia. Patients that are 
suitable and that verbally agree to participate will be given a participant information sheet and 
consent form and will be allowed at least 48 hours to consider the written information and 
decide if they wish to participate. If agreeable and after informed consent is received, 
participants will be asked to do the following:  
 complete a detailed health and lifestyle questionnaire to obtain information on diet, 
general health, drug and supplement use. 
 complete physiological function tests (e.g. blood pressure, DXA scans and a battery of 
cognitive function tests). The researchers will be trained in how to administer the 
cognitive tests by a consultant physician (Dr. F. Tracey CHSST). 
 have their height, weight and waist/hip measurements taken. 
 provide a non-fasting blood sample (50ml). Blood samples will be taken by a qualified 
phlebotomist. 
 Provide a buccal swab 
 
Blood samples will be analysed for the following:  
 routine clinical markers of health (e.g. renal function, liver function, lipids, full blood 
count, glucose, glycosylated haemoglobin) will be performed at the participating 
hospital laboratory; 
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 vitamin B12 biomarkers - serum total vitamin B12 (microbiological assay), serum 
transcobalamin (holoTC, microparticle enzyme immunoassay) and plasma 
methylmalonic acid (GCMS) at Trinity College Dublin; 
 plasma homocysteine (immunoassay), serum folate and red cell folate 
(microbiological assay) at Trinity College Dublin; 
 riboflavin status (erythrocyte glutathione reductase activation coefficient; EGRac) at 
the University of Ulster; 
 vitamin B6 status (pyridoxal-5-phosphate, PLP by HPLC) at the University of Ulster; 
 bone biomarkers including serum 25-hydroxyvitamin D (ELISA) and serum intact 
parathyroid hormone (PTH; ECIA) at the University of Ulster; and 
 
Blood samples and buccal swabs will be anlaysed for  
 single nucleotide polymorphisms (SNPs) from the perspective of folate/vitamin B12 
and calcium/vitamin D metabolism. 
Blood samples/buccal swabs for the TUDA study will be stored at both Trinity College 





As this is a collaborative all-Ireland study, statistical analysis will be approached centrally. A 
working group on data management and analysis is currently being established which will 
include the task leaders and all PIs in the field of bioinformatics, statistics and epidemiology. 
A workshop will be held to ascertain the possible options for the best architecture and 
warehousing of the data and subsequent centralised training will be arranged in Dublin to 
cover the collection, entry and statistical analysis of data. Dr Cathal Walsh, Lecturer in 




The research associates will be responsible for the collection, input and analysis of all data.  
All data collected for the study will be kept strictly confidential, and subjects will be assigned 
a unique indemnification code. The file containing personal details and study indenification 
numbers will be kept under secure conditions in accordance with the NHS Guidelines 
(HSC99/053) and will be kept for a minimum of 25 years. The data will be archived securely 
in a restricted access room for the duration. The main database involved in the study will be 
stored on a password-protected computer. Any hard copies will be kept under locked 




These are the main ethical issues in relation to this study. 
i) Informed Consent – all potential participants will be given both written and oral 
information about the study before providing informed consent. It is envisaged that 
some of the participants will have difficulties in reading, hearing and writing. 
Participants will be provided with enlarged copies of the information sheet and 
consent form on request and they will be informed that they may nominate 
someone who can sign the consent form on their behalf. Every effort will be made 
to provide a translation of the information relevant to the study for those who do 
not understand written or verbal English. 
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ii) Participant Confidentiality – all participants will be assigned a unique 
identification study code. 
iii) Blood Sampling – blood samples will be taken by a fully trained phlebotomist 
with a first aider on site. 
iv) DXA Scanning – the radiation which the volunteer will be subjected to will be the 
minimum possible dose. Those individuals performing the scans will be fully 
trained and will adhere to all current health and safety regulations (IRMER) and 
DXA performance protocols. 
v) Sample storage – all human samples will be stored as per requirements under the 
Human Tissue Act (HTA). 
vi) Data Records – all participant data will be stored on a password protected 
computer. Hard copies of data will be stored in locked cabinets under the custodial 
care of the Chief Investigator. 
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Participant Information Sheet 
Northern Ireland Centre for Food and Health (NICHE) 
School of Biomedical Science 
University of Ulster 
The Trinity, Ulster and Department of Agriculture (TUDA) 
Cohort Study  
(A study to examine the link between diet, genetics and health) 
Invitation 
You are being invited to take part in research being conducted at the University of Ulster in 
collaboration with two Health and Social Care Trusts in Northern Ireland (Western and 
Northern Trusts). Before you decide whether or not to participate, it is important that you 
understand what the research is for and what you will be asked to do. Please read the following 
information and do not hesitate to ask any questions about anything that is unclear to you. Take 
time to consider whether or not you want to take part.  
Thank you for taking the time to consider this invitation. 
What is the purpose of the study?  
High blood pressure, low bone density and mild memory loss are common health problems 
among older adults that can lead to more serious problems if left untreated. A number of  
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factors such as diet, genetic make-up and lifestyle are known to influence the likelihood of a 
person developing these diseases. The purpose of this study is to collect information on these 
factors from adults over 60 years of age who live in the North or South of Ireland, and who 
attend an outpatient clinic for treatment of these conditions. The information gathered will be 
used to try to more fully understand the link between diet, genetic make-up and health that is 
likely to help in the prevention of these common diseases.   
 
Why have I been chosen? 
You have been chosen because you have been diagnosed with high blood pressure or currently 
take medication to lower your blood pressure, and/or you are an outpatient at a clinic in either 
the Northern or Western Health and Social Care Trust and you are over 60 years of age. If you 
accept you will be one of a possible 2000 people participating in this study. However, there are 
several factors that may affect the study results, so the following individuals would not be 
suitable to take part in the study: 
 Anyone under 60 years of age 
 If you or your parents were not born in the North or South of Ireland. 
Anyone with severe dementia. 
 
 
Do I have to take part? 
It is up to you to decide whether or not you take part. If you decide to participate, you will be 
given this information sheet to keep and you will be asked to sign a consent form. You have  
 
the right to withdraw from the study at any time without giving a reason. A decision to 
withdraw at any time, or a decision not to participate, will not affect the standard of care that 
you receive. 
 
What will happen to me if I take part? 
You will be asked to: 
 Have your blood pressure measured 
 Have your height, weight and waist circumference measured 
 Provide one 50ml blood sample 
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 Provide answers to some questions about your diet, lifestyle, use of vitamin 
supplements and medications, your own general health and family history of disease 
 Undergo some tests of memory and mood 
(The above measurements will take place at a clinic within your Health Trust, which is convenient to you.)  
 Have your bone density measured using a bone scanner (this will take place at either 
Altnagelvin Hospital or University of Ulster Coleraine, whichever is more convienent). 
You will have to lie still on a bed for approximately 15 minutes whilst the machine 
takes measurements of your bones.  
Your participation in the study will involve one or two appointments which will take no more 
than 1 hour 30 minutes in total (excluding travel time).  
 
We will use your blood sample to test for some general markers of health such as cholesterol, 
kidney and liver function, and to test your vitamin levels. If you are willing we would also like  
to take a blood sample from you that we will use for DNA analysis. We would also ask for 
your permission to retain your blood samples for use in future studies. 
 
We also ask you if you agree to be contacted by researchers from the University of Ulster at a 
later date and invited to take part in similar nutrition related studies. You will only be agreeing 
to receive information and will not be under any obligation to take part in any future studies.  If 
you decide not to consent to being contacted in the future it will have no influence on your 
involvement in this research study and will not affect any standard of care that you receive. 
 
 
Risks and/or disadvantages of taking part? 
There is a very small risk of bruising when giving a blood sample, but a fully trained 
phlebotomist will take your blood sample to ensure that any discomfort is kept to a minimum 
The bone scan involves the use of extremely small doses of x-ray. The dose you will be 
exposed to is equivalent to the background radiation you would be exposed to naturally if 
outside for approximately three hours.  In the unlikely event that your results show something 
abnormal you will be contacted and the information will be forwarded to your GP.  
 
Are there any possible benefits in taking part? 
There are no direct benefits from taking part in this study although the information gained may 
prove extremely useful in understanding the link between diet, health and related genetic 
factors in people born in the North and South of Ireland. The results of the DNA tests would 
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have no direct relevance to you but may help us understand why Irish people get certain 
chronic diseases. By taking part in the study you will also find out how you perform on a range 
of physical and psychological tests and some clinical blood tests. If we detect any abnormal 
clinical results we will notify your GP. 
 
What if something goes wrong? 
It is very unlikely that something will go wrong during this research. However, you should know 
that the University take complaints and concerns seriously and has procedures in place for 
reporting, investigating, recording and handling them. The University is insured for its staff and 
students to carry out research involving people however, this does not extend to non-negligent 
harm. The University knows about this research project and has approved it. Further details on  
insurance can be found in the University’s research indemnity statement. Ask us if you would like 
a copy. 
 
Will my information be kept confidential? 
Your doctor will be aware of your participation in the study. Besides that, all information 
collected about you for the study will be kept strictly confidential, in accordance with the NHS 
Guidelines (HSC99/053) all data will be kept for a minimum of 25 years. The data will be 
archived securely in a restricted access room for the duration. 
 
Any information that leaves the University of Ulster will have your name and address removed so 
that you cannot be identified. All samples collected from you will be coded so that you cannot be 
identified from them and will be stored in a locked freezer until they are analysed. Information will 
be safely destroyed once it is no longer required. 
 
What will happen to the findings of the research study? 
It is intended that the findings from this study will be published in scientific or medical journals 
and presented at conferences. You will not be identified in any report or publication. Once the 
study is complete we will send you a summary of the results. 
 
Who is organising and funding the research? 
Funding for this study was obtained initially from the Irish Department of Food and Agriculture 
with additional funding obtained from The Department of Employment and Learning (DEL) in 
Northern Ireland. 
175
The TUDA Study Appendix 4 
Version 4.0 07/05/09 
Thank you for taking the time to read this information. 
If you have any questions or would like more information, contact: 
Dr Geraldine Horigan researcher on 028 70323516; gb.horigan@ulster.ac.uk 
Dr Leane Hoey researcher on 028 70323516; l.hoey@ulster.ac.uk 
Professor Sean Strain Chief investigator on 028 70324795; jj.strain@ulster.ac.uk 
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UNIVERSITY OF ULSTER       RESEARCH GOVERNANCE 
 
Consent Form for studies involving the use of human tissue               Participant Identification no: 
 
 












I have been given and have read and understood the information sheet dated 07/05/09 







I understand that my participation is voluntary and that I am free to withdraw at any time 






I understand that the researchers will hold all information and data collected during the 
study securely and in confidence and that all efforts will be made to ensure that I cannot 
be identified as a participant in the study (except as might be required by law) and I give 






I understand that my blood or other tissues are required for the purposes of this study 
and confirm that I have been given details of the amount(s) to be taken and how it will be 











The potential benefits of keeping my blood or other tissues for future research  
studies have been explained to me and: 
 
a. I consent to their indefinite storage and use in any future study including genetic 
    studies, or 
 
b. I consent to their indefinite storage and use in any future study that does not  
    involve the isolation of my genetic material 
 
c.  I do not wish my blood or tissues to be used for any purpose other than 





7. I agree to being contacted at a later date and invited to take part in future studies of a 
similar nature. I understand that I am agreeing only to receive information and I am under 
no obligation to take part in any future studies. 
 
 
     
Name of Participant (please print)  Signature  Date (dd/mmm/yy) 
 
     
The Trinity, Ulster and Department of Agriculture (TUDA) Cohort study 
(A study to examine the link between diet, genetics and health)  
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Name of person taking consent (if 
different from researcher) 
 Signature  Date (dd/mmm/yy) 
     
     

















Time blood collected: 
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Timed up and go:  
 
 
 Hip (cm): 
 
Hand grip strength (kg): (patient to stand upright and use non dominant hand x 3 measures)  
           L / R     1) 
             2) 
             3) 
                                 Av:  
Hours since your last meal (to the nearest whole hour) 
Minutes to blood sample  
 
Weight (kg): 
(without shoes but in normal clothes) 
 
Height (cm)       
(without shoes) 
 
BP (sitting with arm supported)   (circle reference arm)    
          L                                  R 
1st Reading   2nd Reading    
 
(3rd Reading)  (4th Reading)   (5th Reading)   
 
(6th Reading)             Average:  
   
(Please allow 5 minutes in seated position with back and arm supported before 
recording first reading and a further 1-2 minutes before subsequent readings. Continue 
to take readings until two are within 5 mmHg Systolic of each other and take mean of 
these two as actual reading). In the event that no two readings are within 5mmhg of 
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PPI  H2 blockers  BP  Metformin  Other DM Med  Statin   Anti-depressant 
 
Specific Cardiovascular Risk Factors: 
 Hypertension  Yes       No  Don’t Know 
If YES, when diagnosed?______ Age started medication____ 
Anti-hypertensive medication last taken: 
<4 hours ______  4-12 hours _______  >12 hours_______ 
 Diabetes   Yes       No  Don’t Know 
 If YES, when diagnosed? ______ 
 Compliance with diet?  Yes       No   
Compliance with testing? Yes       No  
 Hyperlipidaemia/Hypercholestrolaemia  
Yes       No  Don’t Know 
If YES, when diagnosed? ______ 
 Ishaemic Heart Disease Yes       No  Don’t Know 
 Angina   Yes       No  Don’t Know 
 Heart attack   Yes       No  Don’t Know 
 Heart failure   Yes       No  Don’t Know 
 Atrial Fibrillation  Yes       No  Don’t Know 
 Angioplasty/CABG  Yes       No    Don’t Know 
 Stroke    Yes       No    Don’t Know 
If YES, how many and when?________ 
 TIA    Yes       No  Don’t Know 
If YES, how many and when?________ 
 Peripheral artery disease, e.g. Intermittent claudication? 
Yes       No  Don’t Know 
Have you started any of these medication within the past (tick all that apply):  
1         1  2-6  >6  months 
2         1  2-6  >6  months 
3         1  2-6  >6  months     
4         1  2-6  >6  months      
5         1  2-6  >6  months   
6         1  2-6  >6  months    
7         1  2-6  >6  months       
8         1  2-6  >6  months      
9         1  2-6  >6  months      
10         1  2-6  >6  months     
11         1  2-6  >6  months 
12         1  2-6  >6  months      
13         1  2-6  >6  months       
14         1  2-6  >6  months       
15         1  2-6  >6  months       
16         1  2-6  >6  months       
17         1  2-6  >6  months     
18         1  2-6  >6  months      
19         1  2-6  >6  months      
20         1  2-6  >6  months      
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 ABI/Carotid Artery Dopplers? 
Yes       No  Don’t Know 
 Carotid Endarterectomy Yes       No  Don’t Know 
 Bypass Operations  Yes       No  Don’t Know 
 
Has a doctor ever told you that you had: 
 
Anxiety        Yes   No 
Depression        Yes   No 
Other serious disease (e.g. cancer)    Yes   No 
 






































1) Have you fallen in the last year?  Yes  No  
 (Note: "A fall is an event in which an individual comes to rest on the ground or 
another lower level with or without loss of consciousness,” (Oxford textbook of 
Geriatric Medicine 2nd Edition 2000). 
 
If yes: a) How many times in the past year? _______ 
b) Did you sustain any injuries?   Yes  No  
 
 If yes, what type of injury? 
Soft tissue injury (bruise / laceration) 
State location: _____________________________________ 
Fracture  
State location: _____________________________________ 
 
c) Did you need to see your General Practitioner as a result? 
Yes  No  
 
d) Did you need to go to an Emergency department (A/E) as a 
result?  
Yes  No  
 
e) Did you need to be admitted to hospital as a result?  
Yes  No  
 
2) Do you have to be careful not to stand up too quickly when rising 
from a sitting or lying position?     Yes  No  
 
3) Do you feel dizzy if you stand up too quickly?   Yes  No  
If yes, how often?   Several times a day   
Several times a week   
Several times a month  
Several times a year   
Less than once a year   
 
 4) Do you feel dizzy if you stand for a prolonged period (other than just 
after standing up)?   Yes  No  
If yes, how often?   Several times a day   
Several times a week   
Several times a month  
Several times a year   
Less than once a year   
 
5) Have you ever fainted (i.e. lost consciousness)?   Yes  No  
 
If yes: a) How many times? _______ 
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6) Have you ever felt that you were going to faint but did not?  
Yes  No  
 
If yes: a) How many times?  _______ 
  b) How many times in the past year? _______ 
 
7) Are you afraid of falling?  Yes   No   
 
8)  Do you limit any household activities because you are afraid you 
might fall?       Yes   No 
 
9)  Do you limit any outside activities because you are frightened you 






Have you done any exercise in the past 2 weeks? 
 
If YES:  How many times did you exercise? ________ 
On average, how long did you exercise for on each 
occasion?   _______ 
 
Please place a tick activities partaken in, in the past 2 weeks: 
 
 Walking for exercise 








 Other, please specify ______________ 
186





 Have you ever had a fractured bone?                  Yes    No  
 
 Have you ever had a hip fracture?                        Yes    No  
 
 Have parent(s) ever had hip fracture? Yes   No  
 
 Do you suffer with Rheumatoid Arthritis?             Yes    No  
 
 Do you suffer with Osteoporosis?                         Yes    No    
 
 Have you ever taken Glucocorticoids for more  
 than 3 months?   Yes    No  
 If yes, Duration_______________________   
 Mean daily dose______________________ 
  
 Have you ever suffered from Epilepsy?   Yes    No  
 
 Have you ever taken anti-epileptic medication?  Yes    No  
 If yes, for how long (in months) ___________ 
 Name of medication(s)_____________________________________ 
 
B)   Osteoporotic Medication: Duration (months): 
 
 Protelos           Yes  No  ______________ 
 
 Bisphosphonates     Yes  No    ______________ 
         (Alendronate  / Risedronate  / Ibandronic Acid  / Etidronate  
          Zoledronic acid )  
 
C)   Have you ever taken: Duration (months): 
1. Aromatase Inhibitors:        Yes  No   _______________ 
 (Arimidex  / Femara ) 
 
2. GnRH / LHRH analogues:  Yes  No   _______________ 
 (Zoladex  / Gonapeptyl  / Prostap ) 
 
3. Anti-androgen:  Yes  No   _______________ 





















Current   (i.e. Smoked in last month) 
Past    
Never    
 
Have you ever smoked cigarettes regularly (at least 1/day) for a period 
longer than 6 months? Yes   No  
 
If YES: 
At what age did you start smoking?______ 
 




How many cigarettes do you smoke per day? _______ 





At what age did you stop smoking?_______ 
How many cigarettes did you smoked on average (per day)?______ 
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DIET & SUPPLEMENTS 
 
1. Do you eat any fortified foods? (Researcher, please refer to Aide 
Memoire)   Yes   No  
 
If YES, please specify:   Fortified Breakfast Cereals 
     Fortified Cereal Bars 
     Fortified Bread  
     Fortified Fat Spreads 
     Fortified Drinks 
     Marmite or other yeast extracts 
     Other _________ 
 
For each fortified product ticked, name the product and brand below and state 
how often.  
 
Product 1:   Product 2:   Product 3: 
 
___________________ ___________________ __________________ 
 
 Twice/day or more  Twice/day or more  Twice/day or more 
 Once/day    Once/day    Once/day 
 5-6 times/week   5-6 times/week   5-6 times/week  
 3-4 times/week   3-4 times/week   3-4 times/week  
 1-2 times/week   1-2 times/week   1-2 times/week  
 Other _________  Other _________  Other _________ 
 
 
If YES, when did you last eat these products?  
 
Product 1:   Product 2:   Product 3: 
 




2. Do you take milk? Yes   No  
 
If YES:  
As a drink     In tea/coffee    With cereal  
 
How often?  
 Twice/day or more  Twice/day or more  Twice/day or more 
 Once/day    Once/day    Once/day 
 5-6 times/week   5-6 times/week   5-6 times/week  
 3-4 times/week   3-4 times/week   3-4 times/week  
 1-2 times/week   1-2 times/week   1-2 times/week  
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If YES: Name the brand of milk you typically take ________________ 
 
  Do you typically take - 
 
  Skimmed    Soya   Semi-skimmed    Whole  
 
 




3. Do you eat – 
 
Meat? Yes   No      Poultry? Yes   No  
  
 
If YES, how often?  
 
 Twice/day or more      Twice/day or more 
 Once/day        Once/day 
 5-6 times/week       5-6 times/week  
 3-4 times/week       3-4 times/week  
 1-2 times/week       1-2 times/week  
 Other _________      Other _________ 
 
      
 
4. Do you eat – 
 
White fish? Yes   No     Oily fish? Yes   No  
(e.g. cod/haddock/plaice/fishfingers)   (e.g. salmon/trout/mackerel)  
 
If YES, how often?  
 
 Twice/day or more      Twice/day or more 
 Once/day        Once/day 
 5-6 times/week       5-6 times/week  
 3-4 times/week       3-4 times/week  
 1-2 times/week       1-2 times/week  














5. Do you eat – 
 
Eggs? Yes   No   Cheese?  Yes   No  Yoghurt? Yes   No 
 
If YES, how often?  
 
 Twice/day or more  Twice/day or more  Twice/day or more 
 Once/day    Once/day    Once/day 
 5-6 times/week   5-6 times/week   5-6 times/week  
 3-4 times/week   3-4 times/week   3-4 times/week  
 1-2 times/week   1-2 times/week   1-2 times/week  
 Other _________  Other _________  Other _________ 
   
 
 
6. Do you take any vitamin supplements (e.g. vitamins in tablet form, 
cod liver oil, etc)? Yes   No  
 
If YES, how often?  
 
 Twice/day or more 
 Once/day 
 5-6 times/week 
 3-4 times/week 
 1-2 times/week 
 Other _________ 
 
If on FOLIC ACID when last taken?____________________________ 
 
If YES, name the supplement(s) (Researcher please put product name in 
capitals) -   
 
 
(i)__________________ (ii)_________________    (iii)_________________ 
 
 
How long have you been taking each supplement? 
 
 
(i)__________________ (ii)________________    (iii)__________________
       
 
Was the name of the supplement(s) verified by researcher (Researcher 
please tick) -  
At interview (examination of product)   
In a follow-up phone call     
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7. When you are outdoors during the sunny months, do you stay in the 
sun or do you seek the shade? 
 
 I try to avoid staying in direct sunshine   
 I stay sometimes in the sunshine    
 I enjoy staying often in the sunshine   
 
 
8. During the sunny months, how often would you apply sun protection 
factor? 
 
Never     Rarely     Sometimes     Usually     Always     Other  
 
 
What sun protection factor do you usually apply?   __________________ 
 
 
9. Have you been on a sunny holiday in the last 6 months? 
  
Yes   No  
 
If YES, please specify: 
 
(i) where you went, (ii) during which month(s) and (iii) how long (no of days) 
(Researcher, ensure response to (iii) is the total number of days of ALL 






10. Apart from the last 6 months, do you generally tend to go on sunny 
holidays? 
 
Yes   No  
 





11. Do you use a sun-lamp or sun-bed regularly? 
 
Yes   No  
 











Do you drink alcohol 
 Yes, currently (within the past year) 
 No, but I have in the past (more than 1 year ago) 
 No, never 
 
How often do you drink alcohol? _________ (days per month) 
 
How many units (of each type) of alcohol do you consume per week?  
(1 unit = ½ pint of beer, 1 glass of wine, 1 measure of spirits; 1 bottle of 
wine=10 units) 
  
Beer   _____ 
  
Wine  _____ 
  
Spirits  _____ 
 
 










1) Do you have any concerns with regard to your memory? 
Yes     No  
 
2) Does your family have any concerns with regard to your memory? 






















Below is a list of the ways you might have felt or behaved. Please 
respond on how often you have felt this way during the PAST WEEK, by 
ticking the most appropriate box. 
 
 
I was bothered by things that 
usually don’t bother me 
0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 days)  
2 Occasionally (3-4 days)     
3 Most of the time (5-7 days) 
 
I did not feel like eating; my appetite 
was poor 
 
0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 days)  
2 Occasionally (3-4 days)     
3 Most of the time (5-7 days) 
 
I felt that I could not shake off the 
blues even with help from my family 
or friends  
 
0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 days)  
2 Occasionally (3-4 days)     
3 Most of the time (5-7 days) 
 
I felt that I was just as good as other 
people  
 
3 Never or Rarely (less than 1 day) 
2 Some of the time (1-2 days)  
1 Occasionally (3-4 days)     
0 Most of the time (5-7 days) 
 
I had trouble keeping my mind on 
what I was doing 
 
0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 days)  
2 Occasionally (3-4 days)     
3 Most of the time (5-7 days) 
 
I felt depressed 
 
0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 days)  
2 Occasionally (3-4 days)     
3 Most of the time (5-7 days) 
 
I felt that everything I did was an 
effort 
 
0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 days)  
2 Occasionally (3-4 days)     
3 Most of the time (5-7 days) 
 
I felt hopeful about the future 
 
3 Never or Rarely (less than 1 day) 
2 Some of the time (1-2 days)  
1 Occasionally (3-4 days)     
0 Most of the time (5-7 days) 
 
I thought my life had been a failure 
 
0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 days)  
2 Occasionally (3-4 days)     
3 Most of the time (5-7 days) 
 
I felt fearful     
    
 
0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 days)  
2 Occasionally (3-4 days)     
3 Most of the time (5-7 days) 
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My sleep was restless 
 
0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 days)  
2 Occasionally (3-4 days)     
3 Most of the time (5-7 days) 
 
I was happy 
 
3 Never or Rarely (less than 1 day) 
2 Some of the time (1-2 days)  
1 Occasionally (3-4 days)     
0 Most of the time (5-7 days) 
 
I talked less than usual  
  
   
 
0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 days)  
2 Occasionally (3-4 days)     
3 Most of the time (5-7 days) 
 
I felt lonely 
 
0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 days)  
2 Occasionally (3-4 days)     
3 Most of the time (5-7 days) 
 
People were unfriendly 
 
0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 days)  
2 Occasionally (3-4 days)     
3 Most of the time (5-7 days) 
 
I enjoyed life 
 
3 Never or Rarely (less than 1 day) 
2 Some of the time (1-2 days)  
1 Occasionally (3-4 days)     




0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 days)  
2 Occasionally (3-4 days)     
3 Most of the time (5-7 days) 
 
I felt sad 0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 days)  
2 Occasionally (3-4 days)     
3 Most of the time (5-7 days) 
 
I felt that people disliked me 
 
0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 day)  
2 Occasionally (3-4 days)     
3 Most of the time (5-7 days) 
 
I could not get “going” 0 Never or Rarely (less than 1 day) 
1 Some of the time (1-2 days) 
2 Occasionally (3-4 days)     











In general do you ever feel  
I feel tense or wound 
up… 
 
Most of the 
time 
3 






Not at all 
 
0 
I get a sort of 
frightened feeling as 
if something awful is 














go through my 
mind… 
A great deal 
of the time 
 
3 
























Not at all 
 
3 
I get a sort of 
frightened feeling 
like butterflies in the 
stomach… 












I feel restless as if I 











Not at all 
 
0 
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PHYSICAL SELF MAINTENANCE SCALE 
 
1)  Do you eat: 
3  Without any help 
 2  With some help (e.g. cutting food, etc.) 
 1  Someone must feed me 
 
2)  Do you dress and undress yourself: 
3  Without help (able to pick out clothes & dress) 
 2  With some help  
 1  No, someone must dress and undress me 
 
3)  Do you take care of your own appearance? (e.g. combing your hair, 
or for men, shaving) 
3  Yes, without help 
 2  Yes, with some help 
 1  No, someone must help me with this type of thing 
 
4)  Are you able to get around your house/apartment without any help? 
3  Yes, without help of any kind (except a cane) 
2  Yes, with some help (from a person, walker, crutches, or chair) 
1  No, I cannot get around my home unless someone moves me 
 
5)  Are you able to get in and out of bed yourself? 
3  Yes, without help or aid 
 2  Yes, with some help (from a person or device) 
 1  No, I cannot get out of bed unless someone lifts me 
 
6)  Are you able to bathe, --that is, take a bath, shower, or sponge bath 
by yourself? 
3  Yes, without help 
 2  Yes, with some help (from a person or device) 
1  No, someone must bathe me and lift me in and out of the bath 
 
7) a. Do you ever have trouble getting to the bathroom on time? 
1 Yes  
2 No 
 
b. About how often would you wet or soil yourself during the day or     
night? 
4  Never 
3  Less than once a week 
2  Once or twice a week 
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INSTRUMENTAL ACTIVITIES OF DAILY LIVING 
1)  Can you the use the telephone? 
 3  Yes, without help 
 2  Yes, with some help 
 1  No, I am completely unable to use the telephone 
 
2)  Can you get to places out of walking distance? 
 3  Yes, without help 
 2  Yes, with some help 
1  No, I am completely unable to travel unless special arrangements 
are made 
 
3)  Can you go shopping for groceries? 
 3  Yes, without help 
 2  Yes, with some help 
 1  No, I am completely unable to do any shopping 
 
4)  Can you prepare your own meals? 
 3  Yes, without help 
 2  Yes, with some help 
 1  No, I am completely unable to prepare meals 
 
5)  Can you do your own housework? 
 3  Yes, without help 
 2  Yes, with some help 
 1  No, I am completely unable to do my own housework 
 
6) Can you do your own handyman work? 
 3  Yes, without help 
 2  Yes, with some help 
 1  No, I am completely unable to do my own handyman work 
 
7)   Can you do your own laundry? 
3  Yes, without help 
 2  Yes, with some help 
 1  No, I am completely unable to do any laundry at all 
 
8)  a. Do you take or use any medications? 
 1  Yes 
 2  No 
     b.  Do you take your own medicine? 
     c.  If you had to take medicine, can you do it: 
3  Without help, taking the right dose at the right time 
2  With some help (e.g. someone prepares it for you, or reminds you) 
 1  I am completely unable to take my own medicines 
 
9)   Can you manage your own money? 
 3  Yes, without help 
 2  Yes, with some help 
      1  No, I am completely unable to handle money            TOTAL SCORE: 
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Maximum  Score 
Score     ORIENTATION 
 
5  (       )  What is the (year) (season) (date) (day) (month)? 
 
5  (       )  Where are we: country, county, town, street, room? 
 
     REGISTRATION 
 
3  (        )  Name 3 objects: 1 second to say each. Then ask the 
volunteer to repeat all three after you have said them. Give 1 point for each 
correct answer. Then repeat the trials until he/she either learns all 3 or has 
had 6 trials. Count all trials and record them. 
 
    No of Trials...................... 
 
 ATTENTION AND CALCULATION 
 
5  (        )  Begin with 100 and count backwards by subtracting 7.  
Stop after 5 answers.  Score 1 point for each correct answer. Alternatively 




3  (         ) Ask for the three objects learned above. Give 1 point  




2  (          ) Name a pencil and a watch. 
 
1  (          ) Repeat the following “No ifs ands or buts”. 
 
3  (          ) Follow a 3-stage command: 
“Take a sheet of paper in your right hand, fold it         in half, and put 
it on the floor”. 
 
1  (          ) Read and obey the following: 
     CLOSE YOUR EYES 
 
1  (          ) Write a sentence. 
 


























FRONTAL ASSESSMENT BATTERY 
 
 
1.  Similarities (conceptualization) 
“In what way are they alike?” 
 
A banana and a orange (In the event of total failure: “they are not alike” or partial failure “both have a peel”, help the 
patient by saying “both a banana and an orange are….”; but credit 0 for the item; do not help the patient for the tow 
following items) 
 
A table and a chair 
 
A tulip, a rose, and a daisy 
 
Score: only category responses (fruits, furniture, flowers) are considered correct. 
            Three correct: 3 
            Two correct: 2 
            One correct: 1 
            None correct: 0  
2.  Lexical fluency (mental flexibility) 
“Say as many words as you can beginning with the letter ‘S’, any words except surnames or proper nouns.” 
 
If the patient gives no response during the first 5 seconds, say: “For instance, snake.”  If the patient pauses 10 
seconds, stimulate him by saying: “any word beginning with the letter ‘S’.  The time allowed is 60 seconds. 
 
Score: word repetitions or variations (shoe, shoemaker), surnames, or proper nouns are not counted as correct 
responses. 
            More than nine words: 3 
            Six to nine words: 2 
            Three to five words: 1 
            Less than three words:  0  
3.  Motor series (programming) 
“Look carefully at what I’m doing.” 
 
The examiner, seated in front of the patient, performs alone three times with his left hand the series of Luria “fist-edge-
palm.”  “Now, with your right hand do the same series, first with me, then alone.”  The examiner performs the series 
three times with the patient, and then says to him/her: “Now, do it on your own.” 
 
Score: 
            Patient performs six correct, consecutive series alone:  3 
            Patient performs at least three correct consecutive series alone:  2 
            Patient fails alone, but performs three correct consecutive series with the examiner:  1 
            Patient cannot perform three correct consecutive series even with the examiner:  0  
4.  Conflicting instructions (sensitivity to interference) 
“Tap twice when I tap once.” 
 
To be sure that the patient has understood the instructions, a series of three trials is run: 1 – 1 – 1.  “Tap once when I 
tap twice.”   To be sure the patient has understood the instructions, a series of three trials is run: 2 – 2 – 2.  The 
examiner performs the following series:  1 – 1 – 2 – 1 – 2 – 2 – 2 – 1 – 1 – 2. 
 
Score: 
            No error: 3 
            One or two errors:  2 
            More than 2 errors:  1 





FRONTAL ASSESSMENT BATTERY 
 
 
5.  Go-No-Go (inhibitory control) 
“Tap once when I tap once.” 
 
To be sure that the patient has understood the instructions, a series of three trials is run: 1 – 1 – 1.  “Do not tap when I 
tap twice.”  To be sure the patient has understood the instructions, a series of three trials is run: 2 – 2 – 2.  The 
examiner performs the series:   1 – 1 – 2 – 1 – 2 – 2 – 2 – 1 – 1 – 2. 
 
Score: 
            No errors:  3 
            One or two errors:  2 
            More than two errors:  1 
            Patient taps like the examiner at least four consecutive times:  0  
6.  Prehension behavior (environmental autonomy) 
“Do not take my hands.” 
 
The examiner is seated in front of the patient.  Place the patient’s hands palm up on his/her knees.  Without saying 
anything or looking at the patient, the examiner brings his/her hands close to the patient’s hands and touches the 
palms of both the patient’s hand, to see if he/she will spontaneously take them.  If the patient takes the hands, the 
examiner will try again after asking him/her:  “Now, do not take my hands.” 
 
Score: 
            Patient does not take the examiner’s hands:  3 
            Patient hesitates and asks what he/she has to do:  2 
            Patient takes the hands without hesitation:  1 







EXAMINER:_____________________________          DATE:_______________ 
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Northern Ireland Centre for Food and Health (NICHE)  
 




Thank you for agreeing to take part in this TUDA follow up study. We are interested in 
relating your dietary intake of B-vitamins to your blood levels.  
 
Enclosed within this letter is a 4 day food diary. The diary should be recorded on 4 
consecutive days including a Saturday and a Sunday. Instructions on how food and 
drink are to be recorded are explained at the front of the food diary so please read 
thoroughly before starting to keep your food diary. You don’t need to weigh everything but 
simply describe the amount eaten using household measures, for example, 1 small bowl 
of Kellogg’s Corn Flakes. Brand names, type and portion sizes of each food must be 
recorded. It is important to record all food and drink over the 4 day period including 
alcohol and snacks. Do not change your eating habits as we are not going to judge your 
diet and it is crucial that we get an accurate picture of your habitual (usual) eating 
patterns.  
 
Please bring the completed diary to your scheduled appointment or if it is not completed 
in time please return the completed diary as soon as possible in the self-addressed 
envelope enclosed. If you have any queries or questions please do not hesitate to leave 
us a message on the office phone: 028 7012 3529.  
 
Yours sincerely 
Kirsty Porter/Katie Moore    
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FOOD DIARY  
 




DATE:  …………………………………………………. 
Please keep this diary for 4 days in total: 
2 consecutive weekdays and 2 consecutive weekend days 
 
Contact details: 
Miss Kirsty Porter/Miss Katie Moore 
Room W2020 
Biomedical Sciences 




Tel: 028 70323529 






cohort study  
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FOOD DIARY INSTRUCTIONS 
 
Please record ALL the foods you eat on the days requested. 
 
For each food please describe: 
1. The method of cooking e.g. fried, boiled, grilled, stewed, microwaved etc. 
2. If possible please give the brand and name of the product used and the weight given on the 
packet were appropriate. 
3. For milk please state type i.e. whole milk, semi-skimmed or skimmed. 
4. For butter, margarine, cooking oil etc please give exact brand name. 





To estimate a portion size use the following household measurements: 
 
RICE/PASTA 




State the number of slices/ rolls/ crisp breads eaten. 
 
BREAKFAST CEREALS 
Estimate the portion size as small/ medium/ large, or give the number of tablespoons eaten. 
 
MEAT & FISH 
Estimate the portion size as small/ medium/ large. For fish fingers, state the number eaten. 
 
FRUIT 
For whole fruit give the number eaten and estimate the size of the fruit as small/ medium/ large. 
For tinned fruit estimate the number of tablespoons eaten or state the size of the can if the whole 
tin is consumed. 
For dried fruit estimate the amount consumed in tablespoons. 
For grapes estimate the number eaten. 
 
VEGETABLES 
Estimate the portion size as small/medium/large or give the number of tablespoons eaten. 
 
NUTS 
Estimate the number eaten or give the size of the bag. 
 
MILK 
Estimate the amount consumed in pints. 
 
CHEESE  
Estimate the number of slices eaten and state whether the slices were small medium or large. 
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EGGS 
State the number eaten. 
 
BISCUITS 
State the number eaten. 
 
CAKES 
Estimate the size of the slice as small, medium or large. 
 
CRISPS, SWEETS, CHOCOLATE, FIZZY DRINKS ETC 
Report the brand name and weight as stated on the packet. 
 
DRINKS 
State whether cup or mug. For glasses state whether small, medium (1/2 pint) or large (pint). 
 
SAUCES, CHUTNEYS ETC 
Estimate the number of tablespoons consumed. 
 
SUGAR, JAMS ETC 
Estimate the amount consumed in teaspoons. 
 
OTHER FOOD 
Estimate the number of teaspoons consumed. 
 
 
An example of how to complete a food diary is provided for you on 
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EXAMPLE 
Day: Monday      Date: 12/10/14 
FOR OFFICE 
USE ONLY 
 CODE WT (g) 
BREAKFAST 
 
1 cup coffee (1 teaspoon sugar & Dale farm semi-skimmed milk) 
 
6 tablespoons Kelloggs cornflakes with ¼ pint semi-skimmed milk 
 
1 slice of Brennans white bread toasted with flora margarine thinly 
spread 
 




Cheese and tomato sandwich 2 slices Hovis wholemeal bread, spread 
thinly with flora, 3 medium thick slices of Coleraine cheddar cheese, 1 
small tomato, 2 teaspoons HP brown sauce) 
 
1 packet cheese and onion crisps (Tayto) 
 
1 small orange and 1 medium sized banana 
 




1 medium sized chicken breast (without skin) fried in vegetable oil 
 
3 medium sized potatoes 
 
5 tablespoons boiled carrots 
 
3 tablespoons bisto gravy (made with bisto gravy granules) 
 
1 small glass white wine 
 
medium slice of appletart (homemade) & coffee made as above 
  
BETWEEN MEAL SNACKS 
 
2 cups of tea (each cup 1 teaspoon sugar and semi-skimmed milk) 
 
1 mars bar 
 
1 pot yoplait full fat strawberry yoghurt 
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Day:       Date:  
             FOR OFFICE 
     USE ONLY 
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Office for Research Ethics Committees 
Northern Ireland                      (ORECNI) 
Customer Care & Performance Directorate 
Office Suite 3 
Lisburn Square House 
Haslem’s Lane 
Lisburn 
Co. Antrim BT28 1TW 
Tel:+44 (0) 28 9260 3107 
www.orecni.hscni.net 
HSC REC B 
27 November 2014 
Prof Sean  Strain 
Director of Northern Ireland Centre for Food and Health (NICHE) 
University of Ulster 




Dear Prof Strain 
Study title: The Trinity, Ulster and Department of Agriculture (TUDA) 
Cohort study 
REC reference: 08/NIR03/113 
Amendment number: Substantial Amendment 10 – 24/10/2014 
Amendment date: 24 October 2014 
IRAS project ID: 
The above amendment was reviewed at the meeting of the Sub-Committee held on 26 November 
2014. 
Ethical opinion 
The members of the Committee taking part in the review gave a favourable ethical opinion of the 
amendment on the basis described in the notice of amendment form and supporting documentation. 
Approved documents 
The documents reviewed and approved at the meeting were: 
Document Version Date 
Notice of Substantial Amendment (non-CTIMP) IRAS 
Version 3.5 
24 October 2014 
Other [Email from C Hughes] 24 October 2014 
Other [CI Signature] 24 October 2014 
Other [CV - Katie Moore (Appendix 12)] 
Participant information sheet (PIS) [Clean] Version 7.0 07 March 2014 
Participant information sheet (PIS) [Tracked] Version 8.0 22 October 2014 
Participant information sheet (PIS) [Clean] Version 8.0 22 October 2014 
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Research protocol or project proposal [Clean]  Version 6.0  22 October 2014  
Research protocol or project proposal  Version 5.0  07 March 2014  
 
Membership of the Committee 
 




All investigators and research collaborators in the NHS should notify the R&D office for the relevant 
NHS care organisation of this amendment and check whether it affects R&D approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for Research Ethics 
Committees and complies fully with the Standard Operating Procedures for Research Ethics 
Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ training 
days – see details at http://www.hra.nhs.uk/hra-training/  
 




pp Ms Sue Trouton 
Alternate Vice-Chair – Chair of the meeting 
E-mail: RECB@hscni.net  
 
 
Enclosures: List of names and professions of members who took part in the review 
 
Copy to: Mr Nick Curry, University of Ulster 
Mrs Sally Doherty, Western HSC Trust 
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Attendance at Sub-Committee of the REC meeting on 26 November 2014 
 
  
Committee Members:  
 
Name   Profession   Present    Notes   
Ms Marilyn Trimble    Yes     
Ms Sue Trouton  Community Midwifery Sister   Yes   AVC – Chair of the meeting 
  
Also in attendance:  
 
Name   Position (or reason for attending)   
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Research Protocol 
Title 
The Trinity, Ulster and Department of Agriculture (TUDA) Cohort Study 
Background 
Cardiovascular disease (CVD), osteoporosis and Alzheimer’s disease are chronic diseases of 
ageing that impact adversely on the lives of those affected and have major health, social and 
economic consequences. 
A number of factors are considered to be implicated in these diseases, ranging from the more 
established factors to those that are less well recognised. Lifestyle factors such as diet, body 
weight, smoking, physical activity and years of education are acknowledged as risk factors for 
the development of these chronic diseases. Of the nutritional factors, calcium and vitamin D 
are well-established as important nutrients for the maintenance of bone mineral density 
(BMD) and the prevention of osteoporosis (Lanham-New, 2008). However, new research now 
suggests that elevated homocysteine and/or sub-optimal status of the metabolically related B-
vitamins (folate, vitamin B12) may be associated not only with a higher risk of osteoporosis 
(Cagnacci et al, 2003; Dhonukshe-Rutten et al, 2005; Gjesdal et al, 2006), but also of CVD, in 
particular stroke (Hcy studies collaboration, 2002; Wald et al, 2002; Wang et al, 2007), and of 
cognitive decline and dementia (Quadri et al, 2004; Kado et al, 2005; Haan et al, 2007). In 
addition, genetic factors are increasingly recognised as playing a critical role in disease risk. 
Individuals who are homozygous (TT genotype) for the common 677C→T polymorphism in 
the gene coding for the enzyme methylenetetrahydrofolate reductase (MTHFR) that plays an 
important role in folate/homocysteine metabolism, are reported to have a higher risk of 
hypertension (Jiang et al, 2004), CVD (Wald et al, 2002; Klerk et al, 2002) and osteoporosis 
(Riancho et al, 2006) compared to those without the 677C →T polymorphism. Likewise, 
polymorphisms of the vitamin D receptor (VDR) gene have been associated with an increased 
risk of osteoporosis (Uitterlinden et al, 2006; Moffett et al, 2007). However, there are 
inconsistencies in the literature as to the importance of such genetic variants in disease risk. It 
is possible that the detrimental health effects associated with these genetic factors may only 
occur in particular population subgroups, such as those with low nutritional status. There is 
evidence to suggest that the typical phenotype (i.e. elevated homocysteine concentrations) 
associated with homozygosity for the MTHFR 677C→T polymorphism can be modified by 
folate (Klerk et al, 2002) and riboflavin status (McNulty et al, 2006), and that the risk of 
osteoporosis associated with polymorphisms of the VDR gene only occurs in those with low 
calcium intakes (MacDonald, 2003). 
Although the interplay between relevant genetic and nutrient factors (gene-nutrient 
interactions) is considered to be highly relevant in the development (and prevention) of 
chronic diseases of ageing, this relatively new area of research is as yet poorly understood. 
The collection of clinical, lifestyle, nutritional and genetic data on large numbers of patients 
would permit the investigation of those nutrients which interact with specific genes to 
increase the likelihood of a person developing chronic diseases of ageing. Funding has 
recently been secured from both Governments (Irish and UK) for a large cross-border project 
to investigate this research area. 
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Study Aim 
 
The aim of this study was to collect detailed clinical, lifestyle, dietary, genetic and 
biochemical data to investigate gene-nutrient interactions (particularly from the perspective of 
the B-vitamins and vitamin D/calcium) in the development of CVD, osteoporosis and 
Alzheimer’s disease by studying older adults exhibiting the early stages of these common 
diseases, namely hypertension, low bone mineral density, and early memory loss, 
respectively. 
 
Secondary aims (follow up investigation)  
 To re-assess clinical, nutritional, genetic and biochemical factors in relation to 
neuropsychiatric function in a subset of TUDA study participants, five years after 
initial investigation. 
 To investigate the effect of low does B-vitamin supplementation for 2 years on brain 
health.   
 
 
Study Design and Methods 
 
Initial investigation (recruitment and sampling completed by October 2012)  
The current study (Trinity, Ulster and Department of Agriculture; TUDA) was one of three 
studies being undertaken as part of a cross-border collaborative project (the National Nutrition 
Phenotype Database Project), involving four universities: University College Dublin, Trinity 
College Dublin, University College Cork and the University of Ulster. The TUDA study is an 
observational study of a convenience sample of 5,201 patients recruited from both the North 
and South of Ireland with phenotypic early evidence of Alzheimer’s disease, osteoporosis and 
CVD. Ethical approval has been applied for, and obtained in the South for the cognitively 
impaired (n=2000) and the osteoporotic cohorts (n=2000) who will be recruited from St 
James’s Hospital Dublin. Ethical approval is being sought here only for the recruitment of the 
2100 hypertensive patients who are under the care of Consultant Cardiologists at two separate 
Trusts in Northern Ireland (Western Health and Social Care Trust and, Northern Health and 
Social Care Trust) and for the examination of data from all 5,201 participants.  
 
Patients under the care of the Consultant Cardiologists will be approached. Those patients 
who give their permission will be contacted by telephone by the researchers who will fully 
explain the study to them and then invite them to participate once current suitability is 
established according to the inclusion/exclusion criteria. The inclusion criteria are: patients 
over 60 years of age who attend (or have attended) a cardiology clinic and have been 
diagnosed with hypertension defined as a blood pressure of greater than 140/90 mmHg 
(British Hypertension Society, 2006) or are currently taking hypertensive medication. The 
exclusion criteria are as follows: patients under 60 years of age, patient (or their parent) not 
born in either the North or South of Ireland and those with severe dementia. Patients that are 
suitable and that verbally agree to participate will be given a participant information sheet and 
consent form and allowed at least 48 hours to consider the written information and decide if 
they wish to participate. If agreeable and after informed consent is received, participants will 
be asked to do the following:  
 complete a detailed health and lifestyle questionnaire to obtain information on diet, 
general health, drug and supplement use. 
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 complete physiological function tests (e.g. blood pressure, DXA scans and a battery of 
cognitive function tests). The researchers will be trained in how to administer the 
cognitive tests by a consultant physician (Dr. F. Tracey CHSST). 
 have their height, weight and waist/hip measurements taken. 
 provide a non-fasting blood sample (50ml). Blood samples will be taken by a qualified 
phlebotomist. 
 Provide a buccal swab 
 
Blood samples will be analysed for the following:  
 routine clinical markers of health (e.g. renal function, liver function, lipids, full blood 
count, glucose, glycosylated haemoglobin) will be performed at the participating 
hospital laboratory; 
 vitamin B12 biomarkers - serum total vitamin B12 (microbiological assay), serum 
transcobalamin (holoTC, microparticle enzyme immunoassay) and plasma 
methylmalonic acid (GCMS) at Trinity College Dublin; 
 plasma homocysteine (immunoassay), serum folate and red cell folate 
(microbiological assay) at Trinity College Dublin; 
 riboflavin status (erythrocyte glutathione reductase activation coefficient; EGRac) at 
the University of Ulster; 
 vitamin B6 status (pyridoxal-5-phosphate, PLP by HPLC) at the University of Ulster; 
 Pepsinogen 1 and 2 will be measured using Biohit Pepsinogen I and II ELISA kits at 
the University of Ulster   
 bone biomarkers including serum 25-hydroxyvitamin D (ELISA) and serum intact 
parathyroid hormone (PTH; ECIA) at the University of Ulster; and 
 
Blood samples and buccal swabs will be anlaysed for  
 single nucleotide polymorphisms (SNPs) from the perspective of folate/vitamin B12 
and calcium/vitamin D metabolism and the Apolipoprotein E gene. 
Blood samples/buccal swabs for the TUDA study will be stored at both Trinity College 
Dublin and the University of Ulster. 
 
In addition, volunteers who have previously had a bone scan at the University of Ulster as 
part of a research study (and have agreed to be recontacted) were invited to participate.  
 If agreeable and after informed consent was received, participants were asked complete the 
study protocol as above with the omission of the DXA scan.  
 
Five to seven year follow-up investigation  
We propose to conduct a follow-up investigation in a subset of participants (n=444). Only 
patients that consented to be re-contacted for further research will be contacted via the 
telephone by the researchers. In addition a subset of participants n 222 will be randomised to 
receive either placebo or low dose B vitamin for two years. All participants are eligible except 
those with a MMSE score <25 (i.e. indicative of mild cognitive impairment).  Those that 
verbally agree to participate will be given a participant information sheet and will be allowed 
at least 48 hours to consider this. If agreeable, participants will be asked to complete 
procedures identical to those outlined above at both time points with the following exception. 
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Statistical analysis 
 
As this is a collaborative all-Ireland study, statistical analysis will be approached centrally. A 
working group on data management and analysis is currently being established which will 
include the task leaders and all PIs in the field of bioinformatics, statistics and epidemiology. 
A workshop will be held to ascertain the possible options for the best architecture and 
warehousing of the data and subsequent centralised training will be arranged in Dublin to 
cover the collection, entry and statistical analysis of data. Dr Cathal Walsh, Lecturer in 




The study investigators (please see revised research team) will be responsible for the 
collection, input and analysis of all data.  
All data collected for the study will be kept strictly confidential, and subjects will be assigned 
a unique identification code. The file containing personal details and study identification 
numbers will be kept under secure conditions in accordance with the NHS Guidelines 
(HSC99/053) and will be kept for a minimum of 25 years. The data will be archived securely 
in a restricted access room for the duration. The main database involved in the study will be 
stored on a password-protected computer. Any hard copies will be kept under locked 





These are the main ethical issues in relation to this study. 
i) Informed Consent – all potential participants will be given both written and oral 
information about the study before providing informed consent. It is envisaged that 
some of the participants will have difficulties in reading, hearing and writing. 
Participants will be provided with enlarged copies of the information sheet and 
consent form on request and they will be informed that they may nominate 
someone who can sign the consent form on their behalf. Every effort will be made 
to provide a translation of the information relevant to the study for those who do 
not understand written or verbal English. 
ii) Participant Confidentiality – all participants will be assigned a unique 
identification study code. 
iii) Blood Sampling – blood samples will be taken by a fully trained phlebotomist 
with a first aider on site. 
iv) DXA Scanning – the radiation which the volunteer will be subjected to will be the 
minimum possible dose. Those individuals performing the scans will be fully 
trained and will adhere to all current health and safety regulations (IRMER) and 
DXA performance protocols. 
v) Sample storage – all human samples will be stored as per requirements under the 
Human Tissue Act (HTA). 
vi) Data Records – all participant data will be stored on a password protected 
computer. Hard copies of data will be stored in locked cabinets under the custodial 
care of the Chief Investigator. 




The TUDA Study                                                                                  Appendix 1 
Version 6.0  22/10/2014 
References 
British Hypertension Society (2006) Hypertension: Management of hypertension in adults 
in primary care (partial update of NICE guideline 18), London: NICE. 
Cagnacci A, Baldassari F, Rivolta G, Arangino S, Volpe A. Relation of homocysteine, 
folate, and vitamin B12 to bone mineral density of postmenopausal women. Bone 
2003;33:956-9. 
 
Dhonukshe-Rutten RAM, Pluijm SMF, de Groot LCPGM, Lips P, Smit JH, van Staveren 
WA. Homocysteine and vitamin B12 status relate to bone turnover markers, broadband 
ultrasound attenuation and fractures in healthy elderly people. J Bone Miner Res 
2005;20:921-9. 
Gjesdal CG, Vollset SE, Ueland PM, et al. Plasma total homocysteine level and bone mineral 
density: the Hordaland Homocysteine Study. Arch Intern Med 2006;166:88-94. 
 
Haan MN, Miller JW, Aiello AE, et al. Homocysteine, B vitamins and the incidence of 
dementia and cognitive impairment: results from the Sacramento Area Latino Study on 
Aging. AJCN 2007;85:511-7. 
Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and 
stroke. JAMA 2002;288:2015-22. 
 
Jiang S, Hsu YH, Xu X, et al. The C677T polymorphism of the methylenetetrahydrofolate 
reductase gene is associated with the level of decrease on diastolic blood pressure in essential 
hypertension patients treated by angiotensin-converting enzyme inhibitor. Thromb Res 
2004;113:361-9. 
 
Kado DM, Karlamangla AS, Huang M-H, Troen A, Rowe JW, Selhub J, Seeman TE. 
Homocysteine versus the vitamins folate, B6, and B12 as predictors of cognitive function and 
decline in older high-functioning adults: MacArthur Studies of Successful Aging. Am J Med 
2005;118:161-7. 
 
Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG and the MTHFR Studies 
Collaboration Group. MTHFR 677C→T polymorphism and risk of coronary heart disease. 
JAMA 2002;288:2023-31. 
 
Lanham-New SA. Importance of calcium, vitamin D and vitamin K for osteoporosis 
prevention and treatment. Proc Nutr Soc 2008;67:163-76. 
 
MacDonald HM. Nutrient-Gene Interations Influencing the Skeleton in Nutritional Aspects of 
Bone Health. Cambridge: The Royal Society of Chemistry, 2003. 
 
McNulty H, Dowey LC, Strain JJ, et al. Riboflavin lowers homocysteine in individuals 
homozygous for the MTHFR 677C→T polymorphism. Circulation 2006;113:74-80. 
 
Moffett SP, Zmuda JM, Cauley JA, et al. Association of the VDR translation start site 
polymorphism and fracture risk in older women. J Bone Miner Res 2007;22:730-6. 
241
The TUDA Study                                                                                  Appendix 1 
Version 6.0  22/10/2014 
 
Quadri P, Fragiacomo C, Pezzati R, Zanda E, Forloni G, Tettamanti M, Lucca U. 
Homocysteine , folate, and vitamin B12 in mild cognitive impairment, Alzheimer disease, and 
vascular dementia. AJCN 2004;80:114-122. 
 
Riancho JA, Valero C, Zarrabeitia MT. MTHFR polymorphism and bone mineral density: 
meta-analysis of published studies. Calcif Tissue Int 2006;79:289-93. 
 
Uitterlinden AG, Ralston SH, Brandi ML, et al. The association between common vitamin D 
receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann Intern Med 
2006;145:255-64. 
 
Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on 
causality from a meta-analysis. BMJ 2002;325:1202-6  
 
Wang X, Qin X, Demirtas H, et al. Efficacy of folic acid supplementation in stroke 






Participant information sheet (Chapter 4) 
243
The TUDA Study       Appendix 4 
Version 8.0 22/10/2014 
Participant Information Sheet 
Northern Ireland Centre for Food and Health (NICHE) 
School of Biomedical Science 
University of Ulster 
The Trinity, Ulster and Department of Agriculture (TUDA) 
Cohort Study  
(A study to examine the link between diet, genetics and health) 
Invitation 
You are being invited to take part in research being conducted at the University of Ulster in 
collaboration with two Health and Social Care Trusts in Northern Ireland (Western and 
Northern Trusts). Before you decide whether or not to participate, it is important that you 
understand what the research is for and what you will be asked to do. Please read the following 
information and do not hesitate to ask any questions about anything that is unclear to you. Take 
time to consider whether or not you want to take part.  
Thank you for taking the time to consider this invitation. 
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What is the purpose of the study?  
High blood pressure, low bone density and mild memory loss are common health problems 
among older adults that can lead to more serious problems if left untreated. A number of  
factors such as diet, genetic make-up and lifestyle are known to influence the likelihood of a 
person developing these diseases. The purpose of this study is to collect information on these 
factors from adults over 60 years of age who live in the North or South of Ireland. The 
information gathered will be used to try to more fully understand the link between diet, genetic 
make-up and health that is likely to help in the prevention of these common diseases.   
 
This study is a follow up from the original TUDA study conducted by the University of Ulster 
in which you took part. The purpose on this occasion is to re-examine the same health and 
lifestyle measurements 5-7 years later.  
 
Why have I been chosen? 
You have been chosen because you previously took part in the original TUDA study conducted 
at the University of Ulster and agreed to be re contacted by researchers. If you agree to take 
part, you will be one of 444 people taking part in this study. 
 
Do I have to take part? 
It is up to you to decide whether or not you take part. If you decide to participate, you will be 
given this information sheet to keep and you will be asked to sign a consent form. You have 
the right to withdraw from the study at any time without giving a reason. A decision to 
withdraw at any time, or a decision not to participate, will not affect the standard of care that 
you receive. 
 
What will happen to me if I take part? 
The assessment will be very similar to the previous assessment that you took part in 
You will be asked to: 
 Have your blood pressure measured 
 Have your height, weight and waist circumference measured 
 Provide one 50ml blood sample 
 Provide a buccal swab (a cotton swab is rubbed gently on the inside of your cheek) 
 Provide answers to some questions about your diet, lifestyle, use of vitamin 
supplements and medications, your own general health  
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 Undergo some tests of memory and mood 
 Take a low dose B vitamin or dummy capsule for 2 years (sub-set n 222) 
(The above measurements will take place at the University of Ulster or a clinic within your Health Trust, 
which is convenient to you.)  
Your participation in the study will involve no more than two appointments each of which will 
take approximately 1 hour 15 minutes in total (excluding travel time).  
 
We will use your blood sample to test for some general markers of health such as cholesterol, 
kidney and liver function, and to test your vitamin levels. If you are willing we would also like  
to take a blood and buccal swab sample from you that we will use for DNA analysis. We 
would also ask for your permission to retain your blood samples for use in future studies. 
 
We also ask you if you agree to be contacted by researchers from the University of Ulster at a 
later date and invited to take part in similar nutrition related studies. You will only be agreeing 
to receive information and will not be under any obligation to take part in any future studies.  If 
you decide not to consent to being contacted in the future it will have no influence on your 
involvement in this research study and will not affect any standard of care that you receive. 
 
Risks and/or disadvantages of taking part? 
There is a very small risk of bruising when giving a blood sample, but a fully trained 
phlebotomist will take your blood sample to ensure that any discomfort is kept to a minimum. 
In the unlikely event that your results show something abnormal you will be contacted and the 
information will be forwarded to your GP.  
 
Are there any possible benefits in taking part? 
There are no direct benefits from taking part in this study although the information gained may 
prove extremely useful in understanding the link between diet, health and related genetic 
factors in people born in the North and South of Ireland. The results of the DNA tests would 
have no direct relevance to you but may help us understand why Irish people get certain 
chronic diseases. By taking part in the study you will also find out how you perform on a range 
of physical and psychological tests and some clinical blood tests. If we detect any abnormal 
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What if something goes wrong? 
It is very unlikely that something will go wrong during this research. However, you should 
know that the University take complaints and concerns seriously and has procedures in place 
for reporting, investigating, recording and handling them. The University is insured for its staff 
and students to carry out research involving people however, this does not extend to non-
negligent harm. The University knows about this research project and has approved it. Further 
details on insurance can be found in the University’s research indemnity statement. Ask us if 
you would like a copy. 
 
Will my information be kept confidential? 
Your doctor will be aware of your participation in the study. Besides that, all information 
collected about you for the study will be kept strictly confidential, in accordance with the NHS 
Guidelines (HSC99/053) all data will be kept for a minimum of 25 years. The data will be 
archived securely in a restricted access room for the duration. 
 
Any information that leaves the University of Ulster will have your name and address removed so 
that you cannot be identified. All samples collected from you will be coded so that you cannot be 
identified from them and will be stored in a locked freezer until they are analysed. Information will 
be safely destroyed once it is no longer required. 
 
What will happen to the findings of the research study? 
It is intended that the findings from this study will be published in scientific or medical journals 
and presented at conferences. You will not be identified in any report or publication. Once the 
study is complete we will send you a summary of the results. 
 
Who is organising and funding the research? 
Funding for this study was obtained initially from the Irish Department of Food and Agriculture 
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Thank you for taking the time to read this information. 
If you have any questions or would like more information, contact: 
Miss Kirsty Porter PhD student on 028 7012 3529; Porter-K7@email.ulster.ac.uk  
Miss Katie Moore PhD student on 02870123529: Moore-K@ulster.ac.uk 
Dr Catherine Hughes researcher on 028 7012 3516; c.hughes@ulster.ac.uk 
Dr Leane Hoey researcher on 02870124781; l.hoey@ulster.ac.uk 
Professor Sean Strain Chief investigator on 028 70124795; jj.strain@ulster.ac.uk 
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ULSTER UNIVERSITY    RESEARCH GOVERNANCE 
Consent Form for studies involving the use of human tissue  Participant Identification no: 
Title of Study 
Chief Investigator 
Please confirm, by marking the boxes provided, that you agree with the following statements:  
1. I have been given and have read and understood the information sheet dated
22/10/2014 (version 8.0) for the above study and have asked and received answers to
any questions raised
2. I understand that my participation is voluntary and that I am free to withdraw at any time
without giving any reason and without my rights being affected in any way
3. I understand that the researchers will hold all information and data collected during the
study securely and in confidence and that all efforts will be made to ensure that I cannot
be identified as a participant in the study (except as might be required by law) and I give
permission for the researchers to hold relevant personal data
4. I understand that my blood or other tissues are required for the purposes of this study
and confirm that I have been given details of the amount(s) to be taken and how it will be
stored, used and the method of disposal
5. I agree to take part in the above study
6. The potential benefits of keeping my blood or other tissues for future research
studies have been explained to me and:
a. I consent to their indefinite storage and use in any future study including genetic
studies, or
b. I consent to their indefinite storage and use in any future study that does not
involve the isolation of my genetic material
c. I do not wish my blood or tissues to be used for any purpose other than
this study
7. I agree to being contacted at a later date and invited to take part in future studies of a
similar nature. I understand that I am agreeing only to receive information and I am under
no obligation to take part in any future studies.
Name of Participant (please print) Signature Date (dd/mmm/yy) 
Name of Researcher Signature Date (dd/mmm/yy) 
The Trinity, Ulster and Department of Agriculture (TUDA) Cohort study 
(A study to examine the link between diet, genetics and health)  
Professor Sean Strain Tel: 028 70324795; email: jj.strain@ulster.ac.uk 
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Office for Research Ethics Committees 
Northern Ireland                      (ORECNI) 
Customer Care & Performance Directorate 





Tel: 028 95361400 
www.orecni.hscni.net 
HSC REC B 
09 May 2017
Professor Sean Strain 
Director of the centre for molecular biosciences 
University of Ulster 




Dear Professor Strain 
Study title: The Trinity, Ulster and Department of Agriculture 
(TUDA) Cohort study 
REC reference: 08/NIR03/113 
Amendment number: Amendment 14 
Amendment date: 28 April 2017 
IRAS project ID: N / A 
The above amendment was reviewed by the Sub-Committee in correspondence. 
Ethical opinion 
The members of the Committee taking part in the review gave a favourable ethical opinion 
of the amendment on the basis described in the notice of amendment form and supporting 
documentation. 
Approved documents 
The documents reviewed and approved at the meeting were: 
Document Version Date 
Notice of Substantial Amendment (non-CTIMP) Amendment 
14 
28 April 2017 
Other [Hubert Cecotti CV] 
Other [Professor Girijesh Prasad CV] 
Participant information sheet (PIS) [Appendix 6 Participant 1 14 April 2017 
252
Information Sheet and consent form for MEG scan]  
Research protocol or project proposal [Appendix 1 Research 
Protocol tracked changes]  
9  14 April 2017  
Research protocol or project proposal [Appendix 1 Research 
Protocol clean]  
9  14 April 2017  
 
Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the attached sheet. 
 
Working with NHS Care Organisations 
 
Sponsors should ensure that they notify the R&D office for the relevant NHS care 
organisation of this amendment in line with the terms detailed in the categorisation email 
issued by the lead nation for the study. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff at our Research Ethics Committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/  
 




pp Dr Sarah Anne Moorhead 





Enclosures: List of names and professions of members who took part in the 
review 
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Committee Members:  
 
Name   Profession   Present    Notes   
Dr Sarah Anne  Moorhead  Lecturer in Health & 
Interpersonal 
Communication  
Yes    Chair 
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Research Protocol 
Title 
The Trinity, Ulster and Department of Agriculture (TUDA) Cohort Study 
Background 
Cardiovascular disease (CVD), osteoporosis and Alzheimer’s disease are chronic diseases of 
ageing that impact adversely on the lives of those affected and have major health, social and 
economic consequences. 
A number of factors are considered to be implicated in these diseases, ranging from the more 
established factors to those that are less well recognised. Lifestyle factors such as diet, body 
weight, smoking, physical activity and years of education are acknowledged as risk factors for 
the development of these chronic diseases. Of the nutritional factors, calcium and vitamin D 
are well-established as important nutrients for the maintenance of bone mineral density 
(BMD) and the prevention of osteoporosis (Lanham-New, 2008). However, new research now 
suggests that elevated homocysteine and/or sub-optimal status of the metabolically related B-
vitamins (folate, vitamin B12) may be associated not only with a higher risk of osteoporosis 
(Cagnacci et al, 2003; Dhonukshe-Rutten et al, 2005; Gjesdal et al, 2006), but also of CVD, in 
particular stroke (Hcy studies collaboration, 2002; Wald et al, 2002; Wang et al, 2007), and of 
cognitive decline and dementia (Quadri et al, 2004; Kado et al, 2005; Haan et al, 2007). In 
addition, genetic factors are increasingly recognised as playing a critical role in disease risk. 
Individuals who are homozygous (TT genotype) for the common 677C→T polymorphism in 
the gene coding for the enzyme methylenetetrahydrofolate reductase (MTHFR) that plays an 
important role in folate/homocysteine metabolism, are reported to have a higher risk of 
hypertension (Jiang et al, 2004), CVD (Wald et al, 2002; Klerk et al, 2002) and osteoporosis 
(Riancho et al, 2006) compared to those without the 677C →T polymorphism. Likewise, 
polymorphisms of the vitamin D receptor (VDR) gene have been associated with an increased 
risk of osteoporosis (Uitterlinden et al, 2006; Moffett et al, 2007). However, there are 
inconsistencies in the literature as to the importance of such genetic variants in disease risk. It 
is possible that the detrimental health effects associated with these genetic factors may only 
occur in particular population subgroups, such as those with low nutritional status. There is 
evidence to suggest that the typical phenotype (i.e. elevated homocysteine concentrations) 
associated with homozygosity for the MTHFR 677C→T polymorphism can be modified by 
folate (Klerk et al, 2002) and riboflavin status (McNulty et al, 2006), and that the risk of 
osteoporosis associated with polymorphisms of the VDR gene only occurs in those with low 
calcium intakes (MacDonald, 2003). 
Although the interplay between relevant genetic and nutrient factors (gene-nutrient 
interactions) is considered to be highly relevant in the development (and prevention) of 
chronic diseases of ageing, this relatively new area of research is as yet poorly understood. 
The collection of clinical, lifestyle, nutritional and genetic data on large numbers of patients 
would permit the investigation of those nutrients which interact with specific genes to 
increase the likelihood of a person developing chronic diseases of ageing. Funding has 
recently been secured from both Governments (Irish and UK) for a large cross-border project 
to investigate this research area. 
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Study Aim 
 
The aim of this study was to collect detailed clinical, lifestyle, dietary, genetic and 
biochemical data to investigate gene-nutrient interactions (particularly from the perspective of 
the B-vitamins and vitamin D/calcium) in the development of CVD, osteoporosis and 
Alzheimer’s disease by studying older adults exhibiting the early stages of these common 
diseases, namely hypertension, low bone mineral density, and early memory loss, 
respectively. 
 
Secondary aims (follow up investigation)  
 To re-assess clinical, nutritional, genetic and biochemical factors in relation to 
neuropsychiatric function in a subset of TUDA study participants, five years after 
initial investigation. 
 To investigate the effect of low does B-vitamin supplementation for 2 years on brain 
health.   
 To investigate brain function using Magnetoencephalography (MEG) in a subset 
participants with optimal versus sub-optimal B-vitamins status. 
 
 
Study Design and Methods 
 
Initial investigation (recruitment and sampling completed by October 2012)  
The current study (Trinity, Ulster and Department of Agriculture; TUDA) was one of three 
studies being undertaken as part of a cross-border collaborative project (the National Nutrition 
Phenotype Database Project), involving four universities: University College Dublin, Trinity 
College Dublin, University College Cork and the University of Ulster. The TUDA study is an 
observational study of a convenience sample of 5,201 patients recruited from both the North 
and South of Ireland with phenotypic early evidence of Alzheimer’s disease, osteoporosis and 
CVD. Ethical approval has been applied for, and obtained in the South for the cognitively 
impaired (n=2000) and the osteoporotic cohorts (n=2000) who will be recruited from St 
James’s Hospital Dublin. Ethical approval is being sought here only for the recruitment of the 
2100 hypertensive patients who are under the care of Consultant Cardiologists at two separate 
Trusts in Northern Ireland (Western Health and Social Care Trust and, Northern Health and 
Social Care Trust) and for the examination of data from all 5,201 participants.  
 
Patients under the care of the Consultant Cardiologists will be approached. Those patients 
who give their permission will be contacted by telephone by the researchers who will fully 
explain the study to them and then invite them to participate once current suitability is 
established according to the inclusion/exclusion criteria. The inclusion criteria are: patients 
over 60 years of age who attend (or have attended) a cardiology clinic and have been 
diagnosed with hypertension defined as a blood pressure of greater than 140/90 mmHg 
(British Hypertension Society, 2006) or are currently taking hypertensive medication. The 
exclusion criteria are as follows: patients under 60 years of age, patient (or their parent) not 
born in either the North or South of Ireland and those with severe dementia. Patients that are 
suitable and that verbally agree to participate will be given a participant information sheet and 
consent form and allowed at least 48 hours to consider the written information and decide if 
they wish to participate. If agreeable and after informed consent is received, participants will 
be asked to do the following:  
 complete a detailed health and lifestyle questionnaire to obtain information on diet, 
general health, drug and supplement use. 
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 complete physiological function tests (e.g. blood pressure, DXA scans and a battery of 
cognitive function tests). The researchers will be trained in how to administer the 
cognitive tests by a consultant physician (Dr. F. Tracey CHSST). 
 have their height, weight and waist/hip measurements taken. 
 provide a non-fasting blood sample (50ml). Blood samples will be taken by a qualified 
phlebotomist. 
 Provide a buccal swab 
 Hand grip strength 
 Undergo Magnetoencephalography (MEG) (Elekta Neuroimag Truix) brain scan to 
assess brain function by passively measuring the magnetic fields produced by neurons 
in the brain. It is a safe, non invasive technique that measures electo-physiological 
responses in terms of brain magnetic activities recorded from extra-cranial sensors. This 
will take place at the Intelligent Systems Research Centre (ISRC) at Ulster University 
Magee. 
 
Blood samples will be analysed for the following:  
 routine clinical markers of health (e.g. renal function, liver function, lipids, full blood 
count, glucose, glycosylated haemoglobin) will be performed at the participating 
hospital laboratory; 
 vitamin B12 biomarkers - serum total vitamin B12 (microbiological assay), serum 
transcobalamin (holoTC, microparticle enzyme immunoassay) and plasma 
methylmalonic acid (GCMS) at Trinity College Dublin; 
 plasma homocysteine (immunoassay), serum folate and red cell folate 
(microbiological assay) at Trinity College Dublin; 
 riboflavin status (erythrocyte glutathione reductase activation coefficient; EGRac) at 
the University of Ulster; 
 vitamin B6 status (pyridoxal-5-phosphate, PLP by HPLC) at the University of Ulster; 
 Pepsinogen 1 and 2 will be measured using Biohit Pepsinogen I and II ELISA kits at 
the University of Ulster   
 bone biomarkers including serum 25-hydroxyvitamin D (ELISA) and serum intact 
parathyroid hormone (PTH; ECIA) at the University of Ulster; and 
 
Blood samples and buccal swabs will be anlaysed for  
 single nucleotide polymorphisms (SNPs) from the perspective of folate/vitamin B12 
and calcium/vitamin D metabolism and the Apolipoprotein E gene. 
Blood samples/buccal swabs for the TUDA study will be stored at both Trinity College 
Dublin and the University of Ulster. 
 
In addition, volunteers who have previously had a bone scan at the University of Ulster as 
part of a research study (and have agreed to be recontacted) were invited to participate.  
 If agreeable and after informed consent was received, participants were asked complete the 
study protocol as above with the omission of the DXA scan.  
 
Five to seven year follow-up investigation  
We propose to conduct a follow-up investigation in a subset of participants (n=600-650). 
Only patients that consented to be re-contacted for further research will be contacted via the 
telephone by the researchers. In addition a subset of TUDA participants (and their partners) n 
<300 will be randomised to receive either placebo or low dose B vitamin for two years, of 
which a selection of participants (n 50) will undergo brain function assessments using 
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magnetoencephalography (MEG). All participants are eligible except those with a MMSE 
score <25 (i.e. indicative of mild cognitive impairment).  Those that verbally agree to 
participate will be given a participant information sheet and will be allowed at least 48 hours 
to consider this. If agreeable, participants will be asked to complete procedures identical to 
those outlined above at both time points with the following exception. A DXA scan will not 






As this is a collaborative all-Ireland study, statistical analysis will be approached centrally. A 
working group on data management and analysis is currently being established which will 
include the task leaders and all PIs in the field of bioinformatics, statistics and epidemiology. 
A workshop will be held to ascertain the possible options for the best architecture and 
warehousing of the data and subsequent centralised training will be arranged in Dublin to 
cover the collection, entry and statistical analysis of data. Dr Cathal Walsh, Lecturer in 




The study investigators (please see revised research team) will be responsible for the 
collection, input and analysis of all data.  
All data collected for the study will be kept strictly confidential, and subjects will be assigned 
a unique identification code. The file containing personal details and study identification 
numbers will be kept under secure conditions in accordance with the NHS Guidelines 
(HSC99/053) and will be kept for a minimum of 25 years. The data will be archived securely 
in a restricted access room for the duration. The main database involved in the study will be 
stored on a password-protected computer. Any hard copies will be kept under locked 





These are the main ethical issues in relation to this study. 
i) Informed Consent – all potential participants will be given both written and oral 
information about the study before providing informed consent. It is envisaged that 
some of the participants will have difficulties in reading, hearing and writing. 
Participants will be provided with enlarged copies of the information sheet and 
consent form on request and they will be informed that they may nominate 
someone who can sign the consent form on their behalf. Every effort will be made 
to provide a translation of the information relevant to the study for those who do 
not understand written or verbal English. 
ii) Participant Confidentiality – all participants will be assigned a unique 
identification study code. 
iii) Blood Sampling – blood samples will be taken by a fully trained phlebotomist 
with a first aider on site. 
iv) DXA Scanning – the radiation which the volunteer will be subjected to will be the 
minimum possible dose. Those individuals performing the scans will be fully 
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trained and will adhere to all current health and safety regulations (IRMER) and 
DXA performance protocols. 
v) Sample storage – all human samples will be stored as per requirements under the 
Human Tissue Act (HTA). 
vi) Data Records – all participant data will be stored on a password protected 
computer. Hard copies of data will be stored in locked cabinets under the custodial 
care of the Chief Investigator. 
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Participant Information Sheet 
Northern Ireland Centre for Food and Health (NICHE) 
School of Biomedical Science 
University of Ulster 
The Trinity, Ulster and Department of Agriculture (TUDA) 
Cohort Study  
Magnetoencephalography Pilot Study 
Invitation 
You are being invited to take part in research being conducted at the University of Ulster in collaboration 
with two Health and Social Care Trusts in Northern Ireland (Western and Northern Trusts). Before you 
decide whether or not to participate, it is important that you understand what the research is for and what 
you will be asked to do. Please read the following information and do not hesitate to ask any questions about 
anything that is unclear to you. Take time to consider whether or not you want to take part.  
Thank you for taking the time to consider this invitation. 
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What is the purpose of the study?  
Declining brain health including mild memory loss, depression and anxiety are common health problems 
among older adults that can lead to more serious problems if left untreated. A number of factors such as diet, 
genetic make-up and lifestyle are known to influence the likelihood of a person developing these diseases. 
The purpose of this pilot study is to carry out the novel, safe and non-invasive Magnetoencephalography 
(MEG) (Elekta Neuroimag Truix) brain scan to assess brain function in those with optimised verses non-
optimised B-vitamin status. The information gathered will be used to try to more fully understand the link 
between diet, genetic make-up and health that is likely to help in the prevention of these common diseases.   
 
What is MEG? 
Magnetoencephalography (MEG) is a modern non-invasive technique for measuring magnetic fields 
generated by the brain in the space above the scalp. It is a completely safe and non-invasive brain imaging 
technique which records the small magnetic fields produced by the brain using delicate sensors. MEG is 
housed in a magnetic shielded room (MSR) for reducing noise from the surrounding environment. It allows 
very fast measurement of ongoing brain activity. As seen in Fig. 1, study participants will be seated on a 
comfortable chair with their head placed inside the helmet of MEG sensors that are able to detect extremely 
small magnetic signals produced by the brain.  
 
Fig. 2: A participant seated in the MEG scanner 
 
Do I have to take part? 
As with the wider study it is up to you to decide whether or not you take part. If you decide to participate, 
you will be given this information sheet to keep and you will be asked to sign a consent form. You have the 
right to withdraw from the study at any time without giving a reason. A decision to withdraw at any time, or 
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What will happen to me if I take part? 
You will be invited to come for an appointment at the Intelligent Systems Research Centre (ISRC), Ulster 
University, Magee campus. Experiments will take place in ISRC’s Northern Ireland Functional Brain 
Mapping (NIFBM) facility where your Magnetoencephalography (MEG) brain scan will be recorded. The 
MEG brain scan is a modern method of measuring signals produced by the brain.  
This will involve some preparation consisting of attaching a few electrodes and converting the signals into a 
digital image of your head following a standard operating procedure (SOP). Once ready, you will be seated 
in an arm-chair in front of a projector or computer screen. Please note that currents or voltages will not be 
applied to your head at any stage. 
A typical experiment will consist of about 30 minutes of scanning. Your participation in the study will 
involve no more than one appointment which will take approximately 1 hour in total (excluding travel time).  
 
Will my information be kept confidential? 
As with the wider study all information obtained during this investigation will be kept strictly confidential 
using your unique ID number and held securely on a password protected computer.  
 
 
Thank you for taking the time to read this information. 
If you have any questions or would like more information, contact: 
Miss Katie Moore PhD student on 02870123529: Moore-K@ulster.ac.uk 
Dr Catherine Hughes researcher on 028 7012 3516; c.hughes@ulster.ac.uk 
Dr Leane Hoey researcher on 02870124781; l.hoey@ulster.ac.uk 
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ULSTER UNIVERSITY        RESEARCH GOVERNANCE 
 
Consent Form for Magnetoencephalography (MEG) study               Participant Identification no: 
 
 












I have been given and have read and understood the information sheet dated 14/04/17 







I understand that my participation is voluntary and that I am free to withdraw at any time 






I understand that the researchers will hold all information and data collected during the 
study securely and in confidence and that all efforts will be made to ensure that I cannot 
be identified as a participant in the study (except as might be required by law) and I give 
permission for the researchers to hold relevant personal data  
 
 
4 I agree to take part in the above study  
 
     
Name of Participant (please print)  Signature  Date (dd/mmm/yy) 
 
     




The Trinity, Ulster and Department of Agriculture (TUDA) Cohort study 
Magnetoencephalography Pilot Study 
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Effect of Area-Level Socioeconomic Deprivation on Risk of
Cognitive Dysfunction in Older Adults
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OBJECTIVES: To investigate the relationship between
area-level deprivation and risk of cognitive dysfunction.
DESIGN: Cross-sectional analysis.
SETTING: The Trinity, Ulster, and Department of Agri-
culture (TUDA) study from 2008 to 2012.
PARTICIPANTS: Community-dwelling adults aged
74.0  8.3 without dementia (N = 5,186; 67% female).
MEASUREMENTS: Adopting a cross-jurisdictional app-
roach, geo-referenced address-based information was used
to map and link participants to official socioeconomic indi-
cators of deprivation within the United Kingdom and the
Republic of Ireland. Participants were assigned an individual
deprivation score related to the smallest administrative area
in which they lived. These scores were categorized into com-
parable quintiles, that were then used to integrate the data-
sets from both countries. Cognitive health was assessed
using the Mini-Mental State Examination (MMSE); cogni-
tive dysfunction was defined as a MMSE score of 24 or less.
RESULTS: Approximately one-quarter of the cohort
resided within the most-deprived districts in both coun-
tries. Greater area-level deprivation was associated with
significantly lower MMSE scores; fewer years of formal
education; greater anxiety, depression, smoking and
alcohol use, and obesity; and more adverse outcomes,
including higher blood pressure and diabetes risk. After
adjustment for relevant covariates, area deprivation was
associated with significantly higher risk of cognitive dys-
function (odds ratio =1.40, 95% confidence inter-
val = 1.05–1.87, P = .02, for most vs least deprived).
CONCLUSION: This analysis combining data from two
health systems shows that area deprivation is an indepen-
dent risk factor for cognitive dysfunction in older adults.
Adults living in areas of greatest socioeconomic depriva-
tion may benefit from targeted strategies aimed at
improving modifiable risk factors for dementia. Further
cross-national analysis investigating the impact of area-
level deprivation is needed to address socioeconomic dis-
parities and shape future policy to improve health out-
comes in older adults. J Am Geriatr Soc 2018.
Key words: older adults; cross-jurisdictional; geo-
referencing; area-level deprivation; cognition
Health, well-being, and socioeconomic status are clo-sely linked, with considerable evidence showing
poorer health1 and earlier morbidity and death2–4 in per-
sons at lower socioeconomic levels. There has been grow-
ing interest in whether the area in which a person lives can
influence health in addition to the effects of individual
socioeconomic factors.5 Area deprivation indices represent
a geographic area-based composite measure of the socioe-
conomic deprivation of neighborhoods. They are typically
constructed from a range of domains relating to depriva-
tion such as income, employment, education, proximity to
services, living environment, and crime and disorder and
are presented as a single value or score for each neighbor-
hood or area. Higher index values represent greater levels
of deprivation in an area, and available evidence suggests
that higher area deprivation is associated with greater risk
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of chronic disease and premature mortality6,7 independent
of individual socioeconomic circumstances.6,8–10
Cognitive function in aging has become a global pub-
lic health priority because it has important implications for
independence and quality of life of older adults.11 With
the prevalence of dementia predicted to triple by 2050, it
is important to identify individuals at greatest risk of
developing cognitive dysfunction, an early predictor of
dementia.11 Few previous studies have examined the influ-
ence of area-level deprivation on cognitive health in older
adults, although one study from England reported that
greater area-level deprivation was not significantly associ-
ated with cognitive impairment and dementia after
accounting for individual-level factors.12 To our knowl-
edge, no previous study has investigated area-level depriva-
tion in relation to cognitive health in cross-national
research.
Some progress has been made in advancing the devel-
opment of standardized deprivation indicators at a Eur-
opean Union level13 and more detailed comparisons of
small area-level deprivation for a selection of countries
within Europe,14 demonstrating the potential for using
such measures in cross-national health inequality research.
The aim of this study was to investigate the effect of area-
level socioeconomic deprivation on the risk of cognitive
dysfunction and related health and lifestyle factors in older
adults by combining data from two jurisdictions within
the island of Ireland: Northern Ireland (NI), United King-
dom, and the Republic of Ireland (RoI).
METHODS
Participants and Study Design
This investigation was conducted as an observational study
using data from the Trinity, Ulster, and Department of
Agriculture (TUDA) cohort, as described in detail else-
where.15 The TUDA study included 5,186 community-
dwelling, noninstitutionalized adults aged 60 and older
recruited between 2008 and 2012 from NI and RoI and
initially sought to investigate the role of nutritional and
related lifestyle factors in the development of three com-
mon diseases of aging—cardiovascular disease, osteoporo-
sis, and dementia. TUDA participants were recruited using
standardized protocols from general practice or hospital
outpatient clinics and deemed suitable if they (or their par-
ents) were born on the island of Ireland and did not have
a diagnosis of dementia. Participants who were able to
provide informed consent were considered eligible. The
final study cohort was composed of 2,093 participants
recruited in NI and 3,093 in RoI.
The Office for Research Ethics Committees Northern
Ireland granted ethical approval (reference 08/NIR03/113),
with corresponding approvals from the Northern and Wes-
tern Health and Social Care Trusts in NI and the Research
Ethics Committee of St James Hospital and The Adelaide
and Meath Hospital in Dublin.
Health and Lifestyle Data
A health and lifestyle questionnaire was administered to
participants to collect general information relevant to
medical history, medication use, smoking status, and alco-
hol consumption. Weight and height were recorded to the
nearest 0.01 kg and 0.01 m, respectively, using portable
scales and stadiometer (Seca; Brosch Direct Ltd, Peterbor-
ough, United Kingdom), and body mass index (BMI; kg/
m2) was calculated. Waist and hip measurements were
recorded to the nearest 0.1 cm using a flexible tape mea-
sure and standardized protocols. The Timed Up-and-Go
(TUG) test was administered as a measure of functional
mobility.16 Participants were asked to stand from a seated
position (seat height approximately 46 cm), walk 3 m at
their usual pace, turn around, walk back to the chair, and
sit down. No physical assistance was given, and the time
taken from command “Go” to completion of the task was
measured using a stopwatch. Blood pressure (BP) measure-
ments were taken in accordance with standard operating
procedures. In brief, two measurements were taken from
the reference arm (the arm with the highest BP reading),
with a 5- to 10-minute interval between each measure-
ment, and the mean of the two values was used as the BP
value. Nonfasting blood samples were collected, stored,
and analyzed using standard operating procedures and
routine hospital laboratory assays.
Cognitive health was assessed using the Mini-Mental
State Examination (MMSE),17 a short, structured cognitive
test that evaluates global cognitive function by assessing
the domains of orientation, registration, attention and con-
centration, recall and language and is the most widely used
screening tool in clinical settings worldwide for identifying
cognitive impairment or dementia. The maximum score
achievable is 30, with a score less than 25 indicating a
possibility of cognitive impairment and a score less than
20 indicating dementia. Anxiety and depression were also
assessed, using the Hospital Anxiety and Depression
Scale18 and the Center for Epidemiologic Studies Depres-
sion Scale, respectively.19
Measurement of Area Deprivation
Deprivation indices are used in the United Kingdom and
Ireland on a factor analytical approach that reduces a
large number of indicator variables to a smaller number of
underlying domains or factors that are presented as a sin-
gle value or score. Participants from NI were initially
mapped using their house number, street name, unit post-
code, town information, and the Land and Property Ser-
vices Ordnance Survey of Northern Ireland POINTER
Geo-referencing database.20 After cleaning and verification
of the address information, 1,982 participants (94.7%)
were geo-referenced and linked to an area deprivation
score based on the Census Output Area (COA) in which
they lived using data from the Northern Ireland Multiple
Deprivation Measure 2010,21 which comprises 7 domains
of deprivation, each developed to measure a distinct form
or type of deprivation: income, employment, health, edu-
cation, proximity to services, living environment, and
crime. These domains were then presented as a single
value or area deprivation score, which was then catego-
rized according to quintile (each quintile representing 20%
of all COAs in NI) ranging from least (Q1) to most (Q5)
deprived. This was the preferred measure of deprivation
because it was calculated at the smallest area-level
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available (with a mean number of households of 125 and
a mean population of 340).
In the absence of a comparable postal code reference
system in the RoI, an alternative geocoding method using
Irish Grid X and Y co-ordinates22 was used to map and link
participants to the appropriate socioeconomic indicators of
area-level deprivation using the 2011 Pobal HP Deprivation
Index for Small Areas in the Republic of Ireland,23 which
conceptualizes underlying indicators of deprivation based
on earlier deprivation indices for Ireland and analyses from
other countries to identify three domains of affluence or dis-
advantage: demographic profile, social class composition,
and labor market situation. After address information was
cleaned and verified, 3,066 participants (99.1%) were allo-
cated to a Small Area Population Statistics (SAPS) area (with
a mean number of households of 107 and mean population
of 248) and given an area deprivation score. Again, the sin-
gle area deprivation scores were categorized according to
quintile, with each quintile representing 20% of all SAPS
areas in RoI, ranging from least (Q1) to most (Q5) deprived.
Using local area deprivation data and the appropriate
geo-referencing methods for each jurisdiction, comparable
area deprivation scores categorized as quintiles could be
generated, allowing for TUDA study data from two differ-
ent countries within the island of Ireland (NI, RoI) to be
effectively linked and integrated. One hundred thirty-eight
(2.7%) participants of the study cohort were not allocated
an area deprivation quintile because of incomplete address
information.
Statistical Analysis
Statistical analysis was performed using SPSS version 23.0
(IBM Corp., Armonk, NY). Before statistical analysis was
performed, tests for normality were performed, and vari-
ables were log-transformed as appropriate. Between-group
differences were analyzed using analysis of covariance
(controlling for relevant covariates) with Bonferroni cor-
rection for multiple comparisons or chi-square tests using
standardized residuals. The effect of area deprivation on
the main study outcome, cognitive dysfunction, was inves-
tigated using logistic regression. In line with current clini-
cal practice in the United Kingdom and Ireland,
participants were classified according to MMSE score into
two groups—normal cognitive function (MMSE score ≥25,
reference) and cognitive dysfunction (MMSE score ≤24).
Area deprivation was categorized into quintiles, and the
model was adjusted for factors relevant to cognitive dys-
function. These covariates included age, sex, education,
depression, anxiety, BMI, TUG test, smoking, alcohol,
blood pressure, blood lipids, and diabetes.
RESULTS
Relevant characteristics of the TUDA study cohort are
shown in Table 1. Of the 5,186 TUDA study participants,
5,048 (97.3%) were allocated to an area deprivation quin-
tile. Figure 1 shows the geographical distribution of TUDA
participants in NI and RoI according to area deprivation
category. Marginally higher proportions of TUDA partici-
pants were found in the least- (21.2%) and most- (26.2%)
deprived quintiles than in the other quintiles.
Participant characteristics and disease risk factors were
then examined in relation to area-level socioeconomic
deprivation (Table 2). MMSE score was significantly lower
at the highest levels of area deprivation (Q4, Q5). With
increasing area deprivation, the number of years spent in
formal education decreased, and anxiety, depression,
smoking, alcohol use, and obesity all increased, along with
disease risk factors, including blood pressure and diabetes
risk.
Table 3 shows determinants of cognitive dysfunction
in older Irish adults, calculated using logistic regression
analysis. Area-level socioeconomic deprivation was associ-
ated with greater risk of cognitive dysfunction (odds
ratio = 1.40; 95% confidence interval = 1.05–1.87;
P = .02 for most vs least deprived) after adjustment for
other relevant factors. A comparison of logistic regression
analysis with and without area deprivation showed that
the inclusion of area deprivation significantly strengthened
the model (likelihood ratio test; see Table 3 footnote).
DISCUSSION
This study showed that area-level socioeconomic depriva-
tion in older people is associated with poor cognition and
an adverse general health profile. Older adults living in
areas with the greatest socioeconomic deprivation in NI
and the RoI had a 40% greater risk of cognitive dysfunc-
tion than those living in areas of least deprivation, after
adjustment for other relevant risk factors.
There is accumulating evidence that the place where a
person lives influences their disease risk, even after
Table 1. Relevant Characteristics of Trinity, Ulster,




Age, mean  SD 74.0  8.3
Female, n (%) 3,487 (67)
Age finished education, mean  SD 16.0  3.0
Mini-Mental State Examination score,
mean  SD
27.1  2.6
Center for Epidemiologic Studies Depression
Scale score, mean  SD
6.1  7.5
Hospital Anxiety and Depression Scale score 3.2  3.7
Lifestyle and clinical risk factors
BMI, kg/m2, mean  SD 27.9  5.4
Obese (BMI ≥30 kg/m2), n (%) 341 (34)
Waist-to-hip ratio, mean  SD 0.91  0.08
Timed Up-and-Go time, seconds, mean  SD 14  9
Current smoker, n (%) 623 (12)
Alcohol intake, units/wk, mean 7.8  12.5
Systolic blood pressure, mmHg, mean  SD 144  21
Diastolic blood pressure, mmHg, mean  SD 78  11
Total cholesterol, mmol/L, mean  SD 4.6  1.0
Low-density lipoprotein, mmol/L, mean  SD 2.4  0.9
High-density lipoprotein, mmol/L, mean  SD 1.5  0.5
Triglycerides, mmol/L, mean  SD 1.6  0.9
HbA1c, %, mean  SD 5.9  0.8
With or at risk of diabetes, n (%)a 1,145 (23)
SD = standard deviation; BMI = body mass index.
aGlycosylated hemoglobin (HbA1c) ≥ 6.1% or antidiabetic medication use.
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accounting for individual factors.6–10,24–26 Area depriva-
tion refers to a geographical measure of the socioeconomic
deprivation in an area or region. In the current cross-juris-
dictional study, greater area deprivation was associated
with significantly lower MMSE scores, fewer years spent
in formal education, poorer mental health, higher alcohol
use, and smoking (e.g., 8% vs 18% smokers in least vs
most deprived), along with a greater range of disease risk
factors, notably blood pressure, diabetes risk, and obesity
(e.g., 27% vs 35% obese in least vs most deprived). These
observations are generally consistent with findings from
other studies undertaken in Sweden, Australia, England,
and the United States.27–30 Most previous studies investi-
gating area-based deprivation have focused on mortality7
and cardiovascular diseases or diabetes,6,31 and there is a
paucity of research investigating the influence of area
deprivation on cognitive dysfunction; in particular, no pre-
vious study has addressed this relationship across different
jurisdictions. In the current study, consistent with previous
reports,32,33 older people living in areas of higher depriva-
tion were found to have higher rates of depression and
anxiety. Poor mental health (in particular depression) is in
turn an established risk factor for cognitive dysfunction,
and the current results showed that depression was an
independent factor contributing to cognitive dysfunction.
The mechanisms underlying the relationship between
area deprivation and cognitive dysfunction in the present
study are not clear, but educational attainment34 and
depression35 may be two important mediators in this
complex relationship. One recent population-based longi-
tudinal survey of more than 10,000 older adults in the
United States concluded that higher educational attain-
ment was associated with significantly lower risk of
dementia.36 Likewise, a 2-decade comparison of the
prevalence of dementia in the United Kingdom suggests that
education is a strong modifiable factor in dementia,37
further supporting the view that poor education may be one
of the drivers of the relationship between area deprivation
and cognition shown here. We found significantly lower
educational attainment in older adults living in areas of
greatest deprivation, who had 3 fewer years of formal edu-
cation than those in the least deprived areas. In addition,
depression has been shown to increase cognitive dysfunc-
tion, and poorer cognitive health can also predispose older
adults to depression,38,39 suggesting a bidirectional relation-
ship between the two conditions. Also, in agreement with
the current findings, it was previously observed that
depression in older adults was associated with socioe-
conomic disadvantage, poverty, and deprivation related
to place of residence.40 The association between area
deprivation and cognitive dysfunction observed in the
current study remained significant even after adjustment
for education, depression, and other factors, suggesting
that other social determinants of health could also con-
tribute to this relationship. These include contextual
poverty, income inequality, social cohesion, access to
resources, and relationships with the built and natural
environment.1,12,41
Despite expectations that aging populations globally
would lead to large increases in the number of adults with
dementia, recent studies from the United States and Eur-
ope suggest that the prevalence of dementia in some
Figure 1. Map showing the distribution of Trinity, Ulster, and Department of Agriculture study participants from (A) Northern
Ireland, United Kingdom and (B) the Republic of Ireland, color-coded according to area deprivation category, ranging from
least-deprived 20% of areas (GREEN) to most-deprived 20% of areas (RED) in each jurisdiction.
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Table 2. Participant Characteristics and Disease Risk Factors According to Quintile (Q) of Area Deprivation
Characteristic Q1, n = 1,069 Q2, n = 859 Q3, n = 919 Q4, n = 877 Q5, n = 1,324 P-Value
General characteristics
Age, mean  SD 75.4  8.7 74.0  8.3 73.3  7.9 73.6  8.0 73.9  8.3 <.001
Female, n (%) 734 (69) 585 (68) 591 (64) 597 (68) 886 (67) .36
Age finished education, mean  SD 17.8  3.8 16.6  3.1 15.9  2.7 15.3  2.2 14.8  1.9 <.001
Mini-Mental State Examination score, mean  SD 27.4  2.5 27.4  2.3 27.4  2.3 26.9  2.7 26.5  2.8 .008
Center for Epidemiologic Studies Depression
Scale score, mean  SD
5.2  6.8 5.4  6.8 5.5  7.4 6.3  7.6 7.5  8.2 .001
Hospital Anxiety and Depression Scale score 2.7  3.2 2.8  3.4 3.1  3.6 3.4  3.8 3.7  4.0 .01
Lifestyle and clinical risk factors
BMI, kg/m2, mean  SD 27.1  5.0 27.5  5.1 28.0  5.1 28.7  5.8 28.1  5.8 <.001
Obese (BMI ≥30 kg/m2), n (%) 291 (27) 274 (32) 324 (35) 348 (40) 469 (35) <.001
Waist-to-hip ratio, mean  SD 0.90  0.08 0.90  0.09 0.91  0.08 0.92  0.09 0.91  0.08 .001
Timed Up-and-Go time, seconds, mean  SD 14  10 14  9 13  9 14  9 15  9 .009
Current smoker, n (%) 86 (8) 76 (9) 100 (11) 108 (12) 242 (18) <.001
Alcohol intake, units/wk, mean 6.6  10.9 6.7  10.9 8.0  12.8 8.1  12.9 9.3  14.5 .004
Systolic blood pressure, mmHg, mean  SD 142  20 144  21 147  21 145  21 144  21 .006
Diastolic blood pressure, mmHg, mean  SD 77  11 78  11 79  11 79  11 78  12 .03
Total cholesterol, mmol/L, mean  SD 4.7  1.0 4.7  1.0 4.7  1.1 4.6  1.1 4.6  1.0 .01
Low-density lipoprotein, mmol/L, mean  SD 2.5  0.9 2.4  0.8 2.5  0.9 2.4  0.9 2.4  0.9 .06
High-density lipoprotein, mmol/L, mean  SD 1.6  0.5 1.5  0.5 1.4  0.5 1.4  0.5 1.4  0.5 <.001
Triglycerides, mmol/L, mean  SD 1.5  0.8 1.5  0.9 1.7  0.9 1.6  0.9 1.6  0.9 .001
HbA1c, %, mean  SD 5.8  0.8 5.8  0.8 5.8  0.8 6.0  0.9 5.9  0.8 .20
With or at-risk of diabetes, n (%)a 209 (20) 157 (18) 189 (21) 244 (28) 315 (24) .001
Participants were allocated to a deprivation quintile (1–5) based on the deprivation score of the area in which they lived, with 1 being the least deprived
and 5 the most deprived.
Statistical tests: Between-group analysis of covariance (controlling for age) with Bonferroni correction for multiple comparisons or chi-square test using
standardized residuals. P < .05 was considered significant.
SD = standard deviation; BMI = body mass index.
aGlycosylated hemoglobin (HbA1c) ≥ 6.1% or antidiabetic medication use.
Table 3. Determinants of Cognitive Dysfunction in Older Adults (n = 4,554)
Determinant Beta Value OR (95% Confidence Interval) P-Value
Age 0.059 1.06 (1.05–1.08) <.001
Female sex 0.078 0.93 (0.74–1.15) .49
Age at which finished education 0.151 0.86 (0.82–0.90) <.001
Center for Epidemiologic Studies Depression Scale score 0.040 1.04 (1.03–1.06) <.001
Hospital Anxiety and Depression Scale score 0.016 0.98 (0.96–1.01) .27
Body mass index 0.024 0.98 (0.96–1.00) .02
Timed Up-and-Go test 0.029 1.03 (1.02–1.04) <.001
Current smoker 0.109 1.12 (0.83–1.49) .46
Alcohol consumption in past year 0.084 1.09 (0.83–1.43) .54
Systolic blood pressure 0.002 1.00 (0.99–1.00) .52
Diastolic presssure 0.003 1.00 (0.99–1.01) .50
Total cholesterol 0.025 0.98 (0.88–1.08) .64
Triglycerides 0.074 0.93 (0.81–1.06) .28
With or at risk of diabetesa 0.023 1.02 (0.81–1.29) .85
Country: Republic of Ireland 0.421 1.52 (1.16–1.99) .002
Quintile of area deprivationb
2 0.112 0.89 (0.64–1.25) .51
3 0.246 0.78 (0.55–1.11) .17
4 0.209 1.23 (0.89–1. 70) .20
5 0.337 1.40 (1.05–1.87) .02
Cognitive dysfunction defined as Mini-Mental State Examination (MMSE) score ≤24.
Results obtained from a fully adjusted logistic regression model.
Odds ratio (OR) given as exponentiation of the beta coefficient (Exp B), where Exp B = change in the OR).
Likelihood ratio test indicates a significant improvement in the logistic regression model with the inclusion of area deprivation (with area deprivation: log-
likelihood = 2,907.8, chi-square = 519.2; degrees of freedom (df) = 20, P < .001; without area deprivation: log-likelihood = 2,926.7; chi-square = 500.4,
df = 16, P < .001).
aGlycosylated hemoglovin ≥6.1% or antidiabetic medication use.
bBased on the score of the area in which participants live (reference Q1: least deprived).
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countries may be stabilizing (or even declining), possibly
as a result of improved health in midlife and potential pro-
tection that better educational attainment in early life
affords.36,37 The findings of a recent investigation of epi-
demiological data over time from 5 studies in western Eur-
ope suggest that primary prevention aimed at increasing
cognitive reserve, along with better treatment of vascular
and chronic conditions, could have the greatest effect on
future dementia.37 In addition, deprived social environ-
ments are known to breed social isolation and psychoso-
cial stress and limit access to resources and health services,
all of which can potentially interact with individual sus-
ceptibility to cognitive dysfunction. The current findings
linking area deprivation with not only greater risk of cog-
nitive dysfunction and lower educational attainment, but
also a range of adverse lifestyle and cardiovascular disease
risk factors, points to the living environment as an impor-
tant component in dementia risk and thus a worthwhile
target for efforts to reduce dementia occurrence and dis-
ability. A comprehensive report recently highlighted the
potential for effective dementia prevention through tar-
geted interventions to modify risk factors that could trans-
form the future for society.42
The current study benefited from the use of a large,
well-characterized cohort of older adults. It used individ-
ual-level data on health and disease status and area-level
data on deprivation to determine whether living in a
deprived area increases the risk of poor health, specifically
cognitive dysfunction. A further strength was the use of
novel country-specific geocoding approaches that facili-
tated the integration of regionally independent ethnically
homogenous (Caucasian) datasets, enabling the TUDA
cohort as a whole to be readily described in relation to the
underlying socioeconomic profile of the base population of
the two countries within the island of Ireland. This novel
cross-jurisdictional approach provided a unique opportu-
nity to link area-level deprivation with cognitive outcomes
in older adults from two health systems; to our knowledge,
this is the first time this has been achieved. As such, this
work sets a precedent for future research initiatives seeking
to integrate comparable data from cross-national studies
(e.g., Survey of Health, Ageing and Retirement in
Europe43) to investigate area-level deprivation in relation
to health. The limitations of our approach relate to geo-
graphical coverage, geo-referencing accuracy, scale, and
the direct comparability of measures of deprivation across
jurisdictions. The study also used unique composite mea-
sures of deprivation from each jurisdiction made up of dif-
ferent combinations of univariate socioeconomic
indicators; thus the measures of small area deprivation are
not exactly comparable, but for the purposes of this study,
the measures were categorized into quintiles ranging from
the most- to the least-deprived areas in each jurisdiction,
providing a meaningful measure for comparison across the
deprivation spectrum. In addition, although area-based
income deprivation indicators are associated with health
outcomes, the effect is less pronounced than that of indi-
vidual income measures,44 and as such, the lack of specific
data relating to personal income has a potentially con-
founding residual influence in this analysis. Nevertheless,
this study further underscores the value of using area
deprivation indices (that include domains related to
personal income and wealth), particularly in situations in
which socioeconomic data for individuals are not readily
available. Finally, although the MMSE as a measure of
cognition has sometimes been criticized for its ceiling and
floor effects, it is the most widely used screening cognitive
test in clinical settings and in epidemiological studies
worldwide.45
In conclusion, the novel, cross-jurisdictional approach
of the current study provides a unique insight into the
relationship between area deprivation and cognitive per-
formance and suggests that older Irish adults living in
areas with the greatest level of deprivation are at signifi-
cantly higher risk (40%) of cognitive dysfunction.
Although further research is needed to fully elucidate the
mechanisms explaining our observations, this work repre-
sents a first step toward identifying the specific aspects of
area-level socioeconomic deprivation connected with cog-
nitive health in older adults. Given the widening health
and socioeconomic disparities seen globally, the current
findings identify the potential for effective dementia pre-
vention through targeted interventions to modify risk
factors in communities with the greatest area-level socioe-
conomic deprivation.
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Current evidence linking nutrition with brain
health in ageing
K. Moore, M. O’Shea, C. F. Hughes, L. Hoey, M. Ward and H. McNulty
Northern Ireland Centre for Food and Health, Ulster University Coleraine, Coleraine, UK
Abstract Cognitive dysfunction and depression are significant problems of ageing with
major health and socio-economic impacts; therefore, preventing or delaying the
onset of these disorders should be a public health priority. In particular, there is
a need to identify modifiable factors that could be targeted to promote better
brain health in ageing. Epidemiological studies indicate a protective role for
certain dietary patterns, in particular the Mediterranean diet, and for specific
nutrients, including n-3 polyunsaturated fatty acids, polyphenols and B vitamins.
Although, the evidence to date from randomised controlled trials is generally
inconsistent, there is clearer evidence to support a role for folate and related B
vitamins in slowing the progression of cognitive decline and possibly reducing the
risk of depression in ageing. Future studies incorporating new technologies offer
much promise for the development of effective nutrition strategies that could
reduce the risk of cognitive and mental disorders and improve quality of life in
our ageing population.
Keywords: ageing, B vitamins, cognitive function, depression, fatty acids, nutrition
Introduction
The global population is ageing with the number of
those aged 60 years and over predicted to reach two
billion by 2050 (United Nations Department of Eco-
nomic and Social Affairs/Population Division 2009).
An estimated 46.8 million people are living with
dementia worldwide, and this figure is predicted to
double in the next 20 years, with associated costs to
the global economy currently estimated at over $818
billion/year (Prince et al. 2015). Depression is a lead-
ing cause of disability, currently costing approximately
£7.5 billion annually in England alone, and projected
to increase by 67% by 2026 (National Collaborating
Centre for Mental Health 2010). Given the significant
impact of these conditions, there is a need to identify
modifiable factors that could be targeted to promote
better brain health in ageing populations. Epidemio-
logical evidence supports a role for certain dietary fac-
tors in brain health, opening up new potential avenues
for prevention of dementia and mental illness in age-
ing (Panza et al. 2008; Rechenberg 2016).
The ageing brain
Ageing affects the brain from a cellular to a functional
level. The brain has a high metabolic rate; therefore,
oxidative stress and inflammation are common in age-
ing neural tissue (Bishop et al. 2010). On average,
brain size decreases with age in later life and although
there is no loss of cortical volume, there is white mat-
ter atrophy (Silverman et al. 1997). The rate of this
atrophy is known to be a marker of cognitive decline
(Fox et al. 1999) and white matter lesions in ageing
are linked with late onset depression (Wang et al.
2014). Neurodegeneration is the loss of neuronal
Correspondence: Prof. Helene McNulty, Director, Northern Ireland
Centre for Food and Health, Ulster University Coleraine, Coleraine
BT52 1SA, UK.
E-mail: h.mcnulty@ulster.ac.uk
© 2017 British Nutrition Foundation Nutrition Bulletin, 42, 61–68 61
NEWS AND VIEWS DOI: 10.1111/nbu.12250
277
processes and nerve cells. This can lead to neurode-
generative disorders which are characterised by selec-
tive loss of neurons in the motor, sensory and
cognitive systems. This affects memory, cognition, lan-
guage, personality and mood and can have sporadic
and/or hereditary origins (Gelb 2016).
Mild cognitive impairment can be described as a
rate of cognitive decline greater than expected for an
individual’s age and education level but that does not
interfere notably with activities of daily life (Gauthier
et al. 2006). Of note, however, is that an estimated
50% of those with mild cognitive impairment will go
on to develop dementia within 5 years (Gauthier et al.
2006). Dementia is characterised by progressive deteri-
oration of multiple cognitive domains leading to
impaired daily functioning, with Alzheimer’s disease
being the most common cause of dementia in older
adults (Prince et al. 2014). The World Health Organi-
zation (2014) defines mental health as a state of ‘com-
plete physical, mental and social wellbeing and not
merely the absence of disease or infirmity’; mental ill-
ness includes depression and anxiety as common disor-
ders. A number of modifiable risk factors for declining
cognitive and mental health have been identified,
including dietary patterns and specific nutrients (Smith
2008; Stahl et al. 2014; Gallagher et al. 2016;
Kennedy 2016; Rechenberg 2016). Ageing itself is
associated with a reduction in the quantity of food
consumed, altered metabolism and decreased absorp-
tion of nutrients, all of which can increase the risk of
malnutrition (Wakimoto & Block 2001). Therefore,
nutritional approaches to prevent or slow the progres-
sion of cognitive decline are of much current research
interest.
Foods and brain health
Increasing evidence implicates certain dietary patterns,
such as high intake of fruit and vegetables (Kang et al.
2005) and fish consumption (Barberger-Gateau et al.
2007), as being beneficial to brain health. Compliance
with a Mediterranean diet (typically characterised by
higher intakes of fruit, vegetables, wholegrains, olive
oil and fish) has been associated with a lower risk of
Alzheimer’s disease and slower progression of symp-
toms from mild cognitive impairment to Alzheimer’s
disease (Scarmeas et al. 2006; Solfrizzi et al. 2010;
Singh et al. 2014). Adherence to a Mediterranean
diet also has been associated with a protective effect
against depression (Psaltopoulou et al. 2013). These
findings were recently confirmed in a study of 4470
participants, aged from 45 to 79 years, which found
significantly lower depression scores in those with
greater adherence to a Mediterranean diet (Veronese
et al. 2016). Although there is some biological basis
for the protective role of the Mediterranean diet
in brain health, the findings do not prove causality
as the studies to date have predominantly been
observational.
Specific nutrients and brain health
Fatty acids
The fatty acid composition of the brain membrane is
directly affected by diet, and this has focused attention
on the role of dietary fatty acids in brain health. There
is evidence that long-chain n-3 polyunsaturated fatty
acids, eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA) have potential benefits in cognitive
and mental health. The suggested mechanism for the
effects of these fatty acids is via their antithrombotic
and anti-inflammatory properties (Gillette-Guyonnet
et al. 2013) and their potential interactions with neu-
rotransmitters via phospholipid metabolism and regu-
lation of signal transduction (Grosso et al. 2014a).
Regular consumption of dietary n-3 polyunsaturated
fatty acids has been associated with reduced risk of
cognitive decline and reduced development of incident
dementia in epidemiological studies (Jicha & Markes-
bery 2010). Likewise, higher dietary DHA has been
associated with lower incidence of dementia (Schaefer
et al. 2006; Lopez et al. 2011). Randomised con-
trolled trials (RCTs) of n-3 polyunsaturated fatty acid
supplementation have, however, shown somewhat
inconsistent results with regard to cognitive function
(Freund-Levi et al. 2006; Quinn et al. 2010; Yurko-
Mauro et al. 2010). Furthermore, the relationship
between fatty acids and cognitive outcomes is complex
since higher intakes of n-6 fatty acids, irrespective of
n-3 polyunsaturated fatty acid intake, seem to negate
any of the aforementioned beneficial effects of n-3
polyunsaturated fatty acids (Jicha & Markesbery
2010). One meta-analysis of RCTs intervening with
supplemental n-3 polyunsaturated fatty acids con-
cluded that the beneficial effects on brain health may
be confined only to patients with mild cognitive
impairment (Mazereeuw et al. 2012); however, this
interpretation requires further investigation.
In two recent meta-analysis of RCTs, EPA supple-
mentation was found to benefit patients with a
diagnosis of depression; however, in those with non-
clinical depression, the findings were far less clear
(Grosso et al. 2014b; Hallahan et al. 2016). A recent
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Cochrane review concluded that there was insufficient
evidence to support increased n-3 polyunsaturated
fatty acid intake as a treatment for depression, high-
lighting the need for further investigation in this area
(Appleton et al. 2015).
Protein and carbohydrates
The role of dietary protein in cognitive function and
mental health has not been extensively studied in age-
ing populations. Lower verbal memory scores were,
however, observed in older people with lower dietary
protein intakes (Goodwin et al. 1983). Additionally
higher dietary protein intake was found to be posi-
tively correlated with non-verbal learning and verbal
memory (Koehler et al. 1997) and reduced risk of
mild cognitive impairment or dementia (Roberts et al.
2012). One RCT investigating the effects of dietary
protein from red meat on cognitive function in older
adults is ongoing (Daly et al. 2015).
The association between carbohydrates and cogni-
tive function is unclear because available evidence is
scarce (Power et al. 2015), with a Cochrane review
identifying only one RCT in older adults (Ooi et al.
2011). While more research has focused on carbohy-
drates and depression, the available evidence is some-
what conflicting. One study of community dwelling
older adults found that those with depressive symp-
toms had a diet with a higher glycaemic index (GI)
and glycaemic load (GL) (Mwamburi et al. 2011). A
prospective investigation also reported that a high GI
diet was associated with an increased risk of depres-
sion (Gangwisch et al. 2015). Contrary to these find-
ings, research in institutionalised older adults reported
that those suffering from depression had diets with a
lower GL (Aparicio et al. 2013). Given the inconsis-
tencies within the evidence base in this area, there is
clearly a need for further well-designed studies.
Polyphenols and vitamins
Inflammation is thought to be involved in the neuro-
degenerative cascade resulting in cognitive decline
(Gorelick 2010), and evidence suggests a protective
anti-inflammatory role for flavonoids against cognitive
decline and Alzheimer’s disease (Commenges et al.
2000; Letenneur et al. 2007; Schaffer et al. 2012). In
one large prospective study of 5395 older adults in
The Netherlands, polyphenol intake was associated
with a reduced risk of dementia in smokers (Engelhart
et al. 2002). Likewise, dietary polyphenol intake was
also associated with cognitive performance in 2574
middle-aged French participants (Kesse-Guyot et al.
2012). Of greater note, new evidence from a recent
RCT of healthy older adults reported that intervention
with high doses of cocoa-flavanol enhanced dentate
gyrus function, a brain area essential for learning and
memory, which was measured by magnetic resonance
imagining (MRI) and cognitive tests (Brickman et al.
2014). In the case of depression, animal studies have
shown anti-depressant effects of numerous polyphe-
nols, postulated to be related to their anti-inflamma-
tory and neurotransmitter modulation roles (Pathak
et al. 2013). Although positive effects of cocoa
polyphenols on mood were reported in one small
study of 87 middle-aged participants (Pase et al.
2013), the evidence from human studies is generally
scarce and expert groups have called for further co-
ordinated research in this area (Ward & Pasinetti
2016).
Oxidative stress is thought to be a major contribu-
tor to neurodegeneration and depression; thus, antiox-
idants have received particular attention in the study
of older adults. Although large prospective studies
have failed to demonstrate a protective effect of either
dietary or supplemental ascorbic acid on cognitive
function in older adults (Luchsinger et al. 2003;
Laurin et al. 2004; Devore et al. 2010), the studies
had significant limitations including the lack of a bio-
marker measure of vitamin C status. With regard to
mental health, an early RCT with an antioxidant sup-
plement containing vitamins A, E and C in 205 partic-
ipants reported substantial increases in plasma
ascorbic acid concentrations and correspondingly bet-
ter mood outcomes after one year (Smith et al. 1999).
Likewise, more recent cross-sectional and prospective
studies have reported lower dietary intakes or plasma
concentrations of ascorbic acid among older adults
with depression (Merrill et al. 2008; Hamer et al.
2011; Payne et al. 2012). More robust RCTs, which
include both biomarker and dietary intake measures,
are required to further explore the role of vitamin C
in mental health.
There is extensive literature in the area of vitamin
D and the ageing brain. Of note, a 7-year follow-up
study of 498 women aged 75 years and older identi-
fied significantly lower risk of Alzheimer’s disease for
those participants in the highest quintile of dietary
vitamin D intake at baseline (Annweiler et al. 2012).
In a recent meta-analysis of observational studies,
patients suffering from Alzheimer’s disease were found
to have significantly lower serum vitamin D concentra-
tions compared with matched cognitively healthy con-
trols (Annweiler et al. 2013). However, combined
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supplementation with vitamin D and calcium was not
found to decrease the risk of dementia or cognitive
decline in a RCT involving 4143 older women from
the US (Rossom et al. 2012). In the case of depression,
large cross-sectional (n = 2598) and prospective
(n = 2839) studies have linked lower serum vitamin D
status with an increased risk of depression (Williams
et al. 2014; Brouwer-Brolsma et al. 2016). The avail-
able evidence from intervention studies, however, has
not confirmed a causative relationship for vitamin D
in relation to the risk of depression (Li et al. 2014;
van den Berg et al. 2016).
B vitamins and brain health in ageing
The role of folate and related B vitamins in brain
health in ageing, and related mechanisms involving
one-carbon metabolism, is an area of active research
worldwide. Within one-carbon metabolism, folate,
along with vitamins B12 and B6, and riboflavin are
cofactors in DNA synthesis and repair, amino acid
metabolism and methylation reactions, including the
remethylation of homocysteine to methionine and sub-
sequent generation of S-adenosylmethionine. The latter
metabolite is essential for neurotransmitter synthesis
and thus vital for brain function and activity
(McGarel et al. 2015).
A number of observational studies have shown that
lower status of folate, vitamin B12 and vitamin B6
(and/or higher concentrations of homocysteine) are
associated with cognitive deficit in ageing (Smith &
Refsum 2016). RCTs have addressed the hypothesis
that optimising B vitamin status by supplementing
with folate alone, or in combination with vitamins B12
and/or B6, will delay cognitive decline in older adults.
Available RCTs in older adults that include interven-
tion with high-dose folic acid, vitamin B12 and vitamin
B6 over 2 years or more have shown not only
improved cognitive performance (Durga et al. 2007;
de Jager et al. 2012) but also a reduced rate of brain
atrophy in those incorporating MRI (Smith et al.
2010; Douaud et al. 2013). The RCT evidence is not
entirely conclusive, however, with one notable trial
from New Zealand failing to observe a significant ben-
eficial effect of folic acid, vitamin B12 and vitamin B6
on cognition (McMahon et al. 2006), possibly owing
to the inclusion of participants with generally high
baseline folate status and thus unlikely to benefit from
intervention aimed at improving status. One recent
and rather controversial meta-analysis in this area
concluded that neither folic acid nor vitamin B12 had
a beneficial effect on cognition in older adults (Clarke
et al. 2014). The article was widely criticised at the
time of publication, mainly as a result of the inclusion
criteria used to select the trials for investigation, and
thus, the findings are not generally accepted by the sci-
entific community in this area (Garrard & Jacoby
2015; Smith et al. 2015). It is clear that further well-
designed RCTs are needed, especially those targeting
participants with low B vitamin status as they are
likely to benefit the most from increasing B vitamin
concentrations to achieve better cognitive health in
ageing.
The role of B vitamins in depressive disorders has
not received as much interest as in cognitive function.
However, one meta-analysis of 19 observational stud-
ies reported a significant relationship between low
folate status and risk of depression (Gilbody et al.
2007). Low dietary intake and status of vitamin B12
have also been linked with an increased risk of depres-
sion (Reynolds 2006; Kim et al. 2008; Ng et al. 2009;
Sanchez-Villegas et al. 2009; Robinson et al. 2011;
Moorthy et al. 2012). RCTs of B vitamin supplemen-
tation as an adjunct to anti-depressant medications
(Coppen & Bailey 2000; Almeida et al. 2014) or alone
(Almeida et al. 2010; Walker et al. 2010) have pro-
vided mixed results and no clear conclusions, partly
because of major methodological differences among
studies. Reviews of the available evidence linking B
vitamins with depression have concluded that folate
and vitamin B12 may have roles in the longer term
management of this condition (Taylor et al. 2004;
Almeida et al. 2015).
Use of novel technologies in nutrition and
brain research
Validated questionnaire-based assessments are the
most common means of investigating cognitive and
mental health outcomes and indeed are most informa-
tive in regard to the effect of nutrition on behaviour
(Macready et al. 2010). However, in order to study
the role of nutrition in brain function, the emerging
use of brain imaging techniques in recent years pro-
vides an objective and highly robust means of assess-
ing brain function and response (de Jager &
Kovatcheva 2010). A number of such techniques are
available and have been reviewed in detail elsewhere
(Sizonenko et al. 2013). MRI is a structural imaging
technique that provides detailed pictures of brain tis-
sue (white and grey matter, blood vessels and bone)
using magnetic fields and radiofrequency pulses. Func-
tional MRI (fMRI) uses blood oxygen level-dependant
imaging to visualise changes in blood flow, in order to
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identify areas of neural activity within the brain. Elec-
troencephalography (EEG) and magnetoencephalogra-
phy (MEG) are two techniques for functional brain
imaging that record electric and magnetic activities of
the brain at the scalp and have the highest temporal
resolution compared to other imaging techniques.
In recent years, these imaging techniques have been
utilised in nutrition research. One notable study,
referred to earlier in this review, effectively used MRI
to confirm the beneficial effects of B vitamins on cog-
nition in older adults over a 2-year intervention period
(Smith et al. 2010). Another study used fMRI to
demonstrate higher brain activation in specific regions
of the brain in participants who consumed a nutrition-
ally balanced breakfast (Akitsuki et al. 2011). EEG
has also been used to investigate the effects of diet on
brain function, with one recent report showing
improved memory and functional connectivity in the
delta band in response to Souvenaid, a nutritional
supplement, in mild Alzheimer-type patients (Ritchie
et al. 2014). In recent years, MEG has been approved
by the US Food and Drug Administration (FDA) and
is being used for clinical and research purposes,
including investigating cognitive dysfunction, Alzhei-
mer’s disease and depression (Maestu et al. 2008;
Cheng et al. 2012; de Haan et al. 2012; Kurita et al.
2016). The application of these new technologies in
the field of nutrition, in combination with clinical
and questionnaire-based assessments, provides much
potential for robust investigation in future studies, fur-
thering knowledge and discovery, in an effort to
reduce the burden of declining brain health in ageing.
Conclusions
Undoubtedly, nutrition has an important role in pre-
serving cognitive and mental health and thus improv-
ing quality of life in older age. The impact of specific
nutritional factors on the brain in ageing is an area of
active investigation worldwide. Emerging evidence
implicates subclinical deficiencies of certain nutrients
in cognitive decline and poor mental health in older
adults; however, the threshold for nutrient levels to
prevent or delay declining brain function is still
unknown. If the findings of studies described in this
review, which show promise in relation to B vitamins,
n-3 polyunsaturated fatty acids and polyphenols, are
confirmed, a public health strategy to improve status
of these key nutrients may help to achieve better cog-
nitive and mental health in ageing. Future studies
incorporating imaging techniques offer a robust basis
for confirming effective nutrition interventions that
could reduce the risk of cognitive and mental decline
in ageing and the related burden on health services.
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Globally populations are ageing. By 2050, it is estimated that there will be two billion people
aged 60 years or over, of which 131 million are projected to be affected by dementia, while
depression is predicted to be the second leading cause of disability worldwide by 2020.
Preventing or delaying the onset of these disorders should therefore be a public health pri-
ority. There is some evidence linking certain dietary patterns, particularly the Mediterranean
diet, with a reduced risk of dementia and depression. Specific dietary components have also
been investigated in relation to brain health, with emerging evidence supporting protective
roles for n-3 PUFA, polyphenols, vitamin D and B-vitamins. At this time, the totality of
evidence is strongest in support of a role for folate and the metabolically related B-vitamins
(vitamin B12, vitamin B6 and riboflavin) in slowing the progression of cognitive decline and
possibly reducing the risk of depression in ageing. Future studies incorporating new tech-
nologies, such as MRI and magnetoencephalography, offer much promise in identifying
effective nutrition interventions that could reduce the risk of cognitive and mental disorders.
This review will explore the ageing brain and the emerging evidence linking diet and specific
nutrients with cognitive function and depression in ageing, with the potential to develop
strategies that could improve quality of life in our ageing population.
Nutrition: Cognition: Depression: Ageing: B-vitamins
Globally the population is ageing, with predictions that the
number of people aged 60 years and over will reach up to
two billion by 2050(1). An estimated 23 % of the global bur-
den of disease arises in older people, and mental disorders
are reported as the leading cause of disability and ill
health(2). Dementia and depression are the most common
of these disorders in ageing as identified by the WHO(3).
Cognitive function declines with age, ranging in severity
from mild cognitive impairment (MCI) to dementia, with
up to 50 % of those with MCI going on to develop demen-
tia within 5 years(4). MCI can be defined as cognitive
decline greater than expected for an individual’s age and
education level but that does not interfere notably with
activities of daily life(4), whereas dementia interferes with
activities of daily living(5). Dementia currently affects
46·8 million people worldwide and is projected to affect
over 131 million people by 2050(6), while depression is
anticipated to be the second leading cause of disability
worldwide by 2020(7), with 22 % of males and 28 % of
females over the age of 65 years affected by depression(8).
The economic burden of cognitive decline and depression
is profound. Experts have calculated that dementia will
be a trillion dollar disease by 2018(6). Figures for depression
are currently estimated at over €3 billion in Ireland(9) and
£7·5 billion in England(7). With mental health considered
to be one of the greatest global challenges(10), there is an
urgent need to identify modifiable factors for targeted
interventions to promote better brain health in our ageing
populations. Epidemiological evidence supports a role for
certain dietary factors in brain health, opening up new
potential avenues for prevention of dementia and mental
illness in ageing(11,12).
This review will explore the influence of ageing on
brain health and the emerging evidence linking diet and
specific nutrients with cognitive function and depression
in ageing. The use of novel imaging technologies in
*Corresponding author: H. McNulty, email h.mcnulty@ulster.ac.uk
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; RCT, randomised controlled trial.
Proceedings of the Nutrition Society, Page 1 of 12 doi:10.1017/S0029665117004177






















Downloaded from https://www.cambridge.org/core. University of Ulster- Jordanstown, on 11 Jan 2018 at 20:55:28, subject to the Cambridge Core terms of use, available at
285
nutrition and brain research will be discussed, along with
the potential for nutrition to play a protective role in pre-
serving better brain health in ageing.
The ageing brain
Physiology and pathophysiology
The structure and metabolic pathways within the brain are
progressively altered with ageing, although the precise aeti-
ologies of ageing have not been fully elucidated. As people
age, there is a reduction in brain volume in both grey and
white matter(13), while white matter lesions increase(14) and
there is developmentof amyloidplaques, neurofibrillary tan-
gles, Lewy bodies, synaptic dystrophy and neuron loss(15,16),
whichhavebeen suggested toparallel the progressionof cog-
nitive decline(17). There are also changes in the production of
neurotransmitters, in particular serotonin and dopamine,
which have been reported to decline by up to 10 % per
decade from early adulthood(14). Additionally, there is an
increase in oxidative stress response(18) and more dysfunc-
tion of the blood–brain barrier(19).
Normal ageing is associated with a decline in cognitive
function, with most cognitive change observed in memory
during the ageing process.MCI is a recognised clinical con-
dition where individuals have evidence of cognitive impair-
ment but do not meet the criteria for the diagnosis of
dementia(20). Alzheimer’s disease (AD) is the most
common form of dementia, accounting for 62 % of cases,
with other forms including vascular dementia, mixed,
Lewy body and frontotemporal dementia(21). Depression
in older adults is often referred to as late-life depression
and is reported more commonly in females than
males(22–24). The depressive symptoms of older adults are
thought to be different from those experienced by younger
adults, as somatic and psychological symptoms are often
accompanied by fatigue, hopelessness about the future,
loss of appetite and sleep disturbance(22).
Pharmaceutical treatments
Pharmacological treatment for dementia is prescribed by
specialist clinicians(25), but only a limited number of med-
ications that target the biochemical abnormalities of neur-
onal loss are included within the National Institute for
Health and Care Excellence recommendations for demen-
tia interventions. These include acetylcholinesterase inhi-
bitors (donepezil, galantamine, rivastigmine) and
memantine (N-methyl-D-aspartate receptor antagonists).
There are however a variety of pharmacological treatment
options available for depression including tricyclic
antidepressants, selective serotonin reuptake inhibitors,
serotonin and noradrenaline reuptake inhibitors and
selective noradrenaline reuptake inhibitors(26,27). Overall,
poor response rates to these costly pharmacological treat-
ments for depression have been observed(28,29), and despite
significant investigation into the role of pharmacological
treatments for dementia, no licenced medication can cure
these diseases of the brain. Therefore, much effort is
currently focusing on options for prevention rather than
treatment of brain disorders.
Assessment of brain function
The assessment of brain function for neurodegenerative
diseases and depressive disorders in ageing is a developing
area. There are numerous neurological tests available
which are designed to assess and distinguish different indi-
viduals in their response to day-to-day cognitive tasks(30)
and for the detection of common mental health disor-
ders(31). The National Institute for Health and Care
Excellence has provided guidance on the recommended
diagnostic criteria for depression(32) and dementia(33). For
dementia, the guidelines emphasise the need to assess the
following domains: attention and concentration, orienta-
tion, short- and long-term memory praxis, language and
executive function. Furthermore, the National Institute
for Health and Care Excellence recommends that formal
tests should be conducted, including the mini mental
state examination, six-item cognitive impairment test, gen-
eral practitioner assessment of cognition and 7-min screen,
and that other factors known to influence performance
such as education level, should also be taken into account.
Lastly, only healthcare professionals with expertise in dif-
ferential diagnosis and using international standardised cri-
teria (such as the National Institute of Neurological
Communicative Disorders) should be responsible for diag-
nosing subtypes of dementia(33).
Investigating cognitive and mental health outcomes via
questionnaire-based assessments is the most common
approach for assessing the effects of nutrition(34). For asses-
sing brain health and function in relation to nutritional fac-
tors, studies should be aimed at prevention rather than
treatment, and non-nutrition factors contributing to cogni-
tive impairment and depression should be incorporated
into studies and considered at the time of analysis(35).
Concerning the specific tests to assess cognitive function,
these should be carefully selected and should be based on
a known or hypothesised relationship of a specific food/
nutrient with cognitive function and not solely on their
availability or ease of administration. It is also important
that the tests are suitable for repeated administration, are
appropriate to the population being studied and are rela-
tively simple to interpret and administer. More work is
required using standardised tests across laboratories, so
that the specific tests or markers that are most sensitive to
the nutrients tested can be established(30,35). Lastly, compu-
terised cognitive assessments have been utilised and these
should be considered for use in future trials in terms of
their accuracy and ability to capture reaction-time data,
standardisation of administration, availability of parallel
versions of tasks for testing at multiple time points and
availability in multiple languages(35).
Food, nutrition and brain health in ageing
Foods and dietary patterns
Increasing evidence implicates certain dietary patterns
such as higher intake of fruit and vegetables(36) and
fish(37) as being beneficial to brain health. The
Mediterranean diet is receiving significant attention as
regards its role in preserving cognitive health and






















Downloaded from https://www.cambridge.org/core. University of Ulster- Jordanstown, on 11 Jan 2018 at 20:55:28, subject to the Cambridge Core terms of use, available at
286
protecting against depression in ageing. This diet is
typically characterised by higher intakes of fruit, vegeta-
bles, wholegrains, fish, unsaturated fatty acids and a
regular but moderate consumption of alcohol. A recent
meta-analysis (n 34 168) showed that the highest
Mediterranean diet scorewas associatedwith reduced inci-
dence of developing cognitive disorders (RR 0·79, 95 %CI
0·70, 0·90)(38) while supplementation of theMediterranean
diet with olive oil or nuts was associated with improved
cognitive function(39). Of note, studies using MRI have
shown that adherence to theMediterranean diet was asso-
ciated with larger cortical thickness (which in turn is asso-
ciatedwith a lower risk of cognitive impairment)(40). There
is also accumulating evidence to support a potential role
for the Mediterranean diet in preventing depression in
older adults, with cross-sectional and prospective studies
showing inverse associations between Mediterranean diet
score and risk of depression(41–45). Further well-designed
intervention studies are however required to more fully
investigate the potential role of the Mediterranean diet
as a means of helping to preserve better brain health in
ageing.
Specific nutrients
Protein and carbohydrates. The role of dietary
protein intake on cognitive function or mental health
has not been extensively studied in ageing populations.
Lower verbal memory scores were however observed in
older people with lower dietary protein intakes(46).
Additionally, higher dietary protein intake was found
to be positively correlated with non-verbal learning,
verbal memory and reduced risk of MCI or
dementia(47,48). One randomised controlled trial (RCT)
investigating the effects of dietary protein from red
meat on cognitive function in older adults is in progress
(ACTRN12613001153707) with results expected in
2018(49).
The association between carbohydrates and cognitive
function is unclear because available evidence is scarce,
with one Cochrane review identifying only one relevant
RCT in older adults(50,51). However, higher dietary
carbohydrate and sugar intakes were associated with
lower cortical thickness, which is in turn associated
with high risk of late-life MCI and dementia(40). While
more research has focused on carbohydrates and depres-
sion, the available evidence is somewhat conflicting. One
study of community-dwelling older adults found that
those with depressive symptoms consumed a diet with a
higher glycaemic index and glycaemic load(52). A pro-
spective investigation also reported that a high glycaemic
index diet was associated with an increased risk of
depression(53). Contrary to these findings, however, insti-
tutionalised older adults with depression were reported to
consume diets with a lower glycaemic load (54). Given the
inconsistencies in this area, there is clearly a need for fur-
ther well-designed studies.
n-3 Fatty acids. The fatty acid composition of the
brain membrane is directly affected by diet and this has
focused attention on the role of dietary fatty acids in
brain health. There is evidence that long-chain n-3
PUFA, EPA and DHA, have potential benefits in
cognitive and mental health(55,56). One meta-analysis of
ten randomised trials concluded that n-3 fatty acids
may have a protective effect on certain cognitive
domains in cognitively impaired patients, however, no
effects were seen in healthy people or in AD
sufferers(57). A recent Cochrane review, which identified
three randomised trials for inclusion involving 632
patients with mild to moderate AD, concluded that
there was no convincing evidence that PUFA had a
role in the treatment of people with existing dementia(58).
Conversely, systematic reviews and meta-analyses of
randomised trials have reported significant clinical ben-
efits of n-3 PUFA intervention in the treatment of depres-
sion. The use of predominantly EPA compared with
DHA supplementation appears to have greater
efficacy(59,60). Furthermore, supplementation with
EPA-predominant formulas as an adjuvant therapy to
antidepressants was found to have greater clinical
efficacy in the treatment of depression (compared with
antidepressants alone), but did not prevent depressive
symptoms among populations without a diagnosis of
depression(59,60). A Cochrane review in this area reported
a small to modest non-clinical beneficial effect of n-3
PUFA in depression symptomology, but concluded
that there was not enough good quality evidence to deter-
mine the effect on depression(61).
Polyphenols. The role of these phytochemicals in
brain health and ageing is an emerging area(62–64). Large
prospective studies have identified associations between
the dietary intakes of total or specific polyphenols and
cognitive function after up to 13 years of follow-up
investigation(65–67). Supplementation with cocoa flavanol
for periods of up to 2 months was reported to improve
cognitive performance in a group of cognitively intact
older adults(68). Of note, Brickman et al.(64) conducted a
3-month intervention and showed significant increases in
cerebral blood volume in the dentate gyrus as measured
by functional MRI in subjects who were assigned to a
high flavanol treatment. Research into the role of
polyphenols in depression in human subjects has been
limited(69), although animal studies show promise in
demonstrating antidepressant-like effects of polyphenols
in mouse models(70).
Vitamins. Specific vitamins have been investigated in
relation to brain health and disease. Oxidative stress is
thought to be a major contributor to neurodegeneration
and depression(18), thus antioxidants have received much
interest. The roles of vitamin C(71–74), β-carotene(75–77)
and vitamin E(78–81) have been explored, but no clear
conclusions can be made and further work in the form of
intervention studies is warranted. The postulated roles of
vitamin D and B-vitamins have been more fully
investigated in relation to their effects on brain health in
ageing.
Following the discovery of the vitamin D receptor in
the brain(82), evidence for the role of vitamin D in
brain health has been accumulating. Systematic reviews
and meta-analyses have shown that AD sufferers have
lower serum vitamin D status than healthy controls,
and that low serum vitamin D status is associated with
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worse cognitive outcomes(83–85). Recent longitudinal
studies with mean follow-up periods of over 4 years
found that lower vitamin D status was also associated
with declining mini mental state examination scores
and accelerated cognitive decline(86,87). Furthermore,
Hooshmand et al. used MRI to demonstrate that higher
vitamin D status was associated with greater brain
volumes(88), which is generally regarded as a valid
marker of disease state and progression. Research inves-
tigating the role of vitamin D in depression is much less
clear. Large cross-sectional and prospective studies
reported that lower serum vitamin D status was asso-
ciated with an increased risk of depression(89,90). One
detailed systematic review, which included cross-
sectional, prospective and RCT data, concluded that
lower vitamin D status may be a risk factor for late-life
depression(91).
One-carbon metabolism and related B-vitamins
Historically, B-vitamin deficiencies, in particular fol-
ate(92,93) and vitamin B12
( 94,95), and to a much lesser extent
vitamin B6
( 96), have been linked with poorer psychiatric
wellbeing. These B-vitamins play crucial roles in one-car-
bon metabolic pathways where they act as co-factors in
DNA synthesis and repair, amino acid metabolism and
methylation reactions, including the remethylation of
homocysteine to methionine and subsequent generation
of S-adenosylmethionine. S-adenosylmethionine, the uni-
versal methyl donor, is involved in the methylation of
DNA, phospholipids, proteins and neurotransmitters,
thus reduced status of one or more of the B-vitamins
involved in one-carbon metabolism may impair methyla-
tion processes(97,98). The inhibition of methylation reac-
tions may in turn influence cognitive impairment in
ageing in various ways(99), by perturbing the regulation
of gene expression in the β-amyloid pathway, by reducing
the activity of protein phosphatase-2A or by impairing the
formation of phosphatidylcholine-enriched n-3 fatty
acids(99). Additionally, reduced tissue concentration of
S-adenosylmethionine may be linked to depression
through perturbing monoamine (serotonin, dopamine
and noradrenaline) synthesis and methylation(98). Apart
from folate, vitamins B12 and vitamin B6, which havewell-
recognised roles in these pathways, riboflavin (in its cofac-
tor forms flavin adenine dinucleotide and FMN) is also
essential in one-carbon metabolism but its potential role
in influencing brain health has rarely been considered.
Numerous observational studies have shown that
lower status of folate, vitamin B12 and vitamin B6 (and/
or higher concentrations of homocysteine) are associated
with cognitive deficit in ageing as extensively reviewed
elsewhere(99,100). Randomised trials in older adults that
include intervention with high-dose folic acid, vitamin
B12 and vitamin B6 over 2 years or more have shown,
not only improved cognitive performance(101–104), but
also a reduced rate of brain atrophy in studies which
have incorporated MRI(103,104). Notably the greatest
slowing in atrophy (53 %) was seen among participants
with MCI and the highest homocysteine concentrations
at baseline (>13 µmol/l), while cognitive function was
preserved in those supplemented with B-vitamins
and with a baseline homocysteine concentration
>11·3 µmol/l(102). The RCT evidence is not entirely con-
sistent, however, as one recent and rather controversial
meta-analysis in this area concluded that neither folic
acid nor vitamin B12 had a beneficial effect on cognition
in older adults(105). This paper was however widely criti-
cised at the time of publication, mainly as a result of the
inclusion criteria used to select the trials for investiga-
tion, and thus the findings are in general not widely
accepted by experts in this area(106,107). It is clear that fur-
ther appropriately designed randomised trials are needed,
especially those targeting participants with low
B-vitamin status (and in those at most risk of cognitive
decline) as they are likely to benefit the most from opti-
mising B-vitamin concentrations to achieve better cogni-
tive health in ageing. Furthermore, research investigating
the protective role of riboflavin on cognitive function is
greatly lacking, albeit some evidence from older studies
investigating riboflavin showed that lower biomarker sta-
tus was associated with cognitive impairment(108).
Clearly there is a need for riboflavin to be considered
in future randomised trials.
The role of B-vitamins in depressive disorders has not
received as much interest as studies of cognitive disorders,
although some observational (Table 1) and intervention
(Table 2) evidence exists. A meta-analysis of nineteen
observational studies concluded that low folate status was
associated with a significantly greater risk of depres-
sion(109). Low dietary intakes(110,111) or biomarker sta-
tus(112–115) of vitamin B12 have also been linked with an
increased risk of developing depression. Only a limited
number of studies have considered the role of vitamin B6,
but available evidence suggests an inverse association
between vitamin B6 biomarker status (plasma pyridoxal
5′-phosphate) and depression(111,116,117). Far less evidence
exists in relation to riboflavin, although one early study
reported lower biomarker status of riboflavin in psychiatric
inpatients(96). A number of randomised trials have consid-
ered the role of B-vitamin supplementation alone(118–121) or
as an adjunct to anti-depressant medications(122,123). The
results are somewhat conflicting, however, and no clear
conclusions have emerged, partly because of major meth-
odological differences among studies. Reviews of the avail-
able evidence in relation to depression have concluded that
folate and vitamin B12 may have roles in the longer term
management of this condition(124,125).
Overall, there is considerable evidence to suggest that
folate, vitamin B12 and vitamin B6 have protective effects
on cognitive function, and potentially against depressive
symptoms in ageing, however further randomised trials
of appropriate duration in suitable populations, and
ideally interventions combining all four relevant
B-vitamins, are required to support these findings.
Use of novel imaging technologies in nutrition and brain
research
Following the 2009 Nutrition and Mental Performance
Task Force of the European Branch of the
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International Life Sciences Institute workshop, a recom-
mendation was developed suggesting the inclusion of
brain-imaging biomarkers as secondary endpoints to
clinical and cognitive measures(35). Brain-imaging techni-
ques have been increasingly utilised in recent years and
provide an objective and highly robust means of asses-
sing brain structure, function and response to nutrition,
with advantages and disadvantages associated with
each of their use, as reviewed in detail elsewhere(126)
(Table 3). Electroencephalography and magnetoence-
phalography are two similar techniques for functional
brain imaging and have the highest temporal resolution
compared with other imaging techniques.
In recent years, some of these brain-imaging techni-
ques have been utilised to advance nutrition research in
ageing. One notable study referred to earlier in this
review(103) effectively used MRI and confirmed the ben-
eficial effects of B-vitamins on cognition shown previ-
ously in older adults with MCI, in particular in those
with good status of PUFA(127). Additionally, Brickman
et al. used functional MRI and demonstrated higher
brain activation in specific regions of the brain in partici-
pants who consumed high-dose cocoa flavanols(64). In a
study of 239 older adults, diffusion tensor imaging
(which in some cases has been suggested to be a better
predictor of cognitive decline than other biomarkers)(128),
identified better white matter integrity in those who con-
sumed more n-3 and n-6 PUFA and vitamin E(129).
Electroencephalography has also been used, with one
recent report showing improved memory and functional
connectivity in the δ band in response to Souvaid®, a
nutritional supplement containing PUFA uridine, cho-
line, phospholipids, folic acid, vitamin B6, B12, C, E
and selenium in mild Alzheimer-type patients(130).
Positron emission tomography imaging has also been
conducted within a 3-week intervention study, albeit in
a very small study of only eleven women, leading to
the conclusion that n-3 supplementation did not affect
brain glucose metabolism in healthy older people(131).
It is clear that imaging techniques provide an objective
means to improve the evidence base in this area, in par-
ticular in relation to proposed mechanisms. At this time,
however, the number of studies utilising brain-imaging
techniques to investigate the role of diet in brain health
in ageing are limited. Magnetoencephalography has
been approved by the US Food and Drug
Administration for use within clinical and research set-
tings as a means to assess and investigate cognitive dys-
function(132), AD(133,134) and depression(135). However,
to our knowledge, no work has been published using
magnetoencephalography for nutrition studies in older
adults. The application of these new technologies in the
field of nutrition, in combination with clinical and
questionnaire-based assessments, could provide much
potential for robust investigation in future studies,
furthering knowledge and discovery.
Conclusions
Nutrition has important roles in preserving cognition
and reducing the risk of late-life depression. Emerging
evidence in this area implicates subclinical deficiencies
of certain nutrients in cognitive decline and depression
in older adults. Future studies should address the gaps
in the literature, in particular in identifying of the thresh-
old for optimal nutrient levels required to prevent or
delay declining brain health. At this time, the evidence
for potential protective effects is strongest in relation to
B-vitamins, n-3 PUFA and polyphenols. If confirmed,
a public health strategy to improve status of these key
nutrients may help to achieve better cognitive and mental
health and thus improve quality of life in older age.
Future well-designed randomised trials (ideally
Table 2. Summary of randomised controlled trials investigating the effect of B-vitamin supplementation on depression in older adults






FA: 2·5 mg, B12: 1 mg, B6:
50 mg or placebo






FA:0·4 mg, B12: 0·1 mg or
placebo
2 years FA plus B12 was not effective in reducing depressive






FA: 2 mg, B12: 0·5 mg, B6:
25 mg or placebo
6·9–7·2
years
Reduction in risk of major depression, in participants with no
previous major depressive episodes
Ford et al.(121) Australia n 299
≥75 years
FA: 2 mg, B12: 0·4 mg, B6:
25 mg or placebo
2 years No effect on depressive symptoms or development of
depression in participants without a prior diagnosis of
depression





20–40 g Citalopram with FA: 2
mg, B12: 0·5 mg, B6; 25 mg or
placebo
52 weeks B vitamins did not increase 12-week efficacy of
antidepressants, but enhanced and sustained







20 mg fluoxetine with FA:
500 mg or placebo
10 weeks FA significantly improved the action of fluoxetine in
participants with depression
FA, folic acid.
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incorporating imaging techniques such as magnetoence-
phalography) may provide a more robust basis for confi-
rming effective nutrition interventions, which if
implemented could reduce the risk of cognitive and men-
tal health disorders in ageing and the related burden on
health services and society overall.
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Irish Section Meeting, 21–23 June 2017, What governs what we eat?
Role of fortification and supplementation in achieving optimal biomarker
status of B-vitamins for better mental health in older adults
K. Moore1, C.F. Hughes1, L. Hoey1, M. Ward1, K. Porter1, J.J. Strain1, K. Pentieva1,
A. Molloy2 and H. McNulty1
1Northern Ireland Centre for Food and Health, Ulster University, Coleraine, BT52 1SA and
2Institute of Molecular Medicine, Trinity College, Dublin 2, Ireland
Worldwide the number of adults aged 60 years and over is predicted to reach 2 billion by 2050,(1) and hence the associated chronic
diseases of ageing will continue to increase in the coming decades. Mental health disorders such as depression are common in older
age and are major contributors to disability and poor quality of life.(2) Folate and the related B-vitamins (vitamin B12, vitamin B6 and
riboflavin) involved in one-carbon metabolism are required for normal brain function and thus may have a protective role against
depression. We have recently reported that low biomarker status of the relevant B-vitamins was associated with an increased risk
of depression:(3) however it is unclear whether protective biomarker status can be achieved through natural food sources alone or
if fortification and/or supplementation with B-vitamins is required. The aim of this study was to investigate the role of fortified
food and supplements in optimising B-vitamin biomarker status in older adults, to levels associated with a reduced risk of depression.
This investigation was conducted as part of the Trinity Ulster Department of Agriculture (TUDA) Ageing cohort study (n 5186),
where detailed health and lifestyle information was collected along with measurements of cognitive and mental health. Some 70 % of
participants were fortified food consumers while 11 % were B-vitamin supplement users. Participants were categorised on the basis of
dietary sources of B-vitamins as: natural food sources only; fortified food consumers; or supplement users (with and without concur-
rent consumption of fortified foods) (Table). B-vitamin biomarkers were examined in relation to each dietary category.
Data presented as medians. Differences were assessed using ANCOVA with Bonferroni post hoc tests on log-transformed data
when applicable, controlling for age, gender, BMI and smoking. Values across a row without a common superscript letter are
significantly different (P < 0·05). Abbreviations: RBC, red blood cell; PLP, pyridoxal 5-phosphate; EGRac, erythrocyte glutathione
reductase co-efficient.
Biomarker status of each B-vitamin increased significantly with increasing intakes of fortified foods while non-consumers of for-
tified foods or supplements had the lowest status of all B-vitamin biomarkers. As previously reported,(3) lowest biomarker status
of folate (p 0·003), vitamin B6 (p 0·034) and riboflavin (p 0·011) were, in turn, associated with an increased risk of depression by
47–78 %.
In conclusion, natural food sources alone appear to be insufficient in achieving a biomarker concentration of B-vitamins associated
with lowest risk of depression, while regular consumption of fortified foods or supplements appear to be associated with biomarker
concentrations that may protect mental health in ageing. These findings, if confirmed through randomised controlled trials, may have
implications for dietary recommendations or fortification policy.
1. UN Department of Economic and Social Affairs/Population Division. (2015) New York: United Nations.
2. Prince M, Wu F, Guo Y, et al. (2015) Lancet, 385(9967), 549–562.
3. Moore K, Hughes C, Hoey L, et al. (2016) Proc Nutr Soc, 75, OCE3 E115.
Fortified Food Consumer
Natural Food Sources Low Medium High Supplement User
Servings/week 0 1–4 5–7 8+ 0–8+
TUDA Total % 23·0 9·5 20·7 34·0 10·8
RBC folate (nmol/L) 691a 802b 909c 1138d 1554e
Serum Total Vitamin B12 (pmol/L) 238a 243ab 260b 271c 293c
Plasma Vitamin B6 PLP (nmol/L) 47·0a 54·1b 60·8c 70·3d 70·6d
Riboflavin status (EGRac) 1·35a 1·32b 1·28c 1·28c 1·24d
Homocysteine (μmol/L) 15·2a 13·7b 13·7b 12·6c 12·2c
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Winter Meeting, 6–7 December 2016, Diet, Nutrition and Mental Health and Wellbeing
Biomarkers of folate and related B-vitamins as predictors of cognitive
decline in older Irish adults over a 5 year follow up period.
K. Porter1, C.F. Hughes1, L. Hoey1, M. Ward1, K. Moore1, J.J. Strain1, A. Molloy2,
C. Cunningham3, M.C. Casey3, E. Laird2, K. McCarroll3, K. Pentieva1 and H. McNulty1
1Northern Ireland Centre for Food and Health, Ulster University, Coleraine, BT52 1SA,
2Institute of Molecular Medicine, School of Medicine, Trinity College, Dublin 2, Ireland and
3Mercers Institute for Research on Ageing, St James’s Hospital, Dublin, Ireland
This abstract was awarded the student prize for best original communication presentation
Cognitive dysfunction and dementia are important public health issues in ageing, while optimal nutrition may be important in their
prevention. One-carbon metabolism and the related B-vitamins may be important for maintaining cognitive health in ageing(1) but
few studies have investigated biomarker status of all relevant B-vitamins and furthermore studies in this area are typically observa-
tional cohort studies at one time point. The primary aim of this investigation was to examine the role of baseline status of folate and
the metabolically related B-vitamins (vitamins B12, B6 and riboflavin) as predictors of subsequent cognitive decline over a five-year
follow-up period in healthy older people.
From the total sample recruited to the Trinity, Ulster, Department of Agriculture (TUDA) Ageing Cohort Study (≥60 years; n
5186), as previously described(2), a sample of 2093 participants in Northern Ireland were potentially available, from which a sub-set
(n 587) meeting the selection criteria (aged >67 years at baseline, MMSE score >21, no B12 injections) were recruited for reinvesti-
gation 5 years after the initial TUDA study. The rate of cognitive decline was evaluated by re-assessment of cognition using the ori-
ginal battery of tests including the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Mini-Mental
State Examination (MMSE) and the Frontal Assessment Battery (FAB). Accelerated cognitive decline was defined as the highest
quartile of change in cognitive score over the 5 year follow up period; i.e. ≥7 RBANS;≥ 2 MMSE; ≥3 FAB points. At follow up,
lower vitamin B6 status (PLP below median) and lower riboflavin status (EGRac above median) at baseline were each associated
with an accelerated rate of cognitive decline, as measured by RBANS (Table). A similar relationship was shown with MMSE for
vitamin B6 (OR: 1·485, CI: 1·002–2·200, p 0·049), but not for any other B-vitamin, while no significant relationships were observed
for any B-vitamin biomarker with cognition as assessed by FAB.
The results indicate that vitamin B6 and the metabolically related B-vitamin riboflavin, may have important roles in helping to
maintain better cognitive health in ageing. Further research including RCTs targeted at those with lower B-vitamin status are war-
ranted to investigate the role of all relevant B-vitamins in cognitive function.
1 Smith D, Refsum H (2016) Annual Review of Nutrition 36:211–39.
2 McCarroll K, Beirne A, Casey M et al. (2015) Age & Ageing 44(5):847–853.
B-vitamin Biomarker status1 Accelerated cognitive decline RBANS
OR 95 % CI p value
Plasma Homocysteine (μmol/L) Reference <13·0 vs (13·0–27·5) 0·967 0·660–1·416 0·862
RBC Folate (nmol/L) Reference > 868 vs lower status (185–865) 1·126 0·759–1·670 0·556
Serum Total B12 (pmol/L) Reference > 252 vs lower status (58–251) 0·828 0·564–1·215 0·334
Plasma PLP (B6) (nmol/L) Reference > 61·3 vs lower status (11·6–61·3) 1·537 1·039–2·273 0·032
EGRac (B2)* Reference < 1·30 vs lower status (1·30–2·03) 1·493 1·013–2·201 0·043
Binary logistic regression was performed with adjustment for age (years) and education (years).
Abbreviations: OR, odds ratio; CI, confidence interval; RBC, Red Blood Cell; PLP, Plasma Pyridoxal Phosphate; *EGRac, Erythrocyte Glutathione Reductase
Activation Coefficient- higher EGRac ratio indicates lower riboflavin status.
1 For each biomarker, participants with lower status were identified using the median value as the cut off point.
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Biomarkers of folate and related B-vitamins as predictors of cognitive
decline in older Irish adults over a 5 year follow up period.
K. Porter1, C.F. Hughes1, L. Hoey1, M. Ward1, K. Moore1, J.J. Strain1, A. Molloy2,
C. Cunningham3, M.C. Casey3, E. Laird2, K. McCarroll3, K. Pentieva1 and H. McNulty1
1Northern Ireland Centre for Food and Health, Ulster University, Coleraine, BT52 1SA,
2Institute of Molecular Medicine, School of Medicine, Trinity College, Dublin 2, Ireland and
3Mercers Institute for Research on Ageing, St James’s Hospital, Dublin, Ireland
This abstract was awarded the student prize for best original communication presentation
Cognitive dysfunction and dementia are important public health issues in ageing, while optimal nutrition may be important in their
prevention. One-carbon metabolism and the related B-vitamins may be important for maintaining cognitive health in ageing(1) but
few studies have investigated biomarker status of all relevant B-vitamins and furthermore studies in this area are typically observa-
tional cohort studies at one time point. The primary aim of this investigation was to examine the role of baseline status of folate and
the metabolically related B-vitamins (vitamins B12, B6 and riboflavin) as predictors of subsequent cognitive decline over a five-year
follow-up period in healthy older people.
From the total sample recruited to the Trinity, Ulster, Department of Agriculture (TUDA) Ageing Cohort Study (≥60 years; n
5186), as previously described(2), a sample of 2093 participants in Northern Ireland were potentially available, from which a sub-set
(n 587) meeting the selection criteria (aged >67 years at baseline, MMSE score >21, no B12 injections) were recruited for reinvesti-
gation 5 years after the initial TUDA study. The rate of cognitive decline was evaluated by re-assessment of cognition using the ori-
ginal battery of tests including the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Mini-Mental
State Examination (MMSE) and the Frontal Assessment Battery (FAB). Accelerated cognitive decline was defined as the highest
quartile of change in cognitive score over the 5 year follow up period; i.e. ≥7 RBANS;≥ 2 MMSE; ≥3 FAB points. At follow up,
lower vitamin B6 status (PLP below median) and lower riboflavin status (EGRac above median) at baseline were each associated
with an accelerated rate of cognitive decline, as measured by RBANS (Table). A similar relationship was shown with MMSE for
vitamin B6 (OR: 1·485, CI: 1·002–2·200, p 0·049), but not for any other B-vitamin, while no significant relationships were observed
for any B-vitamin biomarker with cognition as assessed by FAB.
The results indicate that vitamin B6 and the metabolically related B-vitamin riboflavin, may have important roles in helping to
maintain better cognitive health in ageing. Further research including RCTs targeted at those with lower B-vitamin status are war-
ranted to investigate the role of all relevant B-vitamins in cognitive function.
1 Smith D, Refsum H (2016) Annual Review of Nutrition 36:211–39.
2 McCarroll K, Beirne A, Casey M et al. (2015) Age & Ageing 44(5):847–853.
B-vitamin Biomarker status1 Accelerated cognitive decline RBANS
OR 95 % CI p value
Plasma Homocysteine (μmol/L) Reference <13·0 vs (13·0–27·5) 0·967 0·660–1·416 0·862
RBC Folate (nmol/L) Reference > 868 vs lower status (185–865) 1·126 0·759–1·670 0·556
Serum Total B12 (pmol/L) Reference > 252 vs lower status (58–251) 0·828 0·564–1·215 0·334
Plasma PLP (B6) (nmol/L) Reference > 61·3 vs lower status (11·6–61·3) 1·537 1·039–2·273 0·032
EGRac (B2)* Reference < 1·30 vs lower status (1·30–2·03) 1·493 1·013–2·201 0·043
Binary logistic regression was performed with adjustment for age (years) and education (years).
Abbreviations: OR, odds ratio; CI, confidence interval; RBC, Red Blood Cell; PLP, Plasma Pyridoxal Phosphate; *EGRac, Erythrocyte Glutathione Reductase
Activation Coefficient- higher EGRac ratio indicates lower riboflavin status.
1 For each biomarker, participants with lower status were identified using the median value as the cut off point.
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Summer Meeting, 11–14 July 2016, New technology in nutrition research and practice
Role of B-vitamins as determinants of neuropsychiatric health in ageing
K. Moore1, C. F. Hughes1, L. Hoey1, M. Ward1, K. Porter1, J.J. Strain1, A. Molloy2,
C. Cunningham3, M. Casey3, E. Laird2 and H. McNulty1
1Northern Centre for Food and Health, Ulster University Coleraine, Cromore Road, Coleraine, BT52 1SA, 2Institute of
Molecular Medicine, School of Medicine, Trinity College Dublin, Dublin 2, Ireland and 3Mercers Institute for Research
on Ageing, St James’s Hospital, Dublin, Ireland
The number of adults aged 60 years and over is predicted to reach up to 2 billion by 2050 and hence the associated health and socio-
economic costs will continue to increase. Cognitive dysfunction, depression and anxiety are significant problems of ageing. Preventing
or delaying the onset of these disorders should therefore be a public health priority. Accumulating evidence suggests that low status of
folate and the related B-vitamins (B12, B6 and riboflavin) are linked to an increased risk of these conditions1,2,3. The aim of this study
is to investigate whether these B-vitamins are determinants of neuropsychiatric health in ageing.
Participants for this investigation were recruited to the Trinity Ulster Department of Agriculture (TUDA) Ageing cohort study and
health, clinical, medication, lifestyle and nutritional details were collected (n 5186). A non-fasting blood sample was taken for the
analysis of B-vitamin biomarkers. Cognitive function was assessed using the Mini Mental State Examination (MMSE), and depres-
sion and anxiety were assessed by the Centre for Epidemiologic Studies Depression scale (CES-D) (a score ⩾16·0 suggestive of de-
pression) and the Hospital Anxiety and Depression (HADS) scale (a score ⩾11·0 suggestive of anxiety).
Those in the lowest quintile of status for each of the four B-vitamin biomarkers were at the greatest risk of depression, with a 40–57 %
increased risk compared to those with the best status, after adjustment for confounding factors. No significant association was found
between any B-vitamin and anxiety. Likewise, when similar analysis was performed to examine the impact of fortified food consumption,
those with the highest intake (at least one portion of fortified food a day) had a significantly lower risk of depression than those who
depended on natural sources of B vitamins (OR= 0·542, 95 % CI = 0·409-–·718, P⩽ 0·001). These results suggest that a better status
of B-vitamins can have a positive impact on mental health. Confirmation of these findings must await the outcomes of randomised con-
trolled trials.
1. Reynolds E (2002) Folic acid, ageing, depression, and dementia Br Med J 324, 1512–5.
2. Hooshmand B, Solomon A, Kareholt I, et al. (2012) Associations between serum homocysteine, holotranscobalamin, folate and cognition in the
elderly: a longitudinal study J Intern Med 271 204–212.
3. Smith D (2008) The worldwide challenge of the dementias: A role for B vitamins and homocysteine? Food Nutr Bull 29 S143–S172.
B-Vitamin Biomarker2
Depression3 (CES-D) Anxiety4 (HADS)
OR 95 % CI P1 OR 95 % CI P
RBC folate (nmol/l) Q5: Reference ⩾1520
Q1: ⩽623 1·571 1·120–2·202 0·009 0·850 0·543–1·330 0·476
Serum B12 (pmol/l) Q5: Reference ⩾373




Q1: ⩽35·6 1·406 1·005–1·967 0·047 1·457 0·943–2·251 0·090
Riboflavin (EGRac) Q5: Reference ⩽1·19
Q1: ⩾1·46 1·574 1·141–2·170 0·006 1·130 0·746–1·713 0·563
1Binary logistic regression was performed with adjustment for confounding factors as appropriate.
2The highest quintile (Q) of B-vitamin biomarker status was set as the reference category and was compared to the lowest quintile as shown for all biomarkers. P-value
<0·05 was considered significant.
3Depression defined as CES-D score ⩾16·0 4 Anxiety defined as HADS score ⩾11·0.
Abbreviations: RBC, Red Blood Cell; PLP, pyridoxal 5-phosphate; EGRac, erythrocyte glutathione reductase activation coefficient.
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